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Abstract
Elucidating the Molecular Mechanism of Cis-Regulation by the Long Noncoding RNA LincRNA-p21
Lauren Nicole Winkler
2021
Pervasive transcription is a hallmark of mammalian genomes. Although protein-coding genes
span only a small fraction of the genome, more than two-thirds is transcribed, yielding thousands of
noncoding transcripts whose expression exhibits a tight correlation with cell type, disease state, and other
biological phenomena. A subset of these transcripts, termed long noncoding RNAs (lncRNAs) on account
of their length (>200 nucleotides) and lack of apparent coding potential, have been shown to play
functional roles in processes ranging from immune signaling to organogenesis. In contrast to trans-acting
lncRNAs, which may operate in either the nucleus or cytoplasm, cis-acting lncRNAs remain at their site
of transcription and regulate the expression of nearby protein-coding genes. These lncRNAs have been
proposed to act through three main mechanisms: (1) the RNA molecule may interact with protein factors
to enact transcriptional activation or repression; (2) the act of lncRNA transcription may increase the local
concentration of RNA polymerase II or chromatin-modifying factors; or (3) DNA elements within a
lncRNA locus may directly regulate the expression of both the lncRNA and its neighboring gene.
Deconvolving these interlinked mechanisms has proven challenging and necessitates the development and
implementation of new experimental techniques. In this work, we used a suite of independent molecular
and genetic approaches, including a novel ribozyme-based tool for targeted transcript degradation, to
expand our understanding of the molecular “logic” through which cis-acting lncRNAs enact gene
regulation.
We focused on the p53-inducible lncRNA LincRNA-p21, which acts in cis to reinforce the
expression of the nearby protein-coding gene and key p53 target p21/Cdkn1a. To identify the functional
element of cis-regulation at this locus, we generated four mouse strains harboring complementary
LincRNA-p21 loss-of-function mutations that allowed us to separately examine the importance of the
LincRNA-p21 transcriptional process and the underlying DNA sequence. This parallel genetic approach

demonstrated that full-length LincRNA-p21 transcription, processing, and accumulation are dispensable
for cis-regulation and revealed a requirement for a conserved sequence element within exon 1. Further
experiments with molecular tools suggested that active transcription through this conserved region
promotes p21 expression, implicating a dual role for the transcriptional process and sequence elements
within the locus. This comprehensive functional dissection of a single lncRNA locus attests to the
regulatory potential of lncRNA loci and further reveals the biological significance of pervasive genomic
transcription.
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Chapter I: Introduction
The role of noncoding transcription in gene regulation
Pervasive noncoding transcription as a hallmark of mammalian genomes
The advent of modern RNA sequencing technology has given rise to the discovery that
mammalian genomes are transcribed into a wealth of RNAs. Although individual cells express no more
than 40% of the genome at any one point in time (Djebali et al., 2012), anywhere from 70-90% of all
nucleotides are cumulatively transcribed across different cell lines and under disparate environmental
conditions (Birney et al., 2007; Djebali et al., 2012). Curiously, protein-coding genes account for only a
small fraction of this pervasive transcription: in total, exons make up less than 2% of the genome
(International Human Genome Sequencing Consortium, 2004). It therefore follows that the vast majority
of transcripts are noncoding.
The noncoding transcriptome encompasses numerous classes of RNAs with diverse mechanisms
of biogenesis and function. Historically, efforts to study noncoding transcription have focused on welldefined RNA classes associated with translation (tRNAs and rRNAs), splicing (snRNAs), rRNA
biogenesis (snoRNAs), and post-transcriptional gene regulation (miRNAs and siRNAs). However, an
expanding number of studies have implicated additional classes of noncoding RNAs (ncRNAs) in cellular
processes ranging from genomic imprinting to the development of drug resistance in cancer cells (Joung
et al., 2017; Latos et al., 2012).
An emerging class of transcripts known as long ncRNAs (lncRNAs) are operationally defined by
their length (>200 nucleotides) and lack of coding potential. The largely arbitrary size threshold serves as
a heuristic for distinguishing between lncRNAs and ncRNAs from other functional classes (Quek et al.,
2015). The absence of coding potential may be supported by several lines of computational and
experimental evidence, including poor conservation of putative open reading frames (ORFs), failure to
detect ribosomal interactions, and the inability of mass spectrometry to detect corresponding peptides
(Bánfai et al., 2012). Recent studies show that the human genome harbors over 60,000 lncRNAs, more
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than double the number of annotated protein-coding genes (Fang et al., 2018; Iyer et al., 2015). Individual
members of this transcript class demonstrate varying degrees of RNA processing, including capping,
splicing, and polyadenylation, (Djebali et al., 2012) and may localize to either the nucleus or the cytosol
(Kapranov et al., 2007), although the majority of lncRNAs remain within the nucleus (Derrien et al.,
2012; Djebali et al., 2012). LncRNAs therefore represent a heterogeneous class of transcripts exhibiting
variable processing, stability, and localization.
LncRNA loci also show significant diversity in their genomic position and organization with
respect to protein coding genes (Fig. 1)(Derrien et al., 2012). A subset of lncRNAs known as long
intergenic ncRNAs (lincRNAs) derive from transcriptional units that do not overlap with annotated
protein-coding genes or regulatory sequences. Like their coding counterparts, many lincRNAs exhibit the
epigenetic hallmarks of active RNA polymerase II (Pol II) transcription, including peaks of promoterassociated H3K4me3 and enrichment of H3K36me3 along their gene bodies (Guttman et al., 2009). On
account of this, and because they arise from discrete loci that do not share their sequence with other
transcripts, lincRNAs have attracted significant interest as potential mediators of key phenomena in both
the nucleus and cytoplasm.
A second category comprises lncRNA loci that overlap partially or entirely with protein-coding
genes. This broad class includes lncRNAs transcribed from the sense (s) or antisense (as) strand of the
associated coding gene(s). Although s-lncRNAs have received relatively little attention, as-lncRNAs have
been widely studied on account of their intriguing genomic architecture. In particular, the spatial and
sequential relationship between as-lncRNAs and their overlapping loci suggests that these transcripts may
regulate mRNA transcription, stability, or function (Faghihi et al., 2010; Zucchelli et al., 2015). As a
testament to the prevalence of as-transcription—and to the potential importance of as-lncRNAs as a
genome-wide regulatory mechanism—more than 60% of coding genes are associated with antisense
transcripts (Katayama et al., 2005).

2

Figure 1. LncRNAs arise from diverse genomic contexts. LncRNA loci exhibit many different
genomic architectures and may be classified based on their spatial relationship with nearby proteincoding genes or regulatory elements (e.g., enhancers).

Although many s- and as-lncRNAs overlap exons, a subset of these lncRNA loci lie entirely
within introns. Like as-lncRNAs, intronic RNAs exhibit a high genomic prevalence, with an estimated
80% of human genes harboring an intronic lncRNA (Louro et al., 2008). Unlike other lncRNAs, however,
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the majority of intronic lncRNAs consist of only a single exon (Derrien et al., 2012; Nakaya et al., 2007).
LncRNAs from this functional class have been proposed to act to regulate the splicing and stability of
their host transcripts (Nakaya et al., 2007).
LncRNAs may also arise as the result of divergent transcription from the promoters of proteincoding genes. Bidirectional transcription is a hallmark of mammalian promoters: nearly 80% of active
human promoters show evidence of divergent transcription within a kilobase of their transcription start
site (TSS), although divergent transcription most commonly initiates within a 90-120 nucleotide window
(Core et al., 2014). The amount of transcriptional initiation at divergent TSSs commonly correlates with
the activity of the associated gene (Core et al., 2008), prompting suggestions that divergently-transcribed
lncRNAs may promote protein-coding gene expression (Seila et al., 2009). Although some of these
lncRNAs are stable, the majority are rapidly degraded by the exosome (Pefanis et al., 2015; Preker et al.,
2008), potentially arguing that the RNA products of these loci are largely non-functional.
Enhancer RNAs (eRNAs) comprise the final class of lncRNAs. Over the past decade, a number
of transcriptomics studies have confirmed the finding that many enhancers are transcriptionally active
(Kim et al., 2010; Santa et al., 2010). Such enhancers are often bidirectionally transcribed by Pol II to
yield transcripts of variable lengths; although some enhancer-derived transcribed transcripts fall well
short of the arbitrary 200 nucleotide threshold for lncRNA designation (Henriques et al., 2018), others
may be up to several kilobases in length (Djebali et al., 2012; Santa et al., 2010). Other features also mark
eRNAs as a unique class of lncRNAs. While eRNAs are typically capped, they remain largely unspliced
and non-polyadenylated (Andersson et al., 2014; Kim et al., 2010). And like lncRNAs arising from
bidirectional promoters, they are often substrates for the RNA exosome (Pefanis et al., 2015). On account
of this, eRNAs generally have short half-lives and a low cellular abundance (Li et al., 2013b), calling into
question their functionality.
Although transcriptional units from each of these categories have different genomic
organizations, lncRNA loci share a few structural commonalities. Firstly, many lncRNAs are located near
protein-coding genes that play key roles in transcriptional regulation and development (Cabili et al., 2011;
4

Guttman et al., 2009). And although many lncRNAs show poor evolutionary conservation across their
gene bodies, lncRNA promoters show a similar degree of conservation to the promoters of protein-coding
genes (Carninci et al., 2005; Derrien et al., 2012; Guttman et al., 2009). Lastly, many lncRNA loci exhibit
preserved synteny with nearby protein-coding genes (Cabili et al., 2011), hinting at the importance of the
spatial relationship between the two loci.
As demonstrated above, lncRNAs arise from diverse loci across mammalian genomes. However,
the broader significance of this pervasive noncoding transcription remains unclear, in part because our
ability to detect noncoding transcripts far outstrips our ability to assess their function. Initial efforts to
identify and characterize lncRNAs focused primarily on lincRNAs, largely on account of their similarity
to protein-coding genes (Guttman et al., 2009; Wang et al., 2011). Many of these early studies explored
the ability of these lncRNA transcripts to act in trans to effect diverse biological outcomes throughout the
nucleus and cytoplasm. Intriguingly, recent studies have shown that many lncRNAs exhibit significant
chromatin enrichment, remain at or near the site of their transcription, and are co-regulated with nearby
protein-coding genes (Werner and Ruthenburg, 2015; Werner et al., 2017). This finding raises the
possibility that lncRNAs may act in cis to activate or repress neighboring genes. The following work
describes our efforts to investigate the role of the noncoding transcriptome in cis-regulation.

The role of cis-acting noncoding RNAs in homeostasis and disease
As deep sequencing transcriptomics studies have shown, mammalian genomes are pervasively
transcribed, yielding thousands of lncRNAs. While some of these transcripts are expressed ubiquitously,
many lncRNAs show remarkable tissue, cell type, and disease state specificity (Derrien et al., 2012;
Djebali et al., 2012; Iyer et al., 2015). This correlation between lncRNA expression and biological
outcome raises the possibility that cis-acting lncRNAs might play critical roles as mediators of
development, homeostasis, and disease, and implicated them as a potential source of novel therapeutic
targets. Ultimately, large-scale efforts to identify functionally-relevant lncRNAs demonstrate that these
loci and their transcripts may enact previously-unappreciated roles in many biological processes. In the
5

following section, we will highlight some of the cellular and organismic outcomes of cis-regulation and dysregulation by functional noncoding transcriptional units.

Dosage compensation
A number of cis-acting lncRNAs have been shown to play key roles in X-chromosomal dosage
compensation, the process by which eutherian mammals equalize the expression of X-linked genes
between the sexes. Foremost among these is Xist (X-inactive specific transcript), one of the first lncRNAs
to be described (Brown et al., 1991). This X-chromosomal transcript randomly envelops one of the two X
chromosomes in female cells, thereby inducing its heterochromatinization and subsequent silencing of the
inactive X chromosome (XI). Although Xist expression is essential for establishing X-chromosomal
inactivation (XCI) during early embryonic development, its role in XI maintenance remains unclear.
Studies have variously reported that the post-XCI loss of Xist expression leads to consequences ranging
from a mild decrease in viability to a predisposition for certain types of cancer (Yang et al., 2016a;
Yildirim et al., 2013). As a testament to the importance of proper Xist expression, an additional suite of
X-chromosomal lncRNAs work in tandem with Xist to support robust XI silencing and protect the active
X chromosome (XA; reviewed in Furlan and Rougeulle, 2016). For example, Jpx and Ftx (five prime to
Xist), which both escape transcriptional silencing on the XI, appear to reinforce Xist expression (Chureau
et al., 2011; Tian et al., 2010). Meanwhile, Tsix (a lncRNA antisense to Xist) and Xite both repress Xist
expression from the XA, thereby ensuring transcriptional silencing of a single X chromosome (Furlan and
Rougeulle, 2016). Thus, a network of cis-regulatory lncRNAs coordinates dosage compensation in female
eutherian cells.

Imprinting
Cis-acting lncRNAs also play a well-defined role in the establishment and maintenance of
epigenetic imprinting at loci throughout the genome. Airn (Antisense of Igf2r non-protein-coding RNA),
an overlapping as-lncRNA transcribed from the paternal Igf2r/Airn locus, silences Igf2r (insulin-like
6

growth factor 2 receptor) in embryonic, extraembryonic, and adult mouse tissue and may additionally
repress the nearby Slc22a2 and Slc22a3, (solute carrier 22 member 2 and 3, respectively) genes in some
extraembryonic lineages (Latos et al., 2012; Sleutels et al., 2002). Similarly, the as-lncRNA Kcnq1ot1,
which overlaps the Kcnq1 (potassium voltage-gated channel subfamily Q member 1) locus, establishes a
heterochromatic environment in the paternal Kcnq1 domain (Pandey et al., 2008). The human and mouse
genomes are replete with additional examples of as-lncRNAs that overlap imprinted loci (reviewed in
O’Neill, 2005), implicating cis-acting lncRNAs as a common mechanism for enacting allele-specific gene
expression. Significantly, the loss of genetic imprinting underlies numerous genetic disorders (O’Neill,
2005), suggesting that imprinting-associated lncRNAs such as Airn and Kcnq1ot1 play critical roles
during development.

Cardiac development
While Xist and imprinting-associated lncRNAs enforce allele-specific transcriptional control,
other lncRNAs are expressed biallelically and thus play more general roles as activators or repressors of
nearby developmental genes. In particular, a large body of literature has illuminated the importance of
cis-regulatory lncRNAs during cardiac development. The Hand2 (heart and neural crest derivatives
expressed 2) locus is flanked by two lncRNAs, Upperhand and Handsdown (also known as Handlr),
whose antagonistic effects maintain Hand2 expression within a narrow operational window (Anderson et
al., 2016; Ritter et al., 2019). While transcription through the Upperhand locus establishes a permissive
chromatin environment at the Hand2 promoter, thereby facilitating its transcription, transcription of the
Handsdown locus sequesters enhancer elements that would otherwise reinforce Hand2 binding. Hand2
deficiency is lethal in mice (Anderson et al., 2016), and overexpression of Hand2 in humans incurs
significant developmental defects (Tamura et al., 2013), indicating the importance of maintaining Hand2
levels within a narrow operational range. The relationship between Hand and its neighboring lncRNAs
thus highlights the ability of cis-acting lncRNAs to “buffer” genes whose over- and underexpression may
both have deleterious consequences. As further evidence of their broad functionality, cis-acting lncRNAs
7

have been proposed to regulate additional aspects of heart development. Charme and Fendrr have been
implicated in cardiac myogenesis and mesoderm differentiation, respectively (Ballarino et al., 2018;
Grote et al., 2013).

Immune function
Cis-regulatory lncRNAs have increasingly been recognized as an important component of the
immune system, where they underpin processes ranging from cell lineage commitment to immune
activation in response to pathogenic threats. As an initial example of the former, the lncRNA ThymoD
(thymocyte differentiation factor) remodels the local chromatin structure, facilitating interactions between
Bcl11b (B-cell lymphoma/leukemia 11b) and its intergenic enhancers during T-cell development (Isoda et
al., 2017). Strikingly, transcriptional knockdown of this lncRNA predisposes mice to develop lymphoma
or leukemia. Dysregulation of Morbidd (myeloid RNA regulator of Bim-induced death) has similarly
dramatic consequences. This lncRNA regulates the lifespan of myeloid cells by repressing expression of
the pro-apoptotic gene Bim (also known as Bcl2l11)(Kotzin et al., 2016). Notably, knockdown of the
Morbidd transcript or transcriptional process leads to a significant increase in cell mortality in vitro, while
mice deficient for the Morbidd locus have fewer eosinophils, neutrophils, and monocytes. In light of its
role in myeloid cell development, it is unsurprising that Morbidd expression is dysregulated in various
human hematological disorders (Kotzin et al., 2016). Together, Morbidd and ThymoD demonstrate the
role of lncRNAs in specifying cell fate during immune cell development.
Many examples attest to the ability of lncRNAs to act in cis to regulate transient immune
responses. Although rapid and robust immune activation is critical for eliminating threats, immune
signaling must be tightly regulated. Recent studies have identified a number of lncRNAs that either
enhance gene expression during the early stages of the immune response or help dampen the magnitude of
signaling at later timepoints following an immune challenge. For example, the lncRNAs Pacer and
LincRNA-Cox2 both regulate the expression of Ptgs2/Cox2 (prostaglandin endoperoxide synthase 2, also
known as cyclooxygenase 2) in response to inflammatory stimuli (Elling et al., 2018; Krawczyk and
8

Emerson, 2014). Meanwhile, the lncRNA genes Umlilo (upstream master lncRNA of the inflammatory
chemokine locus) and Ifng-as1 (interferon gamma antisense transcript 1) have been proposed to prime
nearby loci for transcription by modulating the chromatin environment (Fanucchi et al., 2019; Petermann
et al., 2019); and while both loci mediate the initial immune response to their respective stimuli, Ifng-as1
plays an additional role as a long-term potentiator of interferon-γ signaling, which it accomplishes by
maintaining a poised epigenetic state around the Ifng (interferon gamma) locus (Petermann et al., 2019).
In contrast to Umlilo and Ifng-as1, which serve as an example of how cis-regulatory lncRNAs can support
rapid gene expression, other lncRNAs may suppress the immune response. For example, the Tnf (tumor
necrosis factor) locus harbors numerous lncRNAs that appear to act in tandem to repress the TNF
signaling pathway (Shi et al., 2014). Cis-acting lncRNAs may thus act to both bolster and suppress the
expression of immune genes.

The p53 tumor suppressor network
The p53 tumor suppressor network includes many lncRNAs that are induced in response to p53
activation (see Chapter II)(Melo et al., 2013; Sánchez et al., 2014; Tesfaye et al.). Recently, our lab
showed that a handful of these lncRNAs are co-regulated with nearby protein-coding genes, suggesting
that they mediate p53-dependent gene expression (Tesfaye et al.). Indeed, cis-regulatory lncRNAs act as
effectors of the p53 pathway under a range of conditions. For example, LincRNA-p21 reinforces
expression of the cell cycle checkpoint inhibitor p21/Cdkn1a (cyclin-dependent kinase inhibitor 1a) in
response to p53 signaling to promote growth arrest (see Chapters II and IV)(Dimitrova et al., 2014).
Similarly, the intergenic lncRNA LincRNA-Gadd45γ has been shown to activate the poorly-characterized
Gadd45γ (growth arrest and DNA damage-inducible 45 gamma) gene (Tesfaye et al.). Although other
members of the Gadd45 gene family play well-established roles in the p53 pathway (Hollander et al.,
1993), Gadd45γ has not been identified as a direct p53 target. The ability of LincRNA-Gadd45γ to
activate Gadd45γ transcription in a p53-dependent manner provides provocative evidence that cis-acting
lncRNAs may recruit noncanonical targets into the p53 transcriptional network. Finally, a p53-inducible
9

isoform of the lncRNA Pvt1 (plasmacytoma variant 1) mediates crosstalk between the p53 and Myc
(myelocytomatosis) networks by downregulating Myc transcription in response to p53 activation, thereby
acting as a check on cell proliferation following DNA damage or oncogenic signaling (Olivero et al.,
2020). Taken together, these examples showcase the potential of cis-regulatory lncRNAs to enact precise
outcomes in response to p53 signaling.

Cancer
As evidenced by the preceding examples, cis-acting lncRNAs serve as an additional layer of gene
regulation, allowing cells to maintain precise spatiotemporal control of transcription. It is therefore
unsurprising that lncRNAs have been implicated in many different types of cancer (Olivero and
Dimitrova, 2020). Some tumorigenic lncRNAs appear to act by repressing the activity of nearby tumor
suppressors. Anril (antisense noncoding RNA in the Ink4 locus), an as-lncRNA overlapping the
Ink4b/Arf/Ink4a locus, is one such lncRNA that has received significant attention. Experimental findings
suggest that Anril transcriptionally silences the Ink4b/Arf/Ink4a locus, which encodes the tumor
suppressor proteins CDKN2A, ARF, and CDKN2B (Yap et al., 2010), thus accounting for the
observation that Anril overexpression promotes cell proliferation, migration, and invasion (Kong et al.,
2018). Clinical evidence further shows that increased Anril expression is associated with an aggressive
disease progression and poor patient survival. Transcription of another cis-regulatory as-lncRNA,
Anrassf1, negatively regulates the expression of the overlapping, tumor-suppressive Rassf1 (RASassociated domain family member 1a) gene. Consistent with this, Anrassf1 is overexpressed in both breast
and prostate cancer cell lines relative to non-tumor controls and is inversely correlated with Rassf1 levels
(Beckedorff et al., 2013).
In keeping with previous examples showing that cis-lncRNAs may enact both positive and
negative regulation, cancer-associated lncRNAs may also enhance the expression of nearby oncogenes.
As one example, CCAT1-L (colorectal cancer-associated transcript 1 long isoform), which is transcribed
from a super-enhancer upstream of the Myc locus, facilitates long-range interactions between Myc and
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nearby regulatory DNA elements. This, in turn, sustains Myc expression in human colorectal cancer cells
(Xiang et al., 2014). A second example, the lncRNA SWINGN, (SWI/SNF interacting Gas6 enhancer
noncoding RNA), boosts the transcription of Gas6 (growth arrest specific 6), promoting cellular
proliferation and delaying the onset of oncogene-induced senescence (Grossi et al., 2020).
It is important to explicitly note the distinction between a lncRNA’s endogenous function and its
pathological role in diseases such as cancer, even in cases where the normal physiological role remains
elusive. For example, the Anril locus harbors many cancer-associated SNPs that may alter its structure,
abundance, and function (Kong et al., 2018), perhaps accounting for its frequent dysregulation in different
types of cancer. The widespread cooption of functional lncRNAs during tumorigenesis serves as further
evidence for the involvement of noncoding transcription in vital cellular processes.

Conclusion
Two common observations arise from genome-wide analyses of the noncoding transcriptome.
Firstly, lncRNAs are enriched near genes encoding transcription factors and key developmental genes
(Mercer et al., 2008; Ulitsky et al., 2011; Wamstad et al., 2012). Secondly, the expression of many
chromatin-associated lncRNAs typically correlates with levels of nearby protein-coding genes (Werner et
al., 2017). The discovery that hundreds of cis-regulatory lncRNAs coordinate gene expression across a
broad range of biological phenomena provides context for these relationships and further helps explain
why lncRNAs and protein-coding gene pairs typically exhibit conserved synteny (Ulitsky et al., 2011).
Although cis-lncRNAs perform a wide range of roles, functional studies all point to one main conclusion:
the unique spatial relationship between lncRNAs and their neighboring genes enables cis-regulatory
lncRNAs to enact rapid and robust activation or repression.

Mechanisms of cis-regulation by noncoding RNAs
Functional studies attest to the widespread involvement of lncRNAs in cis-regulation. However,
the mechanisms by which lncRNA loci enact cis-regulation are often difficult to identify. As a first
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possibility, the lncRNA molecule may itself harbor functional activity. As a second possibility, the act of
lncRNA transcription or processing may effect gene regulation independently from the resulting
transcript. Finally, many purportedly-functional lncRNAs arise from enhancers, promoters, and other
regulatory sequences (Core et al., 2008), giving rise to the prospect that DNA elements within a lncRNA
locus may be sufficient to drive expression of both the lncRNA and its neighboring gene(s). In this case,
lncRNA transcription and accumulation on the chromatin would represent an incidental byproduct of
underlying regulatory processes. Efforts to dissect lncRNA function have implicated these three broad
models as overarching paradigms of cis-regulation. Below, we review the many molecular mechanisms
through which lncRNAs enact each of these paradigms, with attention where necessary to the
methodologies used to demonstrate each function.

The lncRNA molecule
Classical models of lncRNA functionality have emphasized the ability of these RNAs to form
complex secondary and tertiary structures capable of interfacing with a wide range of biomolecules
(Quinn and Chang, 2016). While this mechanistic paradigm inherently encompasses all trans-acting
lncRNAs, it remains unclear whether it is broadly applicable to cis-acting lncRNAs. Nevertheless, there is
compelling evidence that a number of lncRNAs enact cis-regulation through their transcripts.
Xist is, perhaps, the archetypal example of a functional cis-regulatory lncRNA molecule. The 17
kilobase Xist transcript comprises many well-studied RNA domains that interact with more than 80
protein factors to enact XCI (Minajigi et al., 2015, reviewed in Pintacuda et al., 2017). Although the
mechanistic importance of various Xist-protein interactions at different points during XCI has not been
fully resolved, studies have revealed major insights into underlying principles. Firstly, XCI appears to
involve several different Xist-protein interactions that mediate distinct outcomes. For example,
interactions between Xist and the nuclear lamina protein LBR (Lamin B receptor) appear to target the XI
to the nuclear periphery, which in turn facilitates the spread of Xist across the chromatin (Chen et al.,
2016). The bivalent DNA- and RNA-binding protein SAF-A (also known as hnRNP-U) and other
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DNA/RNA-binding proteins further promote XCI by tethering Xist to the chromatin; this provides an
obvious mechanism for the retention and subsequent accumulation of the Xist cloud during the initial
stages of transcriptional silencing (Chen et al., 2016; Hasegawa et al., 2010; Jeon and Lee, 2011).
Additional interaction partners such as SHARP (also known as SPEN) bind to the transcript and recruit
the histone deacetylase HDAC3, which repressively modifies the chromatin in order to exclude Pol II
from the silenced region of the XI (McHugh et al., 2015). Lastly, the Polycomb repressive complexes 1
and 2 (PRC1 and PRC2) have been the subject of ongoing investigation on account of their proposed role
in establishing and maintaining a repressive chromatin environment. However, recent work has called
into question the specificity and functionality of Xist-PRC1/2 interactions (discussed below)(Brockdorff,
2017). As evidenced by these examples, the complex interplay between Xist and its myriad protein factors
enacts multiple functions during XCI. Xist therefore serves as a model for how lncRNAs can act as
modular platforms capable of coordinating multi-step, multimeric interactions.
As elegantly illustrated by Xist, chromatin remodeling is a recurring mechanistic theme of
lncRNA-mediated cis-regulation. A growing number of functional cis-acting lncRNAs have been shown
to interact with chromatin-modifying factors to activate or silence nearby genes. For example, the
lncRNA SWINGN associates with the SWI/SNF chromatin remodeling complex, which promotes local
chromatin accessibility, resulting in activation of the nearby proto-oncogene Gas6 (Grossi et al., 2020).
Similarly, the LncTCF7 RNA binds SWI/SNF components through a stem-loop structure in its 3’ end,
subsequently increasing the occupancy of this protein complex at the neighboring TCF7 promoter (Wang
et al., 2015b) and enhancing its expression. As a final example, the Airn lncRNA molecule has been
proposed to enact epigenetic silencing of the non-overlapping, paternally-imprinted Slc22a3 locus by
recruiting the G9a histone methyltransferase. This leads to the deposition of repressive H3K9me3 marks
around the paternal Slc22a3 locus (Nagano et al., 2008). Thus, many transcribed cis-regulatory loci
appear to act through their transcripts to modulate the local epigenetic environment.
Functional lncRNA molecules may also establish and maintain the larger chromatin environment:
transcripts may themselves act as bridging factors, helping to coordinate 3D chromatin contacts between
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sequentially distant loci (Quinn and Chang, 2016). As a first example, the cancer-associated transcript
CCAT1-L has been proposed to strengthen pre-existing looping interactions between Myc and its
associated super-enhancers through its specific CTCF-binding activity (Xiang et al., 2014). Under this
model, the CCAT1-L RNA may act by increasing the local concentration of CTCF available to CTCF
sites in the Myc locus, facilitating the establishment and maintenance of chromatin looping. A second
example, the lncRNA Firre (functional intergenic repeating RNA element), has been proposed to act in
concert with the nuclear matrix factor SAF-A to coordinate long-range chromatin contacts between the
Firre locus and several other trans-chromosomal loci (Hacisuleyman et al., 2014). Strikingly, deletion of
the Firre locus led to the dissolution of these interchromosomal contacts. While this provides dramatic
evidence for the importance of the Firre locus, it raises the question of whether the DNA sequence or act
of transcription might instead mediate the role of the Firre locus as a chromatin hub.
LncRNA molecules may also cooperate with the underlying DNA sequence to modulate
transcription factor binding at regulatory elements. Many transcription factors exhibit both DNA- and
RNA-binding activity (Cassiday and Maher III, 2002), giving rise to the possibility that they may bind
both enhancer elements and their resulting transcripts. LncRNAs—and in particularly, eRNAs—may
therefore increase the local concentration of these factors. As one example of this, one eRNA has been
shown to bind the bivalent transcription factor YY1 (Yin-Yang 1), subsequently increasing its
concentration at enhancers (Sigova et al., 2015). Other eRNAs have been shown to drive RNA-dependent
reporter gene expression (Melo et al., 2013), lending additional support for a model in which RNAprotein interactions augment the activity of activating DNA elements. Alternatively, lncRNAs may
compete with DNA elements to sequester transcription factors that either activate or repress the
expression of neighboring genes. For example, the activating lnRNA Pacer upregulates Ptgs2 in part by
binding the repressive NF-ΚB subunit p50 (Krawczyk and Emerson, 2014). This interaction decreases the
local concentration of p50 near the Cox2 promoter, subsequently relieving p50-mediated transcriptional
repression.
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Many of the preceding examples attest to the ability of sequential and structural elements within
lncRNA molecules to specifically interact with target proteins. However, there is mounting evidence that
functional transcripts may also operate in a sequence-independent manner. Numerous lncRNAs, including
Anrassf1, Anril, and Morrbid, mediate local gene silencing by interacting with PRC1/2 (Beckedorff et al.,
2013; Kotake et al., 2011; Kotzin et al., 2016). This, in turn, recruits chromatin-modifying complexes that
catalyze the deposition of repressive H3K27me3 on target genes. The discovery that PRC2 often interacts
with target RNAs in a sequence-independent and length-dependent manner has led some to question the
biological significance of these interactions (Davidovich et al., 2013, 2015; Gil and Ulitsky, 2020).
However, PRC2’s promiscuous RNA-binding activity does not preclude a functional role and may
furthermore explain the prevalence of lncRNA-PRC2 interactions in both cis- and trans-repression
(Khalil et al., 2009; Skourti-Stathaki et al., 2019). Taken together, these findings suggest that repressive
lncRNA transcripts may enact their regulatory function through a mechanism that is largely independent
of their underlying sequence, perhaps helping to explain the observation that lncRNAs typically show
poor conservation (Carninci et al., 2005; Derrien et al., 2012).
Like their trans-acting counterparts, cis-regulatory RNAs have the potential to interact with a
range of additional biomolecules, including DNA and other RNAs. Examples of lncRNA-DNA
interactions abound. R-loops, triple-stranded structures characterized by the presence of a DNA-RNA
hybrid, frequently form at lncRNA-protein-coding gene loci, where they have been proposed to serve
important regulatory functions (reviewed in Niehrs and Luke, 2020). For example, R-loops involving
Anrassf1 recruit PRC2 to the overlapping Rassf1a promoter, ultimately resulting in transcriptional
silencing (Beckedorff et al., 2013). Although many R-loops appear to play repressive roles, often through
interactions with PRC2 (Skourti-Stathaki et al., 2019), R-loops may also mediate transcriptional
activation. The lncRNA Vim-as1, which arises from the Vim (vimentin) locus, forms R-loops that support
local chromatin decondensation and permit NF-ΚB binding at the Vim promoter (Boque-Sastre et al.,
2015). As a second mechanism of action, cis-acting lncRNAs may also interact with double-stranded
DNA in order to form a triple helix. The human as-lncRNA Khps1, which overlaps the coregulated Sphk1
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(sphingosine kinase 1) locus, remains tethered to its locus by its two triplex-forming regions
(TFRs)(Postepska-Igielska et al., 2015). These homopurine tracts, which allow the DNA duplex and
Khps1 RNA to engage in Hoogsteen base pairing, serve as an “address label” for this RNA, which also
recruits the histone acetyltransferase p300/CBP. Thus, lncRNAs may act in part through interactions with
the underlying DNA sequence.
While DNA-RNA hybrids appear to be a common theme in lncRNA-mediated cis-regulation,
interactions between cis-regulatory lncRNAs and other RNAs are exceedingly rare. As evidence of this,
one analysis of the human noncoding transcriptome found that less than 1% of lncRNA-mRNA or
lncRNA-pre-mRNA interactions involve cis-lncRNAs (Szcześniak and Makałowska, 2016). Although
theoretically free to utilize diverse mechanisms, it appears that cis-regulatory lncRNAs overwhelmingly
operate through associations with protein and DNA.

The transcriptional process
As demonstrated above, some lncRNA loci generate transcripts that enact cis-regulation through
their sequence and structure. By contrast, other lncRNA loci appear to act through some aspect of the
transcriptional process, including co-transcriptional phenomena. Understanding the mechanisms through
which lncRNA biogenesis coordinates local gene expression will help illustrate the significance of
noncoding transcription throughout the genome.

Transcription:
The intimate spatial relationship between cis-acting lncRNAs and their nearby protein-coding
genes raises the possibility that lncRNAs may act by modulating the local epigenetic and transcriptional
landscape. Indeed, lncRNAs have been shown to enact both negative and positive gene regulation through
their transcriptional process.
Imprinting-associated lncRNAs, including Airn and Kcn1qot1, serve as a model for the ability of
lncRNA transcription to enact gene silencing through one of several mechanisms. The 118 kilobase Airn
16

lncRNA initiates transcription at an antisense promoter within the Igf2r locus (Lyle et al., 2000). Notably,
the insertion of a PAS element within the shared Airn/Igf2r promoter region abolished Airn transcription
and incurred a near-complete loss of Igf2r, Slc22a2, and Slc22a3 silencing, indicating a functional
requirement for Airn transcription or the accumulation of the Airn transcript (Sleutels et al., 2002).
Subsequent work, in which PAS elements were inserted at multiple sites within the Airn locus, showed
that transcription of Airn through the Igf2r promoter is both necessary and sufficient to establish
repressive methylation of the paternal Igf2r allele (Latos et al., 2012). Intriguingly, promoter methylation
and Airn transcription are independently able to silence Igf2r expression (Santoro et al., 2013),
demonstrating that lncRNAs may enact cis-regulation through multiple modes of action. This observation
additionally highlights the mechanistic importance of transcriptional interference, in which transcription
on one strand sterically hinders transcription on the opposite strand.
While it is therefore clear that Airn silences Igf2r through its transcriptional process, the
mechanism of repression for Slc22a2 and Slc22a3 remains elusive. Although genetic imprinting of
Slc22a2 and Slc22a3 is not predicated on transcriptional overlap, premature Airn termination disrupts
silencing at both loci (Sleutels et al., 2002). A couple of explanations may account for this puzzling
observation. As described above, Airn has been proposed to repress Slc22a3 through an RNA-based
mechanism (Nagano et al., 2008). Alternatively, repressive methylation of the Igf2r promoter may initiate
heterochromatinization of the entire locus, including Slc22a2 and Slc22a3 (Sleutels et al., 2002). This has
been documented at other imprinted loci, including the Kcnq1ot1 locus, implicating it as a viable
mechanism that lncRNAs can use to silence more distal genes (Thakur et al., 2003). The full extent to
which transcription through the Airn locus enacts silencing thus remains unresolved.
The lncRNA transcriptional process may also modulate the transcriptional and epigenetic
environment in order to enact positive regulation of nearby protein-coding genes. In the simplest
examples of this phenomenon, transcriptional initiation from or elongation through regulatory elements
such as enhancers establishes or maintains a permissive chromatin environment. This is the case with the
previously-described lncRNA Upperhand. This lncRNA, which shares a bidirectional promoter with the
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cardiac transcription factor gene Hand2, spans a 16.5 kilobase locus that includes a known superenhancer (Anderson et al., 2016). Premature termination of Upperhand transcription upstream of this
enhancer element decreased the prevalence of H3K4me1 and H3K27ac and reduced the occupancy of the
transcription factor Gata4 within this region. Concurrently with this, the loss of Upperhand transcription
mediated a reduction in Pol II occupancy throughout the gene body—but not promoter—of Hand2.
Knockdown of the Upperhand transcript with antisense oligonucleotides (ASOs) did not affect Hand2
levels, implicating a model in which the Upperhand transcriptional process licenses the associated superenhancer to promote Hand2 expression.
In some cases, the act of lncRNA transcription appears to promote the expression of proteincoding genes that are separated by the lncRNA by considerable genomic distances. Transcription through
the 11 kilobase locus of the intergenic lncRNA Maenli (master activator of engrailed-1 in the limb) has
been shown to drive expression of the En-1 (engrailed 1) gene more than 250 kilobasese away (Allou et
al., 2021). Curiously, although insertion of a PAS that abolished ~90% of Maenli transcription led to a
~90% decrease in En-1 RNA levels, the insertion of a GFP-PAS element at the same site led to a more
moderate reduction in En-1 expression. Given that this element inhibited the majority Maenli
transcription while permitting transcription through the ~800 nucleotide GFP reporter, this observation
suggests that transcriptional initiation from the Maenli locus promotes En-1 expression in a lengthdependent, sequence-independent manner. In further support of this, the deletion of sequences
downstream of the PAS insertion site had no effect on En-1 levels. While it remains unclear how Maenli
transmits information about its transcriptional state to the En-1 locus, reported looping interactions
between the two genes provide a physical basis for communication.
The act of transcription may even lead to large-scale changes in chromatin organization and
nuclear positioning. Indeed, one study showed that antisense transcription through alternate promoters
within the Pcdhα (protocadherin alpha) locus establishes enhancer/promoter looping interactions that, in
turn, drive sense transcription from an individual Pcdhα promoter (Canzio et al., 2019). Critically,
antisense transcription promotes CpG demethylation at promoter-proximal CTCF sites, enabling CTCF to
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bind and form de novo chromatin loops. Additional studies attest to the prevalence of this cis-regulatory
mechanism and further reveal the extent to which lncRNAs may regulate nuclear architecture. In addition
to coordinating interactions between the Bcl11b locus and its intergenic enhancers, ThymoD also
repositions the Bcl11b locus from the lamina to the nuclear interior (Isoda et al., 2017). Like antisense
transcription through Pcdhα promoters, ThymoD transcription mediates local CpG demethylation to
permit CTCF binding and chromatin looping. This transcriptional and looping process additionally causes
the entire locus to relocalize to the transcriptionally permissive euchromatic compartment, although the
precise molecular mechanism underlying this repositioning remains unclear.

RNA processing events
Many lncRNAs are extensively processed, suggesting that lncRNA processing—and not merely
transcription—could play a regulatory role. Indeed, several lncRNAs have a mechanistic requirement for
processing events, including both splicing and 3’ end formation.
Although lncRNAs exhibit little overall conservation, the widespread conservation of lncRNA
splicing enhancers implicates splicing as a potential mediator of lncRNA functionality (Haerty and
Ponting, 2015). Several lines of evidence establish the fundamental plausibility of this mechanism. One
study found that deletion of the first 5’ splice site of the murine lncRNA Blustr (bivalent locus (Sfmbt2)
is regulated by the splicing and transcription of an RNA) led to a significant reduction in the expression of
the nearby protein-coding gene Sfmbt2 (SCM-containing gene with four MBT domains 2)(Engreitz et al.,
2016). Curiously, abolishing Blustr splicing at downstream splice sites did not appear to affect Sfmbt2
transcription, pointing to a critical requirement for TSS-proximal splicing. Additional work has shown
that active enhancers often yield spliced lncRNAs, suggesting a positive correlation between splicing and
enhancer activity (Gil and Ulitsky, 2018). While these reports provide exciting evidence that lncRNA
splicing can play an important role in cis-regulation, the underlying mechanism is opaque. TSS-proximal
splicing has previously been shown to enhance gene expression by as much as 100-fold (Brinster et al.,
1988; Fong and Zhou, 2001), likely because associations between the U snRNPs and general transcription
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factors increase the local concentration of these factors at the lncRNA promoter, increasing their
availability for nearby protein-coding genes (Fong and Zhou, 2001). In light of this, it is unclear whether
Sfmbt2 requires splicing per se or whether the requirement for splicing reflects a more general
requirement for transcription from the Blustr promoter.
Other features of lncRNA biogenesis have also been shown to contribute to cis-regulation. The
intergenic lncRNA A-rod (activating regulator of Dkk1) and the nearby protein-coding gene Dkk1
(Dickkopf homolog 1) serve as an example for how cleavage and polyadenylation may mediate lncRNA
function (Ntini et al., 2018). Although A-rod transcription enhances Dkk1 expression, Dkk1 does not
require nascent A-rod, which remains tethered to the chromatin. Instead, the dissociation of spliced and
polyadenylated A-rod from the chromatin permits it to exploit pre-existing chromatin interactions and
localize to the spatially-proximal Dkk1 locus, where it recruits the general transcription factor EBP1. As
illustrated by this example, processes such as 3’ end formation may regulate the accessibility of lncRNAs
to both protein interaction partners and other loci, thereby acting as another mechanism of cis-regulation
(Gil and Ulitsky, 2020).

DNA elements
The genome harbors myriad cis-regulatory elements, including both enhancers and promoters,
that are characterized by features such transcription factor binding sites and a low nucleosome occupancy
(Melé et al., 2017). The observation that Pol II readily initiates transcription from regions of open
chromatin has given rise to the hypothesis that most noncoding transcriptional events are noise and
generate non-functional “junk” RNAs (Kung et al., 2013; Struhl, 2007). Under this paradigm, DNA
sequence elements within a functional lncRNA locus may be wholly sufficient to account for local
regulatory activity; in this case, the transcriptional process and presence of a discrete lncRNA are
biological “red herrings” with no functional relevance to cis-regulation at the locus.
Several studies compellingly show the importance of properly evaluating this “null hypothesis.”
The intergenic lncRNA LockD (lncRNA downstream of Cdkn1b) is transcribed and processed to yield a
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434 nucleotide transcript that is expressed in many mouse tissues (Paralkar et al., 2016). Intriguingly,
deletion of the nearly 20 kilobase locus incurred a significant decrease in the expression of the nearby
protein-coding gene Cdkn1b (cyclin-dependent kinase inhibitor 1b), implicating LockD as a functional
cis-regulatory lncRNA locus. However, the subsequent insertion of a polyadenylation signal (PAS),
which induces premature transcriptional termination, into the first exon of LockD did not affect Cdkn1b
levels in spite of the near-complete loss of spliced and total LockD expression. This demonstrates the
absence of a requirement for transcription at this locus. Similarly, Bendr (Bend4 regulating effects not
dependent on the RNA) transcription and lncRNA accumulation have been shown to be dispensable for
regulation of the neighboring Bend4 (BEN domain-containing 4) gene (Engreitz et al., 2016). The
deletion of the Bendr promoter—but not the loss of Bendr transcription following the insertion of a PAS
sequence—attenuated transcription of Bend4. In both cases, the discordant effects of genetic deletions and
premature transcriptional termination support the conclusion that the transcriptional process does not
mediate cis-regulation at either of these loci.
Underlying DNA sequences thus appear to account for the cis-regulatory capacity of both of these
lncRNA loci. The LockD promoter exhibits DNAse hypersensitivity and binds numerous general
transcription factors (Paralkar et al., 2016). Critically, the 20 kilobase LockD deletion, which spanned the
promoter, abolished the ability of transcription factors to bind at this locus, likely accounting for its
effects on Cdkn1b transcription. Although the Bendr promoter deletion spanned a more modest ~750
nucleotide region, it also encompassed several known transcription factor binding sites, indicating that it
likely serves as an enhancer for Bend4 (Engreitz et al., 2016).
Taken together, these data suggest that DNA elements—and not the act of transcription or the
activity of the RNA—enact cis-regulation at these two lncRNA loci. As an important note, although these
loci appear to function as enhancer-like elements, neither exhibits the epigenetic signature of a “classical”
enhancer (Calo and Wysocka, 2013). While enhancers are typically enriched for H3K4me1 relative to
H3K4me3, the promoters of LockD and Bendr both have prominent H3K4me3 peaks. Moreover, while
enhancer transcription is often bidirectional and commonly gives rise to unspliced, non-polyadenylated
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transcripts (Andersson et al., 2014; Kim et al., 2010), the LockD and Bendr loci are both unidirectionally
transcribed to yield processed RNAs (Engreitz et al., 2016; Paralkar et al., 2016). This raises the
possibility that many lncRNA loci generate non-functional RNAs and instead act primarily as enhancerlike elements. The existence of such a class of transcribed DNA elements with noncanonical chromatin
marks indicates that a gene-like epigenetic signature does not establish a functional requirement for
transcription. These examples therefore illustrate the importance of developing new heuristics for
distinguishing between enhancers and functional lncRNAs. Additionally, they demonstrate the necessity
of properly addressing the possibility that DNA elements may be sufficient to account for the cisregulatory activity of functional lncRNA loci.

Conclusion
As the preceding examples illustrate, cis-regulatory lncRNA loci act through a variety of
mechanisms to modulate the expression of neighboring genes. Careful mechanistic studies have identified
numerous examples of bona fide lncRNAs that act either post- or co-transcriptionally. The existence of
these lncRNAs serves as tantalizing evidence that pervasive genomic transcription may represent more
than transcriptional noise. However, the observation that many enhancer-like elements are incidentally
transcribed to yield dispensable transcripts with many of the traditional hallmarks of functional lncRNAs
demonstrates the importance of experimentally validating putative lncRNA loci. Future work will likely
identify lncRNAs with additional modes of action. This will simultaneously expand our understanding of
the role of noncoding transcription and challenge our ability to resolve new and complex mechanistic
phenomena.
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Tools for studying cis-acting noncoding RNAs
The unique relationship between cis-acting lncRNA loci and their gene products poses major
experimental challenges. The ever-expanding repertoire of molecular and genetic tools provides many
exciting avenues for manipulating gene expression; however, the majority of these strategies disrupt
multiple elements of lncRNA biogenesis and function, making their effects difficult to evaluate. It is
therefore imperative to understand both the advantages and experimental caveats of each approach when
investigating the function of cis-acting lncRNAs (Bassett et al., 2014; Kopp and Mendell, 2018).

Molecular
Molecular tools provide an opportunity for manipulating transcription and RNA accumulation
without altering the underlying DNA sequence (Fig. 2). These approaches are alluring on account of the
relative ease and rapidity with which they can be implemented; however, many have been shown to incur
significant off-target effects, casting doubt on their reliability (Goudarzi et al., 2019; Stojic et al., 2018).
As a result, researchers must take care to use multiple approaches or targeting sequences to confirm the
specificity of any putative phenotype.

RNA interference (RNAi):
RNAi exploits the ability of small interfering RNAs (siRNAs) to mediate the homologydependent cleavage and degradation of target transcripts. In this approach, siRNA “guide strands”
associate with components of the RNA-induced silencing complex (RISC), which includes the
endonuclease Ago2 (Argonaute-2). Ago2, in turn, cleaves within the target RNA, yielding an upstream
fragment that can be degraded by the RNA exosome (Lima et al., 2016) as well as a downstream fragment
that may be degraded by 5’-3’ exonucleases such as XRN1 or XRN2 (Lima et al., 2016).
Although RNAi efficiently depletes cytoplasmic transcripts, its activity in the nucleus is more
controversial (Lennox and Behlke, 2016). Several studies have reported that RNAi factors are present and
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Figure 2. Molecular approaches for interrogating lncRNA function. A number of molecular tools
may perturb lncRNA transcription, processing, accumulation, and function without altering the
underlying DNA sequence. RNAi may attenuate transcription or prevent transcript accumulation,
although its efficacy for knocking down nuclear—and in particular, chromatin-enriched—transcripts
remains controversial. ASO gapmers act co- or post-transcriptionally to trigger RNAse H-dependent
RNA degradation. Alternatively, non-gapmer ASOs may be used to inhibit secondary structure
formation or prevent RNA-protein interactions without incurring RNA knockdown. Catalytically
inactive Cas9/CRISPR-based tools can be used to block transcription or occlude transcription factor
binding sites within a locus. Alternatively, Cas9 may be fused to activating (CRISPRa) or repressive
(CRISPRi) effector domains in order to modulate local transcription. Lastly, programmable RNAtargeting enzymes such as Cas13 may be used to either destabilize target transcripts or impair RNA
processing and function.
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active in the nucleus (Gagnon et al., 2014; Robb et al., 2005), where they have been proposed to mediate
both post-transcriptional RNA knockdown and transcriptional silencing (Morris et al., 2004). However,
other studies have observed lower knockdown efficacies for nuclear targets, casting doubt on the
robustness of this approach (Bassett et al., 2014; Lennox and Behlke, 2016; Lima et al., 2016; Stojic et
al., 2018). It is therefore difficult to evaluate data from studies that use RNAi to knock down cis-acting
lncRNAs.

Antisense oligonucleotides (ASOs):
“Gapmer” ASOs represent a well-established molecular approach for knocking down both
nuclear and cytoplasmic RNAs (Lennox and Behlke, 2016). These single-stranded oligonucleotides
typically comprise a central DNA sequence flanked by nuclease-resistant nucleotides such as locked
nucleic acids. ASOs bind complementary sequences within their target RNAs, forming an RNA:DNA
heteroduplex. RNAse H subsequently cleaves the RNA strand of this hybrid complex (Wu et al., 2004),
yielding unprotected RNA fragments that are rapidly degraded by the RNA exosome (Lima et al., 2016)
and the 5’-end surveillance factors XRN1 and XRN2 (Hori et al., 2015; Lima et al., 2016). Although
gapmers can effect post-transcriptional RNA depletion, as evidenced by their ability to act in the
cytoplasm (Liang et al., 2017), recent work reveals that they may also promote the co-transcriptional
cleavage and degradation of target RNAs (Lai et al., 2020; Lee and Mendell, 2020). Of particular
significance for studies on cis-acting lncRNAs, ASOs targeting sequences proximal to the TSS may
mediate a significant reduction in transcription upstream of the targeting site (Lee and Mendell, 2020),
making it difficult to distinguish between the effects of RNA knockdown and changes in the local
transcriptional landscape. These studies therefore underscore the need for caution when interpreting the
results of gapmer knockdown experiments.
A second class of ASOs can inhibit RNA processing and function without triggering RNAse Hdependent RNA degradation. For example, morpholino oligomers targeting splice sites may impair
splicing and impede the accumulation of mature RNA species (Almada et al., 2013; Ulitsky et al., 2011).
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Alternatively, ASOs targeting splicing enhancers or repressors may promote exon skipping or retention.
Lastly, these ASOs may be used to protect microRNA targets (Choi et al., 2007) or sterically block RNAprotein interactions (Ntini et al., 2018). Together, these tools can help unravel the post-transcriptional role
of noncoding RNAs.

CRISPR/Cas-based approaches:
Since the initial characterization of the CRISPR/Cas9 system in 2013, researchers have reported
many innovative applications for CRISPR-associated (Cas) proteins. In addition to their revolutionary
role in gene editing (discussed below), these proteins have been shown to serve as a programmable
platform for gene regulation. Cas9-based tools have proven particularly versatile as both negative and
positive effectors of transcription. However, ongoing research also implicates other Cas proteins as
exciting tools for regulating RNA processing, editing, and stability.

Loss-of-function:
Researchers have implemented several CRISPR/Cas-based loss-of-function approaches for
studying both coding and noncoding loci. The simplest of these approaches exploits the ability of Cas9 to
sterically block transcriptional elongation when targeted downstream of a TSS (Gilbert et al., 2013; Qi et
al., 2013). To avoid cleaving the DNA target, researchers can either use catalytically dead Cas9 (dCas9)
in conjunction with a standard guide RNA (gRNA) or use active Cas9 in tandem with a 14-15 nucleotide
“dead” gRNA (dRNA) that permits target binding without incurring nuclease activity (Dahlman et al.,
2015). This so-called “transcriptional roadblock” approach has been shown to yield a 60-80% decrease in
gene expression (Gilbert et al., 2013).
Alternatively, Cas9-fusion proteins can be used to modulate the epigenetic landscape around a
TSS (CRISPRi). When fused to Cas9 or dCas9, the repressive Krüppel-associated box (KRAB) recruits
histone-methylating and -deacetylating complexes to a region centered around its binding site, enacting
local repression (Thakore et al., 2015). Although this strategy appears to have minimal off-target activity
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(Moses et al., 2020; Stojic et al., 2018), its consequences for neighboring gene expression remain unclear:
studies have reached mixed conclusions regarding the potential of KRAB to induce heterochromatin
spreading over regions as large as 20 kilobases (Groner et al., 2010; Thakore et al., 2015). Since many
cis-acting lncRNAs are located in close proximity to their neighboring genes, this raises the unfortunate
possibility that KRAB may directly silence both targeted and nearby genes. It may therefore be necessary
to monitor local H3K9me3 levels when investigating cis-regulation over short distances.
Other Cas proteins may enact repression through their interactions with target RNAs. Cas13, the
archetypal CRISPR Class 2 Type VI protein, binds RNAs in a programmable RNA guide-dependent
manner (Konermann et al., 2018). Cas13 proteins mediate the cleavage of target transcripts and have been
reported to mediate a specific 50-90% decrease in RNA levels (Abudayyeh et al., 2017; Konermann et al.,
2018). Intriguingly, the Cas13 family proteins Cas13a and Cas13b have been shown to generate upstream
and downstream fragments with a 2’,3’-cyclic phosphate and a 5’-hydroxyl, respectively (Gootenberg et
al., 2018). This raises the tantalizing possibility that co-transcriptional cleavage may not incur cotranscriptional RNA degradation by XRN2, which exhibits a preference for substrates with 5’-phosphate
groups (West et al., 2004). Like Cas9, Cas13 can be rendered catalytically inactive (dCas13) via point
mutations within each of its two endonuclease domains. This observation implicates CRISPR/Cas13 as a
programmable RNA-binding platform. Indeed, researchers have successfully used dCas13 to restore
normal splicing of Smn2 (survival motor neuron 2) in fibroblasts from patients with spinal muscular
atrophy, a neuromuscular disorder caused by aberrant Smn2 splicing (Du et al., 2020). Additionally,
dCas13-fusion proteins show promise as tools for RNA editing. For example, Cas13-ADAR (adenosine
deaminase acting on RNA) fusion proteins can mediate A-to-I editing, facilitating the site-specific
modification of target transcripts (Cox et al., 2017).
While the identification and implementation of Cas13 family proteins opens up an exciting new
chapter in our ability to regulate RNA expression, two major obstacles remain unaddressed. Firstly, the
principles governing the design of efficient gRNAs are murky. Although some groups claim to have
developed rules for rational gRNA design (Bandaru et al., 2020; Wessels et al., 2020), the paucity of more
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recent studies suggests that this problem requires additional attention. Secondly, and perhaps more
concerningly, RNA guide-matching can trigger Cas13d to cleave “bystander” RNAs (Abudayyeh et al.,
2016; Konermann et al., 2018; Wang et al., 2019a). However, the extent of this so-called “collateral
effect” remains unclear, with one study even reporting that CRISPR/Cas13 collateral activity is virtually
undetectable in mouse and zebrafish embryos (Kushawah et al., 2020). Additional work will doubtlessly
unlock the potential of these tools to enhance our understanding of cis-acting lncRNA function.

Gain-of-function:
By definition, cis-acting lncRNAs regulate gene expression in a locus-specific manner. Common
gain-of-function approaches such as transgene overexpression are therefore ill-suited for studying the
function of lncRNAs whose transcription, processing, or accumulation operates locally. CRISPR/Cas9based technology provides two major strategies for bypassing this problem.
CRISPR/Cas9-based gene activation (CRISPRa) uses Cas9 or dCas9 to recruit transcriptional
activators to a target site. Similar to CRISPRi, Cas9 may be directly fused to transcriptional activators
such as VP16, p65, or RTA (Chavez et al., 2015; Gilbert et al., 2013). While genome-wide screens
demonstrate the fundamental viability of this approach (Gilbert et al., 2014), other strategies may
facilitate more robust transcriptional activation. For example, the synergistic activation mediator (SAM)
system uses a chimeric gRNA harboring two MS2 stem-loops to recruit the MS2 bacteriophage coat
protein. This, in turn, is fused to the bipartite p65-HSF1 transcriptional activator (Konermann et al.,
2015). Since the MS2 coat protein binds its stem-loop as a dimer, this approach allows for one Cas9
complex to bind up to four activator complexes, thereby enhancing its ability to upregulate target genes.
Importantly, CRISPRa appears to mediate efficient transcriptional activation only when targeted within
~200 nucleotides of a TSS (Gilbert et al., 2014; Joung et al., 2017; Konermann et al., 2015). While this
inherently limits the sequence space available for targeting, it suggests that CRISPRa may be a viable
approach for studying lncRNAs that are located in close proximity to their target genes.
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A second class of Cas9-based tools uses dCas9 to recruit exogenous RNAs to a lncRNA locus. In
this approach, termed CRISPR-display, the RNA guide is fused to an exogenous RNA sequence; this, in
turn, facilitates the delivery of the RNA cargo to a locus of interest (Shechner et al., 2015). Since the
chimeric gRNA is exogenously expressed, this strategy provides an opportunity to divorce the locusspecific accumulation of lncRNA molecules from features such as transcription or DNA elements.
Though exciting, this technique has not been widely adopted, making it difficult to evaluate its
experimental value.

Genetic
In contrast to protein-coding genes, whose products may be compromised by small insertions and
deletions that disrupt ORFs, lncRNAs exhibit less obvious sequence requirements, making it difficult to
genetically ablate lncRNA expression without dramatically altering the underlying DNA sequence. Given
the unique considerations and challenges posed by each lncRNA locus, researchers have developed a
number of genetic approaches for modulating lncRNA biogenesis and function both in vitro and in vivo
(Fig. 3). The merits and pitfalls of each approach are discussed below.

Knockout strategies:
A number of studies have used largescale deletion-based approaches to establish the functionality
of lncRNA loci (Dimitrova et al., 2014; Engreitz et al., 2016; Hacisuleyman et al., 2014; Li et al., 2013a;
Schorderet and Duboule, 2011). This approach entails the genetic ablation of either an entire lncRNA
locus or a smaller region encompassing the promoter. While this strategy can provide exciting
preliminary evidence for lncRNA functionality, it cannot distinguish the role of transcription and the
resulting RNA from the role of regulatory DNA elements within the locus (Bassett et al., 2014).
Moreover, large deletions have the potential to disrupt the spacing between protein-coding genes and
regulatory elements outside the locus. This, in turn, may mediate the dysregulation of genes whose
activity is not subject to cis-regulation by the deleted locus.
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Figure 3. Genetic approaches for interrogating lncRNA function. Genetic techniques facilitate the
dissection of lncRNA activity. Large-scale deletion approaches, which abrogate transcription and RNA
accumulation by destroying the entire locus or promoter region, can establish a functional requirement
for a lncRNA locus but cannot specifically test the significance of the transcriptional process.
Similarly, CRISPR/Cas9 mutagenesis experiments may reveal minimal sequence elements that drive
both lncRNA and protein-coding gene expression but cannot distinguish between DNA elements that
act directly and elements that act through lncRNA biogenesis and accumulation. Reporter gene
substitution, which entails the substitution of a reporter gene such as lacZ for all or part of a lncRNA
locus, disrupts DNA elements and the RNA sequence while permitting some degree of transcription.
Locus inversion approaches, which leave critical DNA sequences intact, may be used to test the
functionality of transcription or RNA sequence elements. Similarly, genetic knock-in strategies
interrogate the role of transcription and RNA accumulation without destroying the underlying DNA
sequence. PAS sequences prematurely terminate transcription, while self-cleaving ribozymes promote
RNA destabilization.
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To avoid this potential caveat, other studies have used CRISPR/Cas9 to achieve precise
mutagenesis of known regulatory elements such as transcription factor binding sites and 5’ splice sites
(Engreitz et al., 2016; Korkmaz et al., 2016; Li et al., 2017; Olivero et al., 2020). While this approach
minimally disrupts the chromatin neighborhood surrounding the lncRNA locus, it may attenuate or even
abolish lncRNA transcription and accumulation. In this case, it may still be difficult to distinguish
between a requirement for sequence elements and a requirement for lncRNA transcription (Bassett et al.,
2014).

Transcript substitution:
Transcript substitution entails the partial or complete replacement of a lncRNA locus with a
reporter gene such as LacZ or GFP. While the reporter gene ostensibly recapitulates the expression of the
lncRNA in different cell types and biological conditions (Goff et al., 2015; Groff et al., 2016; Sauvageau
et al., 2013), the absence of key DNA sequence elements may lead to aberrant reporter gene expression
(Bassett et al., 2014). Moreover, although this strategy permits transcription, sequence differences,
including the absence of splice sites in some reporter substitution approaches, may alter the
transcriptional kinetics of the locus (Brinster et al., 1988; Engreitz et al., 2016; Suter et al., 2011). If
nearby genes are sensitive to lncRNA transcription or processing, then this approach may yield a
phenotype even if the DNA sequence does not per se harbor cis-regulatory activity.

Locus inversion:
Inversion-based strategies have the advantage of disrupting lncRNA transcription and function
without deleting key DNA sequence elements (Bassett et al., 2014). Some researchers have inverted
promoter sequences in order to abolish lncRNA transcription (Pease et al., 2013). Others have inverted
regions that harbor putative RNA elements (Senner et al., 2011). While such approaches leave the DNA
sequence intact, large inversions may disrupt the spacing between regulatory elements and their target
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genes (Delpretti et al., 2013). Additionally, the inherent bidirectionality of promoters may limit the utility
of locus inversion as an approach for abrogating transcription. These considerations underscore the need
for caution when interpreting results from locus inversion experiments.

Knock-in strategies:
With a few exceptions, the genetic approaches outlined above perturb both the DNA sequence
and lncRNA biogenesis. Genetic knock-in strategies, in which a sequence element is inserted into an
otherwise-intact locus, provide a means of altering lncRNA transcription and stability without deleting
potentially critical DNA sequence elements.

Polyadenylation signals:
Eukaryotic PAS elements represent a well-established strategy for inducing premature
transcriptional termination both in vitro and in vivo. These elements, which comprise a canonical
A(A/U)UAAA hexamer located 30 nucleotides upstream of a GU-rich tract, stimulate the 3’ endprocessing machinery to cleave and polyadenylate nascent transcripts (Millevoi and Vagner, 2010).
Similar to RNAse H-mediated cleavage, this yields an unprotected downstream fragment that is
progressively degraded by the nuclear 5’ end surveillance factor XRN2. XRN2 displaces RNA
polymerase II from the DNA template, abolishing transcription. This process typically occurs within two
kilobases of the PAS, although transcription may occasionally continue for more than ten kilobases (Core
et al., 2008).
A number of PAS sequences have been shown to successfully suppress transcription from
endogenous loci. The synthetic rabbit β-globin PAS has previously been used to induce premature
transcriptional termination in vitro and appears to be most efficient when inserted within close proximity
to a TSS (Engreitz et al., 2016; Levitt et al., 1989). The short length (49 nucleotides) of this sequence
makes it particularly attractive as a tool for knocking down lncRNA expression, since it minimally
disrupts the spacing of DNA elements within a locus. Longer elements comprising three tandem PAS
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sequences may prove more appropriate for inducing transcriptional termination at regions distal from a
TSS, although they will inherently have more of an effect on the spacing of the locus.
As an important consideration, premature transcriptional termination, particularly termination
upstream of the first intron, may have significant consequences for transcriptional initiation (Brinster et
al., 1988; Engreitz et al., 2016). It has long been known that the U1 small nuclear ribonucleoprotein
(snRNP) can bind general transcription factors (Fong and Zhou, 2001; Kwek et al., 2002). Cotranscriptional splicing may therefore recruit Pol II and enhance transcriptional initiation and elongation.
On account of the tight coupling between splicing and transcription, PAS insertion may attenuate
transcription from a lncRNA TSS in addition to suppressing transcription downstream of the insertion site
(Engreitz et al., 2016).

Self-cleaving ribozymes:
Self-cleaving ribozymes represent an emerging class of tools for dissecting endogenous lncRNA
function. These naturally-occurring RNA sequences form unique secondary and tertiary structures that
enable them to enact site-specific phosphodiester scission (Jimenez et al., 2015). Unlike the cleavage
events mediated by RNAse H and the cleavage and polyadenylation machinery, ribozyme cleavage yields
an upstream fragment with a 2’-3’ cyclic phosphate as well as a downstream fragment with a 5’-hydroxyl
group (Roth et al., 2014). In mammalian cells, the upstream fragment likely undergoes rapid degradation
by the RNA exosome; the fate of the downstream fragment is less obvious. While the nuclear exosome
readily degrades RNAs with 2’-3’ cyclic phosphates (Zinder et al., 2016), 5’-3’ exoribonucleases such as
XRN2 exhibit a stringent requirement for RNAs with 5’-phosphate groups (Doamekpor et al., 2020; Jinek
et al., 2011; Mathy et al., 2007; West et al., 2004). This raises the possibility that fast-acting ribozymes
such as the Hepatitis Delta ribozyme and Twister may cleave lncRNA transcripts without incurring
transcriptional termination by XRN2.
The functional consequences of co-transcriptional ribozyme cleavage remain murky. While selfcleaving ribozymes do not appear to affect mRNA stability in the context of short reporter gene constructs
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(Bird et al., 2005; Fong et al., 2009; NOTT et al., 2003; West et al., 2004), a handful of pioneering studies
show that they can be used to destabilize endogenous lncRNAs (Camblong et al., 2009; Tuck and Bühler,
2021; Tuck et al., 2018; Wery et al., 2018a). The Hammerhead and Hepatitis Delta ribozymes have both
been shown to suppress lncRNA accumulation in mouse and yeast cells, although the knockdown
efficiency varies considerably across lncRNA targets (Camblong et al., 2009; Tuck and Bühler, 2021;
Tuck et al., 2018). The reason for the observed discrepancies in efficiency between mRNAs and lncRNAs
and between individual lncRNAs is presently unclear. It is possible that factors such as the distance of the
ribozyme from a TSS or transcription termination site (TTS) may affect the stability of the nascent
transcript; additionally, the effects of ribozyme cleavage may be more pronounced in the context of
endogenous loci, which are often many times longer than reporter genes and therefore require more time
to generate a full-length, processed transcript. On the whole, the experimental variability in ribozyme
efficiency highlights the lack of clear criteria for determining optimal ribozyme placement. As a further
challenge, the molecular effects of co-transcriptional ribozyme cleavage on lncRNA transcription and
processing are still enigmatic. Subsequently, it remains difficult to determine the mechanistic basis for
any changes to nearby gene expression.

Conclusion
In summary, researchers have developed an extensive set of molecular and genetic tools for
manipulating the expression of cis-acting lncRNAs. On account of their idiosyncrasy, however, cis-acting
lncRNA loci do not lend themselves to a one-size-fits-all approach. The merits of each tool must be
evaluated in the context of each locus; and depending on the unique considerations posed by each gene
neighborhood, individual tools may prove insufficient for distinguishing between competing mechanisms.
In this case, multiple orthogonal strategies may help to resolve outstanding questions at technically
challenging loci. In this work, we used complementary molecular and genetic strategies to identify the
functional element of cis-regulation at the LincRNA-p21 locus. Additionally, we set out to rigorously
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characterize the molecular effects of ribozyme cleavage on transcription in the context of our locus. We
present specific experimental details in Chapters III and IV.
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Chapter II: Project framework
LincRNA-p21: a functional mediator of the p53 pathway
The p53 tumor suppressor pathway
The p53 pathway lies at the heart of the cellular response to stress. On account of its central role
in response to diverse biological stressors, the tumor suppressor protein p53 has earned the appellation
“guardian of the genome” and secured a vaunted spot at the top of the list of the most frequently studied
human genes (Dolgin, 2017). Following exposure to adverse stimuli such as DNA damage, oncogenic
signaling, oxidative stress, and nutrient deprivation (Sermeus and Michiels, 2011), p53 activates complex
transcriptional programs that promote various functional outcomes. These consequences include cell
cycle arrest, DNA damage repair, senescence, and even apoptosis (Vousden and Prives, 2009). Although
the mechanisms through which p53 specifies cell fate in response to disparate stimuli remain murky, the
centrality of p53 in each of these pathways is readily apparent. As a grim testament to its importance, both
humans and mice deficient for p53 show a propensity to develop a broad range of cancers (Donehower et
al., 1992; Olivier et al., 2010). Moreover, the p53 protein is inactivated in more than 50% of cancers,
marking it as the gene most frequently inactivated during tumorigenesis (Kastenhuber and Lowe, 2017).
A poor patient prognosis typically accompanies p53 inactivation (Olivier et al., 2010), further
demonstrating the broad importance of the p53 transcriptional network.
Like p53 loss-of-function, p53 overexpression has deleterious cellular and organismal effects
(Kastenhuber and Lowe, 2017). Cells therefore employ several regulatory mechanisms to escape the
pathological consequences of inappropriate p53 signaling. Under conditions of homeostasis, the
constitutively-translated p53 protein undergoes rapid degradation, primarily as a result of its interactions
with MDM2 (mouse double minute 2). This E3 ubiquitin ligase binds and ubiquitylates p53, mediating its
degradation by the proteasome and subsequently inhibiting p53 accumulation (Haupt et al., 1997;
Kubbutat et al., 1997; Kussie et al., 1996). Other protein factors also exert modest repressive effects on
p53 signaling. For example, the MDM2 homolog MDM4 (mouse double minute 4), which lacks ubiquitin
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ligase activity, binds to and occludes p53’s transactivation domain, preventing it from interacting with
transcriptional co-activators (Toledo and Wahl, 2007). Together, these repressors enact a strict regulatory
paradigm that suppresses signaling under homeostatic conditions while leaving p53 poised for rapid
activation in response to cellular stressors.
Such stressors may activate p53 expression through different context-dependent mechanisms.
Oncogenic signaling, for example, activates the tumor suppressor ARF (alternative reading frame of
CDKN2A), which binds and destabilizes MDM2 (Zhang et al., 1998). This relieves p53 from constitutive
repression, permitting its accumulation within the cell. Alternatively, the presence of DNA damage may
mediate the post-translational modification of p53, altogether abrogating its ability to bind to MDM2
(Shieh et al., 1997). Such post-translational modifications both enhance p53’s stability and contribute to
its ability to effect transactivation.
Once stabilized, p53 translocates into the nucleus, where it induces the expression of myriad
transcriptional targets. To accomplish this, the p53 protein forms tetramers that bind to and “scan”
genomic DNA for p53 responsive elements (p53REs)(Tafvizi et al., 2011). These genomic elements
comprise two decameric half-sites, separated by a spacer of 0-13 nucleotides, with the consensus
sequence 5’-RRRCWWGYYY-3’ (El-Deiry et al., 1992). As a pioneer transcription factor, p53 readily
binds to p53REs in diverse chromatin environments (Laptenko et al., 2011; Nili et al., 2010; Sammons et
al., 2015). Once bound to the chromatin, p53 may recruit chromatin remodeling factors, histone
acetyltransferases, or general transcription factors (Dornan et al., 2003; Lee et al., 2002; Zilfou et al.,
2001). This, in turn, creates a transcriptionally permissive epigenetic environment and facilitates the
expression of nearby gene targets.
Intriguingly, p53 frequently associates with response elements in intergenic regions, including
enhancers (Léveillé et al., 2015; Tesfaye et al.; Younger et al., 2015). Many of these intergenic p53REs
appear to be functional in spite of their large genomic distance from protein-coding genes. Recently, p53
has attracted considerable attention as a potential mediator of long-range chromatin looping (Link et al.,
2013; Melo et al., 2013). p53 primarily binds each p53RE as a tetramer (Stenger et al., 1992, 1994; Wang
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et al., 1995), and p53 tetramers may further oligomerize to promote looping interactions between p53
sites separated by over a kilobase (Stenger et al., 1994). Notably, many p53-bound enhancers are located
in close spatial—if not genomic—proximity to p53-responsive genes, raising the possibility that p53
binding might promote chromatin reorganization. However, 3D chromatin interactions between p53bound enhancers and promoters are largely p53-insensitive (Link et al., 2013; Melo et al., 2013),
suggesting that p53 exploits pre-established chromatin contacts rather than specifying de novo
interactions. These reports, which indicate that p53 is unlikely to be a major determinant of chromatin
architecture, thus provide a plausible alternative mechanism through which distal p53REs can regulate
their target genes.
p53 binding induces the expression of numerous transcriptional targets. Historically, efforts to
investigate the effects of p53 signaling and dysregulation have focused primarily on protein-coding genes,
including the cell cycle arrest mediator p21 (also known as Cdkn1a and p21WAF/Cip1). Although among the
first p53 target genes to be discovered, p21 remains an active subject of investigation on account of its
outsized role in p53-mediated transcriptional repression (Fischer, 2017). Upon exposure to stress, p53
activates p21 transcription through two p53REs within the p21 promoter (El-Deiry et al., 1994; Espinosa
and Emerson, 2001). Once generated, p21 protein may either remain in the cytoplasm or translocate into
the nucleus. There, it enacts its tumor suppressive effects by inhibiting the ability of cyclin-dependent
kinases (CDKs) to phosphorylate Rb (retinoblastoma) family proteins (Brugarolas et al., 1995; Harper et
al., 1995; Wade Harper et al., 1993; Xiong et al., 1993). Since this phosphorylation prevents Rb family
proteins from repressively associating with E2 family (E2F) transcription factors and blocking the
transcription of key cell cycle progression genes (Harbour and Dean, 2000), p21 activity supports
transcriptional repression by the Rb-E2F complex. Using a similar mechanism, p21 also promotes the
assembly of the DREAM (dimerization partner, Rb-like, E2F, and multivulval class B) complex, which
downregulates a broad class of target genes. Additionally, p21 sequesters PCNA, preventing it from
interacting with DNA polmerase δ and initiating DNA replication (Chen et al., 1995; Luo et al., 1995).
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These parallel mechanisms have important cellular consequences. Replication inhibition and
transcriptional repression of cell cycle genes both impede cell cycle progression from G1 into S phase
(Harper et al., 1995). Critically, this prevents cells from replicating damaged DNA and instead provides
them with a critical opportunity to repair compromised templates (Shaltiel et al., 2015). Moreover, the
DREAM complex likely underlies p21’s ability to regulate the G2/M checkpoint (Bunz et al., 1998). In
some cases, p21 activation can also lead to permanent growth arrest (i.e., cellular senescence). How p21
levels influence cells’ decisions to enter transient growth arrest or permanently senesce remains an active
area of investigation (Hsu et al., 2019).
Over the past decade, noncoding RNAs have been implicated as key effectors of the p53 pathway
and have generated significant excitement on account of their proposed role in outcome specificity
(Vousden and Prives, 2009). The discovery of p53-regulated miRNAs dramatically enhanced our
understanding of the downstream mechanisms of p53 signaling. And more recently, transcriptomics
studies have implicated lncRNAs as a novel class of p53 targets in both humans and mice (Sánchez et al.,
2014; Tesfaye et al.). Like protein-coding genes, these p53-inducible lncRNAs may show either universal
or context-specific expression, as elegantly illustrated by one recent study, which used RNA profiling to
examine the consequences of p53 expression in a panel of p53-deficient mouse cancer cell lines. Notably,
cancer cell lines that exhibited similar functional outcomes (i.e., senescence or apoptosis) in response to
p53 activation showed similar p53-dependent lncRNA transcriptional signatures (Tesfaye et al.). This
intriguing correlation between lncRNA expression and functional outcome raises the possibility that
lncRNAs may help govern context-specific p53 outcomes, adding a new regulatory dimension to the p53
tumor suppressor network. Indeed, a growing body of work has demonstrated the ability of p53responsive lncRNAs enact diverse functional consequences (see Chapter I)(Dimitrova et al., 2014;
Olivero et al., 2020; Tesfaye et al.). The remainder of this work will largely focus on the role of the p53inducible lncRNA LincRNA-p21 in transcriptional activation of the nearby p21 gene.
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The long noncoding RNA LincRNA-p21 in the p53 tumor suppressor pathway
The lncRNA LincRNA-p21 has garnered intense interest on account of its enigmatic role within
the p53 pathway. This lncRNA, which in mice spans a ~20 kilobase locus in the intergenic region
between the Srsf3 (serine and arginine rich splicing factor 3) gene and the p21 cell cycle checkpoint
inhibitor, was named for its close proximity to the p21 locus (Fig. 4). Although the human LincRNA-p21
locus occupies a smaller genomic footprint (approximately four kilobases), the human and mouse
LincRNA-p21 loci share several important commonalities. Notably, in both species, the LincRNA-p21 and
p21 transcriptional units constitute a non-overlapping head-to-head pair separated by a distance of just
over ten kilobases. Moreover, although LincRNA-p21 exhibits only modest conservation at the sequence
level, mouse and human LincRNA-p21 share a ~200 nucleotide region of homology at their 5’ ends
(Chillón and Pyle, 2016). In keeping with the finding that lncRNA loci often harbor conserved
transcription factor binding sites, this region includes binding sites for both p53 and hnRNP-K (Chillón
and Pyle, 2016; Wu et al., 2014). Taken together, these conserved features seem to attest to the
importance of the spatial relationship at this locus and hint at a common regulatory role in humans and
mice.
LincRNA-p21 was first identified in a screen for murine lincRNAs with high levels of H3K4me3
and H3K36me3 in their promoters and gene bodies, respectively (Guttman et al., 2009). This so-called
H3K4me3-H3K36me3 signature, a hallmark of active Pol II transcription, suggested that the LincRNAp21 locus might be transcribed into a lncRNA. (Importantly, its CSF score strongly argues against the
possibility that it could be subsequently translated (Guttman et al., 2009)). Indeed, the mouse LincRNAp21 locus gives rise to a 3.1 kilobase RNA that is capped, spliced, and polyadenylated (Guttman et al.,
2009; Huarte et al., 2010). Meanwhile, the human locus has been variously proposed to encode a spliced
transcript or two single-exon isoforms: a short, polyadenylated transcript and a longer, nonpolyadenylated transcript (Chillón and Pyle, 2016; Yoon et al., 2012). Consistent with the observation
that its promoter harbors a p53RE, DNA damage was shown to induce LincRNA-p21 expression in the
context of wildtype, but not p53-deficient, mouse embryonic fibroblasts (MEFs)(Guttman et al., 2009).
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Figure 4. Historical characterization of the LincRNA-p21 locus. Schematic of the murine LincRNAp21 locus highlighting molecular and genetic approaches that established its cis-regulatory function.
Red arrows indicate the location of loxP sites used to generate conditional LincRNA-p21 knockout
cells, while white boxes show the relative position of two ASO gapmers targeting the LincRNA-p21
intron (ASO-I) and second exon (ASO-E2)(Dimitrova et al., 2014). The lacZ substitution strategy is
represented by the blue box (Groff et al., 2016; Sauvageau et al., 2013). The LincRNA-p21 and p21
p53REs are indicated by red asterisks (*).

This observation provided tantalizing preliminary evidence that LincRNA-p21 could play a role in the p53
tumor suppressor pathway.
Subsequent studies in both mouse and human cells implicated LincRNA-p21 as a trans-acting
lncRNA but failed to reach a consensus on its mechanism or function within the p53 pathway (reviewed
in Table 2.1). These early studies, which overwhelmingly favored RNAi-based knockdown and transgene
overexpression strategies (Bao et al., 2015; Huarte et al., 2010; Yang et al., 2014a; Yoon et al., 2012),
suggested the involvement of LincRNA-p21 in processes ranging from angiogenesis and glycolysis to
apoptosis and cell cycle arrest. These studies further proposed wide-ranging and occasionally
contradictory mechanisms for LincRNA-p21 function. Initial experiments in p53-restorable MEFs and
murine tumor cells supported a model in which LincRNA-p21 RNA binds hnRNP-K in order to promote
apoptosis, an outcome accomplished by enacting p53-dependent transcriptional repression of numerous
target genes (Huarte et al., 2010). Under this paradigm, LincRNA-p21 functions in trans, as it modulates
the localization of hnRNP-K across the genome. A second study, this time in mouse pre-iPSCs, proposed
that LincRNA-p21 inhibits cellular reprogramming by associating with hnRNP-K in order to recruit the
SETDB1 and DNMT1 methyltransferases to the promoters of pluripotency genes (Bao et al., 2015).
Curiously, the authors did not detect any changes in apoptotic potential following LincRNA-p21
knockdown.
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Experimental forays into the role of human LincRNA-p21 spurred the development of addition
models for LincRNA-p21 function. One study proposed that LincRNA-p21 RNA acts as a cytoplasmic
repressor of target mRNA translation (Yoon et al., 2012). Although the authors showed that LincRNA-p21
associates with several of its proposed mRNA targets and can also bind polysomes in HeLa cells, it
remains unclear how this lncRNA might be enacting repression. A second study reported entirely
unrelated conclusions: Yang et al. found that LincRNA-p21 RNA inhibits HIF-1α degradation, thereby
promoting glycolysis under conditions of hypoxia (Yang et al., 2014a). Interestingly, they identified a
hypoxia response element within the human LincRNA-p21 promoter and demonstrated that LincRNA-p21
is induced in response to hypoxic stress. They further observed that LincRNA-p21 RNA blocks the
association of HIF-1α with the VHL E3 ubiquitin ligase, which mediates the constitutive degradation of
HIF-1α under normoxic conditions. On account of this, they posited that LincRNA-p21 promotes
glycolysis under hypoxic conditions and implicated it as a novel lncRNA player in the Warburg effect
(Yang et al., 2014a).
While these findings are certainly intriguing, the failure of early studies to converge on a
mechanism for LincRNA-p21 function casts doubt on the robustness of their conclusions. Notably, all of
these studies used RNAi to deplete LincRNA-p21 RNA levels, raising the possibility that off-target effects
could underlie the diverse phenotypes observed in these studies (Dimitrova et al., 2014). As an additional
point of inconsistency, the ascribed cellular localization of LincRNA-p21 RNA varies dramatically. While
the findings of Huarte et al. and Bao et al. imply that LinRNA-p21 RNA is largely chromatin-bound,
Yoon et al. reported that this RNA exhibits extensive cytoplasmic localization in HeLa cells (Bao et al.,
2015; Huarte et al., 2010; Yoon et al., 2012). While this discrepancy may reflect largescale differences in
lncRNA processing between mice and humans (Guo et al., 2020), it may also point to a lack of
methodological robustness.
Indeed, more recent findings have cast doubt on the results of these initial studies and instead
demonstrated that LincRNA-p21 functions as a cis-regulatory locus. In contrast with the RNAi-based
approaches favored in previous work, these subsequent studies made notable use of genetic tools to
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elucidate the mechanism and function of this locus. In one study, researchers generated mice in which the
entire LincRNA-p21 promoter, including the p53RE, had been deleted (Fig. 4)(Dimitrova et al., 2014).
Intriguingly, the resulting LincRNA-p21-deficient MEFs exhibited a specific 30-50% decrease in p21
expression, suggesting that LincRNA-p21 reinforces p21 levels. The authors built on these results, which
they confirmed using ASOs targeting LincRNA-p21 RNA (Fig. 4), to show that the LincRNA-p21
transcriptional process or transcript acts synergistically with hnRNP-K to stabilize p53 binding at the p21
promoter; they thus provided a clear mechanism for the observed role of LincRNA-p21 in G1/S cell cycle
checkpoint inhibition (Table 2.1). In a separate study, researchers used a different genetic approach to
further implicate a cis-regulatory role for LincRNA-p21. Groff et al. genetically engineered mice in which
the entire LincRNA-p21 locus was replaced with a lacZ reporter cassette (Fig. 4)(Groff et al., 2016;
Sauvageau et al., 2013). In keeping with Dimitrova et al., they observed a significant decrease in p21
expression across multiple adult and embryonic mouse tissues; however, they noted that many genes in
the four megabase window surrounding the LincRNA-p21 locus were also dysregulated. Moreover, they
found that their genetic replacement led to a decrease in p21 levels even in tissues lacking LincRNA-p21
expression, leading them to conclude that DNA elements within the LincRNA-p21 locus must act as local
enhancers of gene regulation.
In contrast to earlier work on LincRNA-p21, in which each study seemingly revealed a new
function and mechanism, subsequent reports have largely confirmed a cis-regulatory function for
LincRNA-p21. In particular, two recent studies used CRISPR/Cas9-mediated mutagenesis to disrupt DNA
sequence elements within the LincRNA-p21 locus of mouse and human cancer cells (Korkmaz et al.,
2016; Tesfaye et al.). In both studies, the authors opted to target the p53RE, which has previously been
shown to drive the expression of a synthetic reporter construct (Groff et al., 2016). In keeping with the
role of LincRNA-p21 in the p53 pathway, p53RE mutagenesis abrogated lncRNA transcription (Korkmaz
et al., 2016; Tesfaye et al.). Strikingly, mutagenesis also incurred a specific decrease in p21 expression,
consistent with the findings of the two previous studies.
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Collectively, these four studies imply that the LincRNA-p21 locus harbors cis-regulatory
potential. In line with this, and belying its alleged trans activity, the murine LincRNA-p21 transcript is
present at ~8 molecules per cell and largely remains at its site of transcription in MEFs (Dimitrova et al.,
2014). However, it is unclear what aspect of the LincRNA-p21 locus—DNA elements, the transcriptional
process, or the full-length transcript—enacts cis-regulation. The LincRNA-p21 p53RE certainly harbors
cis-regulatory activity, as it is both necessary for LincRNA-p21/p21 expression and sufficient to drive
reporter gene expression (Groff et al., 2016; Korkmaz et al., 2016; Tesfaye et al.). Other elements in the
human LincRNA-p21 promoter region also appear to co-regulate the two genes (Korkmaz et al., 2016).
However, given that mutagenesis of these elements abolishes LincRNA-p21 transcription, it is unclear
whether they are acting directly or regulating p21 by promoting LincRNA-p21 transcription and RNA
accumulation. ASO-mediated RNA knockdown experiments provide the strongest evidence that
LincRNA-p21 transcription or RNA accumulation contributes to the cis-regulation of p21, although these
experiments cannot distinguish between the act of transcription and the activity of the mature transcript
(see Chapter I)(Dimitrova et al., 2014; Lai et al., 2020; Lee and Mendell, 2020).
Although Groff et al. disputed this mechanism on the basis of their observation that LincRNA-p21
was not transcribed in many dysregulated tissues (Goff et al., 2015; Groff et al., 2016), it is worth noting
that their strategy substituted a short reporter construct for the entire ~20 kilobase LincRNA-p21 locus
(Groff et al., 2016; Sauvageau et al., 2013); such a large deletion may have disrupted the chromatin
architecture of the locus, perturbing the expression of genes that are not regulated by LincRNA-p21 per se
and disrupting p21 levels in tissues that do not exhibit a dependence on LincRNA-p21. In support of this,
embryonic p21 expression, which this model extensively alters, does not uniformly require p53 signaling
(Gartel et al., 2004; Macleod et al., 1995). This suggests that the authors could have disrupted both
LincRNA-p21-dependent and -independent gene regulation at this locus. Moreover, it is clear from their
data that their lacZ reporter does not faithfully recapitulate LincRNA-p21 transcription in all tissue types,
casting scrutiny on their claim that their approach decouples transcription from the underlying DNA
sequence. In summary, the literature seems to tentatively support a model in which DNA elements within
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the LincRNA-p21 locus drive transcription of the LincRNA-p21 lncRNA, which acts in turn to reinforce
p21 expression. However, the field lacks a precise mechanistic understanding of this process.
Intriguingly, a number of studies have demonstrated that LincRNA-p21 RNA binds hnRNP-K
(Bao et al., 2015; Dimitrova et al., 2014; Huarte et al., 2010; Yoon et al., 2012). This observation, which
has been replicated across studies ascribing both cis and trans functions to LincRNA-p21, may help to
shed some light on the function of this lncRNA. The heterogeneous nuclear ribonucleoprotein hnRNP-K
belongs to a class of nucleic acid-binding proteins implicated in diverse aspects of transcription and RNA
processing. In their study, Huarte et al. proposed that hnRNP-K forms a complex with LincRNA-p21
RNA in order to repress target genes (Huarte et al., 2010). This was predicated in part on the observation
that, in LincRNA-p21-proficient cells, hnRNP-K bound the promoters of genes that were derepressed
following LincRNA-p21 knockdown. However, hnRNP-K is known to be enriched at actively transcribed
genes (Li et al., 2019), where it has been proposed to interact with Pol II in order to regulate the
biogenesis and metabolism of nascent transcripts (Li et al., 2019). Huarte et al. additionally implicated
hnRNP-K as a co-mediator of p53-dependent apoptosis. This conclusion is surprising in light of other
work showing that hnRNP-K has an anti-apoptotic effect (Revil et al., 2009; Xiao et al., 2013; Yang et al.,
2014b). In summary, the literature on hnRNP-K is not consistent with its purported role in LincRNA-p21
mediated trans-repression.
In keeping with hnRNP-K’s more broadly accepted role as a transcriptional activator, Dimitrova
et al. set out a model in which hnRNP-K binds nascent or processed LincRNA-p21 in order to stabilize
p53 binding at the p21 promoter. In support of this, hnRNP-K has previously been proposed to serve as a
coactivator for p53 target genes, including p21 (Moumen et al., 2005, 2013). Indeed, hnRNP-K
knockdown strongly inhibits p21 expression following DNA damage (Moumen et al., 2005), meaning
that genetic ablation and ASO-mediated knockdown of LincRNA-p21 recapitulate some of the effects of
hnRNP-K depletion. Taken together, the biology of hnRNP-K appears to align with a model in which
LincRNA-p21 acts in concert with hnRNP-K to promote p21 expression under conditions of p53
activation
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In summary, the molecular mechanism of cis-regulation at the LincRNA-p21 locus remains
unclear. In keeping with the growing consensus that lncRNAs play modest, if necessary, roles in finetuning cellular processes (Gil and Ulitsky, 2020; Schor et al., 2018; Swarr et al., 2019), recent studies
seem to be converging on the consensus that LincRNA-p21 acts in cis to reinforce local gene expression.
Moreover, the evidence seems to suggest that some feature of the LincRNA-p21 transcriptional process or
transcript harbors functional activity. As an important consideration for the field, Dimitrova et al. used
two orthogonal knockdown approaches to identify an apparent role for the transcriptional process,
demonstrating the importance of using multiple experimental strategies for studying lncRNA function.
Although other work provides valuable insight into the involvement of sequence elements at the
LincRNA-p21 locus, each study implemented a single genetic knockdown strategy that perturbed multiple
aspects of lncRNA biogenesis and function and therefore could not resolve a regulatory mechanism. A
more rigorous understanding of the mechanism of cis-regulation at this locus therefore requires the
judicious application of multiple complementary genetic and molecular approaches (see Chapters III and
IV).
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Table 2.1. Reported roles of LincRNA-p21 in homeostasis and disease
h, human; m, mouse; r, rat
Species
Method(s)

Function

Mechanism

Cis or
trans?

Reference

Reinforce G1/S cell cycle
arrest by promoting p21
expression
Enhance the expression of
multiple neighboring
genes, including p21
Reinforce G1/S cell cycle
arrest by promoting p21
expression
Reinforce G1/S cell cycle
arrest by promoting p21
expression
Promote apoptosis

Nascent or mature RNA
recruits hnRNP-K to stabilize
p53 at the p21 promoter
Multiple enhancer elements
within the LincRNA-p21
locus
Unclear

Cis

(Dimitrova et
al., 2014)

Cis

(Groff et al.,
2016)

Cis

(Korkmaz et
al., 2016)

Unclear

Cis

(Tesfaye et al.)

LincRNA-p21 RNA
associates with hnRNP-K to
enact repression at the
promoters of target genes
LincRNA-p21 RNA
associates with polysomes to
repress the translation of
target mRNAs
LincRNA-p21 RNA
sequesters RELA mRNA
LincRNA-p21 RNA blocks
interactions between p53 and
MDM2
LincRNA-p21 RNA blocks
interactions between HIF-1α
and the VHL E3 ligase
LincRNA-p21 RNA
associates with hnRNP-K to
maintain repression at
pluripotency gene promoters
LincRNA-p21 RNA acts as a
sponge for miR-130b
LincRNA-p21 RNA acts as a
sponge for miR-181b
LincRNA-p21 RNA
associates with EZH2 to
repress target genes
LincRNA-p21 RNA acts as a
sponge for miR-30

Trans

(Huarte et al.,
2010)

Trans

(Yoon et al.,
2012)

Trans

(Spurlock et
al., 2014)
(Wu et al.,
2014)

m

Promoter
deletion, ASOs

m

Reporter gene
substitution

h

p53RE
mutagenesis

m

p53RE
mutagenesis

m

RNAi, transgene
overexpression

h

RNAi

Downregulate prooncogenic, prosurvival
genes

h

RNAi

Repress NF-ΚB signaling

h,m

RNAi, transgene
overexpression

Promote apoptosis and
repress proliferation

h

RNAi

Promote glycolysis under
conditions of hypoxia

m

RNAi, transgene
overexpression

Repress cellular
reprogramming

h,m

Transgene
overexpression
Transgene
overexpression
RNAi, transgene
overexpression

Promote apoptosis and
cell cycle progression
Promote PTEN
expression
Suppress metastasis

RNAi, transgene
overexpression

Promote apoptosis by
inducing TGF-β signaling

h
h

m
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Trans

Trans

(Yang et al.,
2014a)

Trans

(Bao et al.,
2015)

Trans

(He et al.,
2015)
(Yu et al.,
2016)
(Liu et al.,
2017)

Trans
Trans

Trans

(Tu et al.,
2017)

h
h
h
h
h
m
h
h

m
h
m
m
h

RNAi, transgene
overexpression
RNAi, transgene
overexpression
RNAi, transgene
overexpression
RNAi, transgene
overexpression
RNAi
RNAi, transgene
overexpression
RNAi, transgene
overexpression
RNAi, transgene
overexpression
Transgene
overexpression
RNAi, transgene
overexpression
RNAi, transgene
overexpression
RNAi, transgene
overexpression
RNAi, transgene
overexpression

h,m

RNAi

h

RNAi, transgene
overexpression
RNAi, transgene
overexpression
Transgene
overexpression

h
h

h

LincRNA-p21 RNA acts as a
sponge for miR-17-5p
LincRNA-p21 RNA acts as a
sponge for miR-130b
LincRNA-p21 RNA acts as a
sponge for miR-451
LincRNA-p21 RNA acts as a
sponge for miR-1277-5p
LincRNA-p21 RNA acts as a
sponge for miR-181a/b/c/d
LincRNA-p21 RNA acts as a
sponge for miR-18b
LincRNA-p21 RNA acts as a
sponge for miR-17-5p
LincRNA-p21 RNA binds to
STAT3 to inhibit its
phosphorylation
LincRNA-p21 RNA acts as a
sponge for miR-221
LincRNA-p21 RNA acts as a
sponge for miR-34c
LincRNA-p21 RNA binds the
CHOP protein
LincRNA-p21 RNA acts as a
sponge for miR-17-5p
Unclear

Unclear

Unclear

Unclear

Promote apoptosis

Unclear

Unclear

Promote apoptosis

Unclear

Unclear

Inhibit cancer stemness
and tumorigenicity

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

Promote apoptosis
Promote apoptosis by
upregulating α-synuclein
Promote inflammation by
upregulating PKC-δ
Promote proliferation
Promote apoptosis
Promote G1/S cell cycle
arrest and apoptosis
Inhibit apoptosis
Inhibit proliferation
Promote apoptosis
Promote apoptosis
Promote apoptosis by
inhibiting the Wnt/βcatenin signaling pathway
Promote apoptosis

h

RNAi

Promote apoptosis by
inducing ER stress
Reinforce G1/S cell cycle
arrest by promoting p21
expression
Promote angiogenesis

r

RNAi

Inhibit proliferation

m

RNAi, transgene
overexpression
Transgene
overexpression

Inhibit the Wnt/β-catenin
signaling pathway
Inhibit proliferation
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Trans
Trans
Trans
Trans
Trans
Trans
Trans
Trans

Trans
Trans
Trans
Trans

(Yu et al.,
2017)
(Han and Liu,
2018)
(Tang et al.,
2018)
(Xu et al.,
2018)
(Ye et al.,
2018)
(Zhang et al.,
2018)
(Ao et al.,
2019)
(Jin et al.,
2019)
(Sun et al.,
2019)
(Yang et al.,
2019b)
(Ge et al.,
2020)
(Wang et al.,
2020)
(Wang et al.,
2014)
(Hall et al.,
2015)
(Ning et al.,
2015)
(Tran et al.,
2015)
(Wang et al.,
2015a)
(Yang et al.,
2015)
(Zheng et al.,
2015)
(Castellano et
al., 2016)
(Han et al.,
2016)

h

RNAi, transgene
overexpression

h

RNAi, transgene
overexpression
RNAi, transgene
overexpression
RNAi, transgene
overexpression

m
h

h

RNAi, transgene
overexpression

h

Transgene
overexpression

h

RNAi

h

RNAi, transgene
overexpression
RNAi, transgene
overexpression
RNAi

h
m

h
r

RNAi, transgene
overexpression
RNAi

h

RNAi

m

RNAi, transgene
overexpression
RNAi, transgene
overexpression
Transgene
overexpression

m
h

m
m

h
h

RNAi, transgene
overexpression
RNAi

Transgene
overexpression
RNAi

Inhibit invasion and
metastasis by repressing
Notch signaling
Inhibit Wnt/β-catenin
signaling
Promote proliferation

Unclear

Unclear

(Jia et al.,
2016)

Unclear

Unclear

Unclear

Unclear

Inhibit invasion and
metastasis by repressing
YAP signaling
Inhibit invasion and
metastasis by repressing
miR-9
Reinforce G1/S cell cycle
arrest by promoting p21
expression
Promote survival under
conditions of hypoxia
Inhibit proliferation by
repressing glycolysis
Promote apoptosis

Unclear

Unclear

(Yang et al.,
2016b)
(Zhou et al.,
2016)
(Chen et al.,
2017)

Unclear

Unclear

(Ding et al.,
2017)

Unclear

Unclear

(Peng et al.,
2017)

Unclear

Unclear

Unclear

Unclear

Stabilize p53 binding at
promoters of target genes
Unclear

Unclear

(Shen et al.,
2017)
(Wang et al.,
2017a)
(Wang et al.,
2017b)
(Xia et al.,
2017)

Unclear

Unclear

Inhibit angiogenesis by
repressing NF-ΚB
signaling
Promote proliferation and
inhibit apoptosis
Promote apoptosis under
conditions of hypoxia
Promote senescence

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

Inhibit proliferation by
repressing the Wnt/βcatenin signaling pathway
Inhibit tumorigenesis

Unclear

Unclear

Unclear

Unclear

Promote senescence by
reinforcing p21
expression
Promote apoptosis

Unclear

Unclear

Unclear

Unclear

Promote apoptosis

Unclear

Unclear

Promote senescence by
inhibiting the Wnt/βcatenin signaling pathway
Promote apoptosis
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Unclear

(Zhou and
Chen, 2017)
(Cui et al.,
2018)
(Meng et al.,
2018)
(Xia et al.,
2018)
(Xie et al.,
2018)
(Chen et al.,
2019)
(Geng et al.,
2019)
(Guo et al.
2019)
(Hu et al.,
2019)
(Wang et al.,
2019b)

h
h
h

h
h
m
m

RNAi, transgene
overexpression
RNAi, transgene
overexpression
Transgene
overexpression
Transgene
overexpression
RNAi, transgene
overexpression
Transgene
overexpression
CRISPRi,
transgene
overexpression

Inhibit apoptosis

Unclear

Unclear

Inhibit apoptosis

Unclear

Unclear

Inhibit invasion and
metastasis by repressing
VEGF and HIF-1α
Promote G1/S cell cycle
arrest
Inhibit proliferation

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

Inhibit apoptosis

Unclear

Unclear

Promote apoptosis

Unclear

Unclear
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(Yang et al.,
2019b)
(Yang et al.,
2019a)
(Ye et al.,
2019)
(Zhang et al.,
2019)
(Zhou et al.,
2019)
(Yang et al.,
2020)
(Chen et al.,
2021)

Chapter III: Development and validation of an inducible selfcleaving ribozyme
Introduction
Cis-acting lncRNAs exhibit regulatory functions that are uniquely dependent on their position
within the genome (see Chapter I). Given the intimate relationship between DNA sequence elements, the
transcriptional process, and the accumulation of mature transcripts, molecular dissection of cis-regulatory
lncRNA function presents complex technical challenges. Although the current suite of molecular and
genetic tools offers a large number of strategies for manipulating different elements of lncRNA biology
(see Chapter I), the ever-expanding mechanistic diversity of cis-acting lncRNAs necessitates the
constant development of new experimental approaches. In this chapter, we describe the development and
validation of an inducible self-cleaving ribozyme as a tool for specific RNA destabilization. We
demonstrate that the active—but not inert—form of this ribozyme mediates the depletion of an exogenous
LincRNA-p21 construct in multiple murine cell lines, illustrating its suitability as a new tool for lncRNA
loss-of-function.

Results
Design of a synthetic LincRNA-p21 construct with an inducible Twister element
The self-cleaving ribozyme Twister presented an attractive candidate for targeted transcript
degradation on account of several factors. Firstly, Twister family ribozymes exhibit faster cleavage
kinetics than other commonly-used ribozyme tools, including the minimal Hammerhead and Hepatitis
Delta ribozymes (Diegelman-Parente and Bevilacqua, 2002; Roth et al., 2014; Stage-Zimmermann and
Uhlenbeck, 1998). Secondly, Twister ribozyme cleavage does not require the presence of specific divalent
metal ions (Panja et al., 2017; Roth et al., 2014), suggesting that Twister might function in a variety of
cellular environments. Finally, a dinucleotide inversion renders this ribozyme catalytically inactive,
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Figure 5. Design of an invertible Twister element for targeted degradation of an exogenous
LincRNA-p21 transcript. (A) Schematic of an environmental Twister sequence showing the cleavage
site (black arrow and scissors) as well as the location of two nucleotides that render the ribozyme
catalytically inactive when inverted (red circle). (B) Schematic of the synthetic LincRNA-p21 construct
harboring the inverted or restored Twister element. Unstable intermediates are indicated (red box).
Also included are the relative positions of the XhoI site (RE) and primers for genotyping (F/R) and RTqPCR analysis (US and DS). (C) The predicted secondary structure of the wildtype LincRNA-p21
transcript (top) as well as the transcript harboring the restored Twister element (bottom)(Reuter and
Mathews, 2010).
C. Olivero designed and cloned the construct described in (B).

providing a control for the possibility that Twister might be acting through some mechanism other than its
intrinsic auto-scissile activity (Fig. 5A)(Roth et al., 2014).
Christiane Olivero (C. Olivero) therefore designed an invertible Twister element that was inserted
into an exogenous LincRNA-p21 overexpression construct (Fig. 5B). In its constitutively inactive form,
this element features the inverted Twister or catalytically dead mutant sequence flanked by two pairs of
noncomplementary loxP sites. Cre recombinase can subsequently induce the stable inversion of this
genetic element, restoring Twister to its active sense orientation. This novel genetic tool was inserted into
an intronless LincRNA-p21 construct in a retroviral expression vector. Its position within exon 1 was
predicted to minimally disrupt the secondary structure of the host transcript, permitting efficient
transcription and folding prior to ribozyme cleavage (Fig. 5C).

Cre recombinase restores Twister to its active orientation
In order to investigate the viability of our genetic tool, we first asked whether Cre expression
could efficiently restore the inverted Twister sequence to its sense orientation. To test this, we stably
infected each construct into Rosa26-CreERT2 MEFs and lung adenocarcinoma cells and isolated genomic
DNA from untreated cells as well as cells treated with the estrogen precursor 4-hydroxytamoxifen, which
promotes translocation of the constitutively-expressed CreERT2 fusion protein into the nucleus, where it
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Figure 6. The invertible Twister element destabilizes the exogenous LincRNA-p21 construct. (A)
PCR genotyping of lung adenocarcinoma cells stably expressing the indicated constructs and cultured
for 24 hours in the absence or presence of 4-hydroxytamoxifen to induce recombination. Expected
bands: 402 nucleotides (inverted); 274 nucleotides (reverted); 86 nucleotides (endogenous). The
asterisk (*) indicates a nonspecific product. EV=empty vector; MUT=catalytically inactive Twister
mutant; TWI=environmental Twister sequence. (B) Enzymatic digestion of PCR-genotyping products
from MEFs treated as described in (A) confirms the identity of the products. Expected bands: 402
nucleotides (-XhoI, inverted); 274 nucleotides (-XhoI, reverted); 229 (*) and 173 (**) nucleotides
(+XhoI, inverted); 87 (†) and 187 (‡) nucleotides (+XhoI, reverted). M=catalytically inactive Twister
mutant; T=environmental Twister sequence. (C) PCR analysis of cDNA from lung adenocarcinoma
cells described in (A) using primers spanning the Twister cleavage site. Expected bands: 402
nucleotides (inverted); 274 nucleotides (reverted). (D) RT-qPCR analysis of cDNA from MEFs
described in (B) using primers upstream (US) or downstream (DS) of the Twister cleavage site.
LincRNA-p21 levels were calculated relative to Gapdh and normalized to untreated cells expressing
LincRNA-p21 harboring the catalytically dead Twister sequence.

can mediate recombination. PCR genotyping suggested that 4-hydroxytamoxifen treatment stably restored
the Twister and mutant sequences to their sense orientation (Fig. 6A). To establish the specificity of our
genotyping approach, we incubated PCR amplicons from untreated and 4-hydroxytamoxifen-treated cells
with the restriction enzyme XhoI. Enzymatic digestion yielded fragments of the expected sizes in both
untreated and treated cells, confirming that our approach was fundamentally successful (Fig. 6B).
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Twister cleavage inhibits the accumulation of the exogenous LincRNA-p21 transcript
Ultimately, we wished to examine the functional consequences of Twister restoration. In service
of this, we first asked whether Twister mediated LincRNA-p21 RNA cleavage in its sense, but not
antisense, orientation. To qualitatively assess the extent of cleavage in transcripts arising from each
sample, we performed gel electrophoresis on RT-PCR products generated using primers spanning the
Twister cleavage site. Consistent with our expectation, the restored Twister sequence showed a significant
reduction in signal relative to the restored mutant sequence (Fig. 6C). Of note, antisense Twister did not
appear to self-cleave in spite of its near-palindromic sequence. These results demonstrate that Twister
exhibits specific autocleavage activity only when present in its sense orientation.
Next, we sought to understand how ribozyme cleavage affects the accumulation of the resulting
LincRNA-p21 RNA fragments. To test this, we used RT-qPCR to analyze LincRNA-p21 expression before
and after Twister restoration (Fig. 6D). Transcripts harboring the antisense Twister sequence were
expressed at similar levels to transcripts harboring either orientation of the catalytically dead mutant
sequence. By contrast, the presence of the restored Twister sequence reduced exogenous LincRNA-p21
levels by ~75% suggesting that Twister cleavage specifically depletes both the upstream and downstream
products. Taken together, these results support a model in which Twister’s auto-scissile ability mediates
the knockdown of host transcripts in diverse cellular environments.

Data summary and conclusion
These data firmly establish the inducible Twister ribozyme as a viable tool for targeted transcript
depletion. Using an invertible genetic system, we showed that Twister self-cleaves and destabilizes host
transcripts only when restored to its sense orientation. These findings demonstrate the broad applicability
of both inducible and constitutively active Twister as tools for studying the role of lncRNAs in diverse
functional and genomic contexts. The inducible Twister element described here has the potential to reveal
the temporal consequences of RNA depletion on local gene regulation, facilitating efforts to investigate
the complex relationship between lncRNA expression and changes in the regulatory landscape of nearby
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protein-coding genes. Additionally, Twister failed to mediate transcript cleavage and destabilization in its
antisense orientation, suggesting that it may represent a powerful strategy for dissecting the function of
antisense lncRNAs that overlap with protein-coding genes. Finally, the ability to replicate these findings
in both MEFs and cancer cells indicates that Twister cleavage is robust across a variety of cellular
environments.
Although we have shown that our approach is fundamentally feasible, the effects of ribozyme
cleavage are likely context specific and may vary based on the position of the ribozyme relative to the
TSS, TTS, or splice sites (Bird et al., 2005; NOTT et al., 2003). Additionally, features such as the
secondary structure of the host transcript may affect the efficiency of autocleavage and the accessibility of
upstream and downstream cleavage products to exonucleases (Akiyama et al., 2016). As a result, the
effects of ribozyme placement on transcript cleavage and destabilization will have to be validated on a
case-by-case basis. Later in this work, we will discuss our efforts to characterize the effects of cotranscriptional Twister cleavage on the transcriptional landscape of the endogenous LincRNA-p21 locus
(see Chapter IV).
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Chapter IV: Elucidating the molecular mechanism of cis-regulation
by LincRNA-p21
Material from this chapter is being prepared for publication as follows: Winkler, L.N., Zimmer, J.T.,
Williams, A., Simon, M.D., and Dimitrova, N.M. “Functional elements of the cis-regulatory LincRNAp21.” Co-author contributions are specified in figure legends and the main text.

Introduction
While it is clear that many lncRNA loci harbor cis-regulatory potential, the mechanisms through
which they effect activation and repression remain largely uncharacterized. In particular, the limitations
of conventional molecular and genetic approaches have hindered attempts to deconvolve the effects of (1)
the mature RNA, (2) transcriptional and co-transcriptional processes, and (3) DNA elements within the
lncRNA locus (Bassett et al., 2014; Kopp and Mendell, 2018). Due to the intrinsically interlinked nature
of these phenomena, it remains unclear whether the majority of genomic transcription is functional or
simply reflects the stochastic association of Pol II with regions of open chromatin near regulatory DNA
elements (Engreitz et al., 2016; Paralkar et al., 2016; Struhl, 2007).
The p53-inducible lncRNA LincRNA-p21 has previously been shown to act in cis to reinforce the
expression of the nearby p53 target and G1/S checkpoint inhibitor p21/Cdkn1a (Dimitrova et al., 2014;
Groff et al., 2016; Korkmaz et al., 2016; Tesfaye et al.). However, the molecular mechanism underlying
this cis-regulatory relationship remains unclear (see Chapter II). Specifically, the use of genetic
approaches that both abolish LincRNA-p21 transcription and destroy DNA elements within the locus has
confounded efforts to elucidate the molecular grammar through which LincRNA-p21 communicates
complex regulatory information to p21. This chapter describes our efforts to resolve this controversy by
implementing a powerful suite of genetic and molecular techniques to manipulate different aspects of
LincRNA-p21 biogenesis. Using complementary experimental approaches, we show that full-length
transcription, splicing, and RNA accumulation are dispensable for cis-regulation. By
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Figure 7. The LincRNA-p21 p53RE reinforces p21 expression in a p53-dependent manner in
MEFs (A) Schematic of p53 expression restoration and stabilization in p53LSL/LSL; Rosa26-CreERT2
MEFs. (B) Top: schematic of LincRNA-p21 p53RE mutagenesis showing the location of the p53RE
(bold), the PAM site (gray box), and Cas9 cleavage site (black arrow). Bottom: representative p53RE
mutations identified by Sanger sequencing in cells described in (A). Mutagenesis rate=100%. (C and
D) RT-qPCR analysis of (C) LincRNA-p21 and (D) p21 expression in p53RE restorable MEFs that
58

were treated with 0.5 µM 4-hydroxytamoxifen to restore p53 expression 24 hours prior to treatment
with 24 hour 0.1 or 0.5 µM doxorubicin. Data represent the mean ± SEM (n=3 biological replicates);
*p<0.05, ***p<0.001, paired t-test. For all samples, LincRNA-p21 and p21 levels were calculated
relative to Gapdh. (E) Representative immunoblot for p21 protein in MEFs treated as described above.
α-tubulin served as a loading control. (F) Proliferation of the indicated p53-restorable MEFs cultured in
the absence or presence of 0.5 µM 4-hydroxytamoxifen. Data represent the mean ± SEM (n=3
biological replicates) n.s., not significant, p<0.0001, paired t-test. (G) Top: schematic of LincRNA-p21
p53RE mutagenesis showing the location of the p53RE (bold), the PAM site (gray box), and Cas9
cleavage site (black arrow). Bottom: representative p53RE mutations identified by Sanger sequencing
in primary MEFs. Mutagenesis rate=90%. (H and I) RT-qPCR analysis for spliced LincRNA-p21 and
p21 RNA in the indicated MEFs. Data represent the mean ± SEM (n=4 biological replicates); *p<0.05,
**p<0.01, paired t-test. LincRNA-p21 and p21 levels were calculated relative to Gapdh and normalized
to Con.

contrast, we implicate transcription through a minimal sequence element in exon 1 of LincRNA-p21 as a
key mediator of regulatory activity at the locus. Our findings unveil the complex molecular grammar of
cis-regulation at the LincRNA-p21 locus and further support a functional role for pervasive genomic
transcription.

Results
The LinRNA-p21 p53RE reinforces p21 expression
The p53-inducible lncRNA LincRNA-p21 harbors a p53RE within its first exon. (Fig. 3)(Huarte et
al., 2010). Since p53 binding within noncoding transcriptional units has previously been shown to activate
the expression of distant p53 targets (Melo et al., 2013), we wondered whether this DNA element might
reinforce p21 expression in response to p53 activation by genotoxic or oncogenic stress. In order to test
this, we used CRISPR/Cas9 to mutagenize the p53RE in a panel of murine cell lines. Under this
approach, we stably infected cells with lentiviral constructs co-expressing spCas9 and either a
nontargeting control gRNA (Con) or a gRNA targeting the p53RE (ΔRE). We reasoned that
CRISPR/Cas9-mediated mutagenesis of the p53RE in ΔRE cells would abolish p53 binding at the
LincRNA-p21 promoter, leading to a reduction in LincRNA-p21 and p21 transcription only in the presence
of p53 signaling.
We first performed CRISPR/Cas9-mediated mutagenesis in p53-restorable MEFs, a powerful
genetic system that enabled us to directly test the role of p53 in the cis-regulatory relationship between
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LincRNA-p21 and p21. In this system, an excisable STOP cassette (LoxP-STOP-LoxP; LSL) in the first
intron of p53 renders cells functionally p53 deficient (Ventura et al., 2007). These cells also express a
Cre-ERT2 fusion protein that mediates the deletion of the LSL upon treatment with 4-hydroxytamoxifen,
permitting p53 expression. Genotoxic stress, including DNA damage induced by doxorubicin, further
stabilizes p53, leading to the induction of its target genes (Fig. 7A). To confirm p53RE mutagenesis in
ΔRE MEFs, we performed Sanger sequencing on gDNA from a bulk population of cells. We observed a
100% mutagenesis rate in ΔRE cells, which showed a corresponding loss in LincRNA-p21 induction
following p53 restoration and treatment with doxorubicin (Fig. 7B-C). Consistent with a p53-dependent
cis-regulatory role for the p53RE, p53-proficient ΔRE MEFs exhibited a significant decrease in p21
levels in both the absence of DNA damage and following treatment with low levels of doxorubicin (Fig.
7D-E). p53-deficient ΔRE MEFs, however, showed normal p21 expression in both the absence and
presence of doxorubicin. In keeping with p21’s role as a cell cycle checkpoint inhibitor, p53-proficient
ΔRE MEFs proliferated faster than p53-proficient Con cells (Fig. 7F). By contrast, p53-deficient ΔRE and
Con MEFs proliferated at similar rates, further indicating that the p53RE acts as a cis-regulatory element
for LincRNA-p21 and p21 only in the presence of p53 signaling.
We next validated these results in primary wildtype E13.5 MEFs. Following mutagenesis, ΔRE
primary MEFs showed a 90% mutagenesis rate as well as a 48% reduction in LincRNA-p21 expression
relative to Con primary cells (Fig. 7G-H). In keeping with previous findings, we observed that ΔRE cells
also exhibited a 27% decrease in p21 expression (Fig. 7I). Taken together, these results indicate that the
LincRNA-p21 p53RE promotes the expression of LincRNA-p21 and p21 in a p53-dependent manner in the
presence of genotoxic stress.
Finally, we performed p53RE mutagenesis in a p53-restorable lung adenocarcinoma cell line, a
model for investigating p53 signaling in response to oncogenic stress. Like the p53-restorable MEFs,
these cells harbor a LSL element that inhibits p53 expression, and constitutively express Cre-ERT2.
Additionally, these cells express the oncogenic G12D Kras allele (Fig. 8A). Using Sanger sequencing, we
observed a 100% mutagenesis rate for the p53RE in these cells (Fig. B). Although loss of the p53RE
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Figure 8. The LincRNA-p21 p53RE does not reinforce p21 expression in a lung adenocarcinoma
cell line. (A) Schematic of p53 expression restoration and stabilization in a KrasG12D/+; p53LSL/LSL;
Rosa26-CreERT2 lung adenocarcinoma cell line. (B) Representative mutations identified by Sanger
sequencing across the LincRNA-p21 p53RE. (C and D) RT-qPCR analysis of (C) LincRNA-p21 and
(D) p21 expression in cells cultured in the absence or presence of 0.5 µM 4-hydroxytamoxifen for 24
hours. Data represent the mean ±SEM (n=4 biological replicates); n.s., not significant, paired t-test. For
all samples, LincRNA-p21 and p21 levels were calculated relative to Gapdh. (E) Representative
immunoblot of p21 protein levels in cells treated as described above. α-tubulin served as a loading
control.

mediated a ~75% reduction in LincRNA-p21 levels in the presence of p53 signaling, we did not observe
any changes in p21 expression (Fig. These findings suggest that this cell line is not a tractable model for
studying the cis-regulatory relationship between LincRNA-p21 and p21 (Fig 8C-E).

Generation and initial characterization of four novel LincRNA-p21 loss-of-function mouse models
Our mutagenesis experiments clearly show that the LincRNA-p21 p53RE acts in cis to activate
p21 expression in response to p53 signaling. Since p53RE mutagenesis also abrogates LincRNA-p21
expression, we wondered whether the p53RE acts directly or mediates its cis-regulatory effects through
the LincRNA-p21 transcriptional process or RNA. We therefore set out to investigate the regulatory
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contributions of each of these elements. To accomplish this, we implemented multiple complementary
genetic strategies for knocking down LincRNA-p21 transcription (see Chapter II). In collaboration with
Adam Williams (A. Williams; the Jackson Laboratory for Genomic Medicine), we used CRISPR/Cas9mediated genome engineering to insert a 49 nucleotide synthetic PAS or the 74 nucleotide Twister
ribozyme (TWI; see Chapter III) into exon 1 of the endogenous LincRNA-p21 locus of C57BL/6J mice
(Fig. 9A)(Engreitz et al., 2016; Levitt et al., 1989; Roth et al., 2014). Briefly, A. Williams electroporated
wildtype blastocysts with Cas9, a gRNA targeting the LincRNA-p21 locus, and a <200 nucleotide ssDNA
donor template comprising the knock-in sequence flanked by two homology arms (Richardson et al.,
2016). Under this strategy, the ssDNA donor template mediated the homology-directed repair (HDR) of
the double-strand break, thus inserting the knock-in sequence into exon 1 of LincRNA-p21 (Williams et
al., 2016).
This process generated chimeric mice, some of which harbored the correct PAS or Twister
insertion (Fig. 9B-C). Additionally, we identified two mouse lines with small deletions that partially
overlap LincRNA-p21 exon 1. These novel alleles comprise a 151 nucleotide deletion (Δ151) that spans
the exon 1-intron junction and a 127 nucleotide deletion (Δ127) that falls entirely within exon 1 (Fig. 9D).
Critically, these deletions leave the canonical p53RE intact. Sanger sequencing further confirmed the
identity of each allele (Fig. 9E). All four founders were back-crossed once with wildtype C57BL/6J mice,
yielding heterozygotes carrying each allele of interest. These offspring were viable and did not display
any abnormalities, consistent with previous findings (Fig. 10)(Dimitrova et al., 2014).
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Figure 9. Generation and identification of novel LincRNA-p21 knockdown alleles. (A) Schematic of
the LincRNA-p21 Exon 1 showing the relative positions of the gRNA, PAS and Twister donor
templates, genotyping primers (black arrows), and p53RE (red asterisk). (B and C) PCR genotyping of
chimeric mice generated using the knock-in strategy described in (A). The tag numbers of the Twister
(B) and PAS (C) founder mice are indicated in red. Expected bands: 558 nucleotides (wildtype); 632
nucleotides (Twister); 607 nucleotides (PAS). (C) The tag numbers of two additional mice with 127 and
151 nucleotide Exon 1 deletions are shown in red and orange. Expected bands: 431 nucleotides (Δ127);
407 nucleotides (Δ151). (D) Schematic showing the location of the novel 127 and 151 nucleotide
deletions relative to Exon 1, including a conserved region. The p53RE is indicated in red. (E) Sanger
sequencing across the PCR amplicons generated as described in (B) and (C) confirms the identity of
each allele.
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Figure 10. Validation of four novel LincRNA-p21 knockdown alleles. (A) Left, mating strategy for
backcrossing chimeric founder mice (red and gray) with wildtype C57BL/6J mice (white) in order to
generate heterozygotes (red and white stripes) carrying each LincRNA-p21 knockdown allele. Right,
mating strategy for generating wildtype (white), heterozygous (red and white stripes), and homozygous
(red) animals and MEFs. (B) PCR genotyping confirms that heterozygote matings described in (A) right
yield offspring of all possible genotypes. Expected bands: 253 nucleotides (PAS), 204 nucleotides
(wildtype); 278 nucleotides (Twister), 204 nucleotides (wildtype); 177 nucleotides (Δ151), 328
nucleotides (wildtype); 203 nucleotides (Δ127), 330 nucleotides (wildtype). (C) Genotype frequencies
for offspring from the indicated LincRNA-p21 heterozygote matings. The expected numbers derive from
a Mendelian distribution.
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Figure 11. Novel genetic tools abolish RNA accumulation and attenuate transcription and
processing at the LincRNA-p21 locus. (A) Left, schematic of the murine LincRNA-p21 locus
highlighting the relative positions of the LincRNA-p21 p53RE (*), the PAS/Twister insertion site, and
primers for detecting total LincRNA-p21 RNA. Right, schematic showing the position of the novel
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deletions within exon 1. (B-E) RT-qPCR analysis of spliced LincRNA-p21 RNA in MEFs of the
indicated genotypes cultured for 8 hours in the absence or presence of 0.5 µM doxorubicin. Data
represent the mean ± SEM (PAS, n=13; TWI, n=7; Δ151, n=3; Δ127, n=18; biological replicates).
**p<0.01, ***p<0.001, and ****p<0.0001, paired t-test. LincRNA-p21 levels were calculated relative
to Gapdh and normalized to untreated wildtype cells. (F-I) RT-qPCR detection of total LincRNA-p21
RNA in MEFs of the indicated genotypes cultured for 24 hours in the absence or presence of 0.5 µM
doxorubicin. Data represent the mean ± SEM (PAS, n=3 biological replicates; TWI, n=3 biological
replicates; Δ151, n=3 technical replicates; Δ127, n=4 biological replicates). For each primer pair,
LincRNA-p21 levels were calculated relative to Gapdh and normalized to untreated wildtype cells.

p21 does not require full-length transcription, splicing, or accumulation of LincRNA-p21 RNA
To characterize the effects of our genetic tools and deletion alleles on LincRNA-p21 biogenesis,
we first analyzed the expression of spliced LincRNA-p21 RNA in primary MEFs. We observed that both
knock-in and deletion MEFs exhibited a near-complete loss of mature LincRNA-p21 accumulation in both
the absence and presence of doxorubicin (Fig. 11B-E). These results indicate that spliced LincRNA-p21
RNA is largely absent from our mutant cells; however, we also wished to understand how each mutation
affects the expression of total (spliced and unspliced) LincRNA-p21. We therefore monitored steady-state
RNA expression across the LincRNA-p21 locus and observed that all four of our loss-of-function alleles
mediate a significant loss of total LincRNA-p21 RNA (Fig. 11F-I).
We subsequently confirmed that the PAS and Twister had similar effects on LincRNA-p21
expression in vitro and in vivo. We compared spliced LincRNA-p21 RNA levels across a panel of tissues
from adult wildtype and knock-in mice (Fig. 12). Both knock-in mouse strains showed a marked loss of
LincRNA-p21 RNA in all tissues, recapitulating the effects of a previously-described LincRNA-p21
promoter deletion mouse model (LincRNA-p21-/-)(Dimitrova et al., 2014). These results
indicate that our genetic tools are active in vivo and mediate the loss of spliced LinRNA-p21 RNA in a
variety of different cellular contexts.
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Figure 12. The PAS and Twister mediate the loss of LincRNA-p21 RNA in vivo. (A) RT-qPCR
analysis of spliced LincRNA-p21 levels in the indicated tissues from LincRNA-p21PAS/PAS and LincRNAp21+/+ mice. Data represent the mean ± SEM (n=3 technical replicates). (B) RT-qPCR analysis of
spliced LincRNA-p21 levels in the indicated tissues from LincRNA-p21TWI/TWI and LincRNA-p21+/+
mice. Data represent the mean ± SEM (n=3 biological replicates). (C) RT-qPCR analysis of spliced
LincRNA-p21 levels in the indicated tissues from LincRNA-p21-/- and LincRNA-p21+/+ mice. Data
represent the mean ± SEM (n=3 technical replicates). For all samples, LincRNA-p21 levels are
expressed relative to Gapdh.
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Figure 13. The Twister ribozyme attenuates transcription across the LincRNA-p21 locus. (A)
Schematic of 4-thiouridine labeling, biotinylation, and enrichment of nascent RNAs. (B) Transient
transcriptome (TT)-qPCR detects metabolically-labeled LincRNA-p21 RNA in MEFs cultured for 24
hours in the absence or presence of 0.5 µM doxorubicin. Data represent the mean ± SEM (n=3
biological replicates); *p<0.05, **p<0.01, ***p<0.001, paired t-test. For each primer pair, LincRNAp21 levels were calculated relative to Gapdh and normalized to untreated wildtype cells.
J. Zimmer performed the nascent RNA enrichment and TT-qPCR analysis described in (B).

Since self-cleaving ribozymes are an emerging strategy for destabilizing endogenous lncRNAs
(Camblong et al., 2009; Tuck and Bühler, 2021; Tuck et al., 2018; Wery et al., 2018b), it was not clear a
priori how Twister cleavage would affect LincRNA-p21 transcription. To address this key question,
Joshua Zimmer (J. Zimmer; Yale University) used transient transcriptome (TT)-qPCR to monitor
transcription at multiple sites across the LincRNA-p21 locus in metabolically-labeled MEFs (Fig. 13).
Strikingly, Twister appeared to suppress transcription from the LincRNA-p21 promoter by ~60% and
incurred a ~90% reduction in transcription near the TTs. Based on these results, we concluded that
Twister mediates the co-transcriptional knockdown of the LincRNA-p21 RNA. Collectively, our steadystate and TT-qPCR experiments define the scope of our loss-of-function alleles on LincRNA-p21
transcription, processing, and accumulation in vitro and in vivo.
We next sought an alternative approach to confirm that our novel genetic models deplete
LincRNA-p21 expression. We therefore used single-molecule RNA fluorescence in situ hybridization
(smRNA-FISH) to visualize intronic and exonic LincRNA-p21 RNA in wildtype and knockdown MEFs.
In keeping with the results of previous experiments, we observed a substantial loss of foci across all of
our knockdown cell lines (Fig. 14). Interestingly, although the majority of LincRNA-p21TWI/TWI cells had
no foci, a modest ~15% of scored cells at least one intronic or exonic focus (Fig. 14B).This corroborates
68

69

Figure 14. Single-molecule RNA fluorescence in situ hybridization (smRNA FISH) confirms the
loss of RNA signal in novel LincRNA-p21 loss-of-function mutants. (A) smRNA FISH detection of
LincRNA-p21 RNA with intronic (green) and exonic (red) probes in indicated MEFs treated for 24
hours with 25 µM etoposide. DNA was counterstained with DAPI. (B-E) Frequency distribution for the
number of intronic (left) and exonic (right) foci in each nucleus of the indicated genotype. MEFs were
treated as described in (A).

our finding that Twister cleavage permits some degree of transcription through the LincRNA-p21 locus.
Ultimately, we wished to test the role of LincRNA-p21 biogenesis in regulating p21 expression.
To accomplish this, we examined p21 expression in wildtype and littermate LincRNA-p21TWI/TWI,
LincRNA-p21PAS/PAS, or LincRNA-p21Δ151/Δ151 MEFs. Curiously, neither premature transcriptional
termination (the PAS) nor the loss of full-length transcription (TWI), canonical splicing (Δ151), or RNA
accumulation (all three models) affected p21 RNA or protein levels in either the absence or presence of
doxorubicin (Fig. 15A-G). Consistent with these results, LincRNA-p21PAS/PAS and LincRNA-p21TWI/TWI
MEFs did not display increased proliferation relative to wildtype littermate controls, further suggesting
that p21 levels are unaltered (Fig. 15H-I). Together, these results reveal that p21 transcription is
insensitive to full-length LincRNA-p21 transcription, processing, and accumulation.
Organismal data largely validates our in vitro findings. Although LincRNA-p21-/- animals show a
pronounced decrease in p21 RNA levels across a panel of tissues relative to wildtype controls, we could
not detect any significant differences in p21 expression between the majority of wildtype and LincRNAp21TWI/TWI tissue samples (Fig. 16). Curiously, we did observe a statistically significant decrease in p21
expression in brain samples from LincRNA-p21TWI/TWI animals. Since LincRNA-p21-deficient mice have
previously been reported to clasp their hindlimbs when lifted by the tail (Sauvageau et al., 2013), we
wondered whether this brain-specific decrease in p21 levels might mediate a similar phenotype in
LincRNA-p21TWI/TWI mice. However, we failed to observe hindlimb clasping or other behavioral
abnormalities in LincRNA-p21TWI/TWI mice or any of our other mutants (data not shown).
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Figure 15. p21 does not require splicing or accumulation of the full-length LincRNA-p21
transcript. (A-C) RT-qPCR analysis of p21 mRNA levels in MEFs of the indicated genotypes cultured
for 8 hours in the absence or presence of 0.5 µM doxorubicin. Data represent the mean ± SEM (PAS,
n=11; TWI, n=9; Δ151, n=3; biological replicates); n.s., not significant, paired t-test. For all samples,
p21 levels were calculated relative to Gapdh and normalized to untreated wildtype cells. (D and E)
Representative immunoblot for p21 and p53 protein from MEFs treated as described in (A and B).
HSP90 served as a loading control. (F and G) Densitometric analysis of p21 protein expression in cells
described in (D and E). p21 levels were normalized to HSP90. Data represent the mean ± SEM (PAS,
n=8; TWI, n=7; biological replicates); n.s., not significant, paired t-test. (H and I) Proliferation of the
indicated pairs of MEFs isolated from littermates. Data are representative of n=2 independent growth
curve experiments.
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Figure 16. Twister does not affect p21 levels in vivo. (A) RT-qPCR analysis of p21 levels in the
indicated tissues from LincRNA-p21TWI/TWI and LincRNA-p21+/+ mice. Data represent the mean ± SEM
(n=3 biological replicates); *p<0.05, paired t-test. (B) RT-qPCR analysis of p21 levels in the indicated
tissues from LincRNA-p21-/- and LincRNA-p21+/+ mice. Data represent the mean ± SEM (n=3 technical
replicates). For all samples, p21 levels are expressed relative to Gapdh.

ASOs targeting LincRNA-p21 likely incur nonspecific effects on p21 expression.
Our results, which show that transcription, processing, and accumulation of full-length LincRNAp21 RNA does not participate in cis-regulation, conflict with previous findings supporting a role for these
processes (Dimitrova et al., 2014). This functionality was identified using ASO gapmers targeting
sequences in the intron (ASO-I) and second exon (ASO-E2), eight and 19 kilobases downstream of the
PAS/Twister insertion site, respectively (Fig. 4). Consistent with prior work, we found that these ASOs
mediated a >90% reduction in the expression of spliced LincRNA-p21 expression and a concurrent 3040% decrease in p21 levels (Fig. 17A-B)(Dimitrova et al., 2014). To further understand the effects of
these ASOs on LincRNA-p21 expression, we monitored steady-state RNA levels across the locus (Fig.
17C). Similar to the PAS and Twister, both ASOs mediated a significant loss of RNA from exon 2.
Although we did not observe a significant knockdown in total LincRNA-p21 levels using primers

72

targeting the exon 1-intron junction or intron, we noted a puzzling decrease in LincRNA-p21 expression
from the upstream TSS.
We next investigated how ASO cleavage affects p21 levels in knock-in MEFs. As expected, ASO
treatment significantly abrogated LincRNA-p21 expression in wildtype control MEFs (Fig. 17D, F). We
could not detect additional knockdown in our mutant cells, which already showed a near-complete loss of
spliced LincRNA-p21 expression. In all samples, however, ASO-I and ASO-E2 mediated a reduction in
p21 levels relative to the nontargeting control ASO (Fig. 17E, G). This perplexing result points to one of
two conclusions: either a small degree of transcription through the LincRNA-p21 locus is sufficient to
reinforce p21 expression or ASO-I and ASO-E2 mediate a nonspecific decrease in p21 expression.
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Figure 17. ASO gapmers targeting downstream of the PAS/Twister insertion site abrogate p21
expression in LincRNA-p21PAS/PAS and LincRNA-p21TWI/TWI MEFs. (A and B) RT-qPCR analysis of
(A) LincRNA-p21 and (B) p21 expression in wildtype MEFs nucleofected with the indicated ASOs.
Data represent the mean ± SEM (n=3 biological replicates), *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001, paired t-test. (C) RT-qPCR for total LincRNA-p21 RNA using the indicated primer
pairs. Red arrows indicate the location of each ASO relative to the primer sites. Data represent the
mean ± SEM (n=3 biological replicates), n.s., not significant, *p<0.05, **p<0.01, ***p<0.001, paired ttest. (D and E) RT-qPCR analysis of (D) LincRNA-p21 and (E) p21 expression in LincRNA-p21PAS/PAS
and wildtype MEFs nucleofected with the indicated ASOs. Data represent the mean (n=3 technical
replicates). (F and G) RT-qPCR analysis of (F) LincRNA-p21 and (G) p21 levels in LincRNAp21TWI/TWI and wildtype MEFs nucleofected with the indicated ASOs. Data represent the mean (n=3
technical replicates).

74

A conserved sequence element reinforces p21 expression in cis
Since transcription, processing, and accumulation of the full length LincRNA-p21 RNA appear to
be dispensable for cis-regulation, we questioned whether other elements of the locus might promote p21
expression, as has been shown for human LincRNA-p21 (Korkmaz et al., 2016). Although LincRNA-p21
exhibits little overall sequence conservation, a ~200 nucleotide region within exon 1 is moderately
conserved and shares significant homology with its counterpart in other mammals (Chillón and Pyle,
2016) (Fig. 18A). We hypothesized that this region, which includes the p53RE, might harbor additional
cis-regulatory potential.
In order to test this, we investigated p21 expression in primary LincRNA-p21Δ127/Δ127 MEFs,
which harbor a deletion that spans the majority of the conserved region without disrupting the canonical
p53RE (Fig. 9D). Strikingly, deletion of the conserved region mediated significant decreases in p21 RNA
and protein levels in both the absence and presence of doxorubicin (Fig. 18B-D). In keeping with the role
of p21 in cell cycle progression, the reduction in p21 expression had clear functional consequences: we
observed that mutant MEFs showed enhanced proliferation relative to wildtype littermate controls (Fig.
18E)(Dimitrova et al., 2014). Together, these results indicate a requirement for sequence elements beyond
the canonical p53RE, demonstrating that the LincRNA-p21 locus is not merely a distal p53RE for p21.
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Figure 18. A conserved sequence element within LincRNA-p21 Exon 1 reinforces p21 expression.
(A). Sequence alignment of the mouse conserved element to homologous regions in rat, human,
chimpanzee, pangolin, dog, and pig. Nucleotides with 100% conservation across these species are
highlighted in yellow. The position of the LincRNA-p21 p53RE is indicated. (B) RT-qPCR analysis for
p21 RNA in wildtype and LincRNA-p21Δ127/Δ127 MEFs cultured for 8 hours in the absence or presence
of 0.5 µM doxorubicin. Data represent the mean ± SEM (n=18 biological replicates); *p<0.05,
****p<0.0001, paired t-test. For all samples, p21 levels were calculated relative to Gapdh and
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normalized to untreated wildtype cells. (F) Representative immunoblot of p21 and p53 protein levels in
cells described in (E). HSP90 was used as a loading control. (G) Densitometric analysis of p21 protein
expression in cells described in (E and F). p21 levels were normalized to HSP90. Data represent the
mean ± SEM (n=6 biological replicates); **p<0.01, ***p<0.001, paired t-test. (H) Proliferation of
littermate wildtype and LincRNA-p21Δ127/Δ127 MEFs. Data are representative of n=3 independent growth
curve experiments.

Stable looping interactions juxtapose the conserved region with the promoter of p21
We next desired to understand how the conserved sequence element reinforces p21 expression.
Many lncRNAs have been proposed to promote chromatin remodeling or stabilize long-range looping
interactions between promoters and regulatory elements (Canzio et al., 2019; Isoda et al., 2017; Melé and
Rinn, 2016; Quinn and Chang, 2016). Additionally, previous work has shown that many distal p53REs
harbor lncRNAs that are transcribed in a p53-dependent manner and participate in looping interactions
that juxtapose the p53-bound response element with the promoter of a protein-coding gene (Melo et al.,
2013). Since the LincRNA-p21 and p21 loci have been shown to physically associate (Groff et al., 2016;
Sahlén et al., 2015), we hypothesized that the conserved region might establish or maintain the local
chromatin architecture, thereby facilitating communication between the two loci. To test this, we used
chromosome conformation capture (3C) to investigate the 3D organization of the LincRNA-p21/p21 locus
in our LincRNA-p21Δ127/Δ127 and wildtype control MEFs in both the presence and absence of doxorubicin.
Notably, although the promoter regions of LincRNA-p21 and p21 associate, providing a mechanism for
long-range communication between the two loci, neither LincRNA-p21 transcription nor deletion of the
conserved region leads to a reorganization of the 3D architecture of the locus (Fig. 19).
In further support of this conclusion, we recapitulated these results in lung adenocarcinoma cells
with intact (Con) or mutagenized (ΔRE) p53REs (Fig. 8). In this system, we observed looping
interactions between the promoters of LincRNA-p21 and p21 (Fig. 19). These looping interactions were
not sensitive to the presence of a functional p53 pathway, since tamoxifen treatment did not alter contact
strength in either cell population. Our results also show that the LincRNA-p21/p21 locus of lung
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Figure 19. Stable looping interactions juxtapose the conserved region with the p21 promoter. (A
and B) Taqman-3C analysis of the LincRNA-p21/p21 locus. Chromatin was digested using the
restriction enzyme BglII and 3C libraries were evaluated using unidirectional primers spanning the
locus. The signal intensity for long-range interactions is shown relative to the signal of a control
amplicon within the LincRNA-p21 locus that does not span a restriction site. (A) MEFs of the indicated
cell lines were cultured for 24 hours in the absence or presence of 0.5 µM doxorubicin. Data represent
the mean ± SEM (n=3 biological replicates); n.s., not significant, paired t-test. (B) Lung
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adenocarcinoma cells of the indicated genotypes were cultured for 24 hours in the absence or presence
of 0.5 µM 4-hydroxytamoxifen. Data represent the mean ± SEM (n=3 technical replicates). (C)
Schematic showing the location of BglII sites, the LincRNA-p21 anchor, and the Taqman probe within
the LincRNA-p21/p21 locus.
adenocarcinoma cells exhibits normal chromatin architecture, demonstrating that aberrant looping cannot
explain the absence of a clear phenotype in ΔRE cells.
Our data therefore implicate the existence of robust chromatin interactions between the promoters
of LincRNA-p21 and p21. In accordance with reports that topological domains are largely consistent
across different cell types (Dixon et al., 2012), the presence of oncogenic signaling in the lung
adenocarcinoma cells did not appear to affect the architecture of the locus. Moreover, looping did not
appear to require LincRNA-p21 transcription, the region absent from the Δ127 allele, the p53RE, or p53
signaling. Although these results do not reveal the role of the conserved sequence element, they provide a
clear mechanistic basis for the exchange of regulatory information between the LincRNA-p21 and p21
promoters.

Investigating the requirement for transcription through exon 1 of LincRNA-p21
Although full-length LinRNA-p21 transcription is dispensable for cis-regulation, we wondered
whether low levels of transcription through exon 1, particularly the conserved region, could still play a
role in reinforcing p21 expression. To address this, we used several molecular approaches to down- and
upregulate LincRNA-p21 expression. We first turned to CRISPRi, which we hoped would enforce
epigenetic silencing of the LincRNA-p21 locus and incur a decrease in p21 expression (Gilbert et al.,
2014). We implemented a doxycycline-inducible dCas9-KRAB system, which should only repress
LincRNA-p21 in the presence of doxycycline. Upon doxycycline treatment, p53-restorable MEFs stably
infected with the dCas9-KRAB expression system showed robust dCas9-Krab RNA induction, indicating
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Figure 20. Epigenetic silencing of LincRNA-p21 does not affect p21 levels. (A) Schematic of
LincRNA-p21 exon 1 showing the relative positions of RNA guides for CRISPRi. The p53RE is
indicated by the red box. (B) RT-qPCR analysis of dCas9-KRAB expression in p53-restorable MEFs
stably infected with a doxycycline-inducible dCas9-KRAB expression vector and treated with the
indicated concentration of doxycycline. Data represent the mean of n=3 technical replicates. For all
samples, dCas9-KRAB levels were calculated relative to Gapdh and normalized to levels in untreated
control cells. (C) RT-qPCR analysis of LincRNA-p21 expression in p53-restorable MEFs expressing
dCas9-KRAB and the indicated gRNA, cultured for 24 hours in the absence or presence of 0.5 µM 4hydroxytamoxifen and cultured for an additional 24 hours in the absence or presence of 0.5 µM
doxorubicin. Data represent the mean ± SD (n=3 technical replicates). For all samples, LincRNA-p21
levels were calculated relative to Gapdh and normalized to levels in untreated control cells. (D and E)
RT-qPCR analysis of LincRNA-p21 and p21 expression. p53-restorable MEFs stably expressing dCas9KRAB and the indicated gRNA were cultured for >1 week in the presence of 2.0 µg mL-1 doxycycline,
cultured for 24 hours in the absence or presence of 0.5 µM 4-hydroxytamoxifen, and cultured for an
additional 24 hours in the absence or presence of 0.5 µM doxorubicin. Data represent the mean ± SEM
(n=3 biological replicates), n.s., not significant, paired t-test. For all samples, LincRNA-p21 and p21
levels were calculated relative to Gapdh.
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the viability of this approach (Fig. 20B). We stably infected these MEFs with constructs expressing one
of nine RNA guides targeting a 400 nucleotide window centered on the LincRNA-p21 TSS (Fig. 19A).
Cells were cultured for over a week in order to allow KRAB sufficient time to enact epigenetic repression
(Kearns et al., 2014).
We observed that guides I-6, I-10, I-12, I-13, and I-14 mediated the knockdown of LincRNA-p21
in both p53-deficient and p53-proficient MEFs (Fig. 20C). However, we chose to focus I-6, I-10, and I12, as I-13 and I-14 both occlude the p53RE. In subsequent experiments, these three guides reduced
LincRNA-p21 levels only modestly and did not appear to perturb p21 expression (Fig. 20D-E). Our results
are therefore inconclusive. The lack of an effect on p21 expression may indicate that LincRNA-p21
transcription is dispensable for cis-regulation; alternatively, these data may support a model in which a
moderate amount of transcription from the LincRNA-p21 locus is sufficient to reinforce p21 activity.
We next wondered whether increased transcription from the LincRNA-p21 locus might upregulate
p21 expression. To test this, we performed CRISPRa in clonal p53-restorable MEFs with mutagenized
(ΔRE) or wildtype (Con) p53REs (Fig. 21A). Elena Martínez-Terroba (E. Martínez-Terroba) designed
lentiviral constructs harboring the SAM system and one of five dRNA guides targeting a 200 nucleotide
window upstream of the LincRNA-p21 TSS (Fig. 21A). These constructs were stably infected into ΔRE
and Con MEFs. In ΔRE cells, dRNA A4 upregulated LincRNA-p21 expression by 400-600% in both the
absence and presence of p53 signaling (Fig. 21B). This increase in LincRNA-p21 transcription correlated
with a significant increase in p21 levels at low levels of stress: p53-deficient cells exhibited a 1500%
upregulation in p21 expression, while p53-restored, unstressed cells showed a 200% increase in p21
levels (Fig. 21C). Unexpectedly, CRISPRa did not increase LincRNA-p21 levels in Con MEFs, perhaps
suggesting that LincRNA-p21 transcription is constrained to a narrow dynamic range in these cells (Fig.
21D). Although several dRNAs mediate significant increases in p21 levels in p53-deficient and p53proficient, unstressed Con cells, their effect size is relatively modest compared to the transcriptional
activation observed in ΔRE cells (Fig. 21E). This may suggest that the increased p21 expression in the
ΔRE cells is a specific consequence of LincRNA-p21 transcriptional activation. If
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Figure 21. LincRNA-p21 activation promotes p21 expression in ΔRE p53-restorable MEFs. (A)
Schematic of LincRNA-p21 exon 1 showing the relative positions of dRNA guides for CRISPRa as
well as the sequence of each allele in clonal ΔRE cells. The p53RE is indicated by the red box. (B and
C) RT-qPCR analysis of (B) LincRNA-p21 and (C) p21 expression in clonal ΔRE cells stably infected
with Cas9, the indicated chimeric dRNA guide harboring two MS2 stem-loops, and the HSF-p64-MS2
binding protein fusion. Data represent the mean ± SEM (n=2 biological replicates), n.s., not significant,
*p<0.05, **p<0.01, paired t-test. For all samples, LincRNA-p21 and p21 levels were calculated relative
to Gapdh and normalized to untreated dCon cells. (D and E) RT-qPCR analysis of (D) LincRNA-p21
and (E) p21 expression in clonal Con cells stably infected with Cas9, the indicated chimeric dRNA
guide harboring two MS2 stem-loops, and the HSF-p64-MS2 binding protein fusion. Data represent the
mean ± SEM (n=2 biological replicates), n.s., not significant, *p<0.05, **p<0.01, paired t-test. For all
samples, LincRNA-p21 and p21 levels were calculated relative to Gapdh and normalized to untreated
dCon cells.
E. Martínez-Terroba designed and cloned the constructs described in (A)
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correct, this interpretation might indicate that p21 is insensitive to LincRNA-p21 levels after they exceed a
critical threshold.
We also sought an alternative approach for addressing the role of transcription through the
conserved region of exon 1 in the context of primary MEFs. To accomplish this, we used dRNA guides to
target Cas9 to exon 1 of LincRNA-p21 and occlude transcription without engaging its endonuclease
activity (Fig. 22A)(Dahlman et al., 2015; Qi et al., 2013). Although a dRNA targeting a region
immediately downstream of the TSS (d2) did not significantly reduce the expression of spliced LincRNAp21, likely due to the presence of a second TSS downstream of the p53RE, it did mediate an ~80% loss of
transcription upstream of the p53RE (Fig. 22B). Intriguingly, both this dRNA and a positive control
dRNA targeting the p53RE (d1) suppressed p21 RNA levels by 21% and 35%, respectively (Fig. 22B).
These results, in conjunction with our data showing that Twister permits ~40% of wildtype transcription
through exon 1 (Fig. 22C), raised the exciting possibility that a small amount of active transcription may
be essential for cis-regulation, hinting at a dual requirement for both transcription and the conserved
sequence element.
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Figure 22. LincRNA-p21 transcriptional inhibition correlates with a reduction in p21 levels. (A)
Schematic showing the position of each dRNA guide and amplicon relative to LincRNA-p21 Exon 1.
(B) RT-qPCR analysis of spliced and total LincRNA-p21 RNA levels in MEFs co-expressing Cas9 and
the indicated dRNA guide. Data represent the mean ± SEM (Spliced LincRNA-p21 n=4; E1_1 n=3;
E1_2 n=3; biological replicates); *p<0.05, **p<0.01, ***p<0.001. For each primer pair, LincRNA-p21
levels were calculated relative to Gapdh and normalized to cells expressing dCon. (C) RT-qPCR
analysis of p21 RNA expression in the MEFs described in (B-D). Data represent the mean ± SEM (n=4
biological replicates); *p<0.05, ***p<0.001, paired t-test. p21 levels were calculated relative to Gapdh
and normalized to cells expressing dCon.
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Data summary and conclusion
Although recent genetic studies have converged on the consensus that LincRNA-p21 acts locally
to reinforce p21 expression (Dimitrova et al., 2014; Groff et al., 2016; Korkmaz et al., 2016), its
mechanism of action has remained the subject of scrutiny. To elucidate the molecular logic underlying
this cis-regulatory relationship, we performed an extensive genetic and molecular dissection of the
LincRNA-p21 locus. As a result of our efforts, which we report in this chapter, we exclude full-length
transcription, transcript processing, and RNA accumulation as effecters of cis-regulation; instead, we
provide evidence that transcription through a conserved region within exon 1 of LincRNA-p21 supports
p21 expression. We show that it likely accomplishes this by exploiting stable chromatin interactions
between the promoters of both loci, thereby providing a mechanistic basis for the exchange of information
about LincRNA-p21’s regulatory state.
This finding is consistent with several known mechanisms of cis-regulatory lncRNA function.
LncRNAs have been proposed to recruit transcription factors with dual DNA/RNA binding activity
(Sigova et al., 2015), and the LincRNA-p21 transcript has previously been shown to interact with the
transcriptional activator hnRNP-K (Dimitrova et al., 2014; Huarte et al., 2010; Yoon et al., 2012). It is
therefore possible that the conserved sequence element is transcribed into an RNA scaffold for protein
factors that act, in turn, to reinforce p21 expression. Alternatively, the process of transcriptional initiation
may promote transcription factor binding by “licensing” enhancer elements within the conserved region
(Scruggs et al., 2015). Indeed, transcription has been observed to promote epigenetic remodeling at
enhancers under diverse biological contexts (Anderson et al., 2016; Kaikkonen et al., 2013), although the
functional significance of this relationship remains unclear.
Our data support several key findings from previous genetic studies of both mouse and human
LincRNA-p21. In particular, we confirm reports that enhancer-like DNA elements within exon 1 harbor
cis-regulatory activity (Groff et al., 2016; Korkmaz et al., 2016) and show that the locus is a functional
driver of p21 expression (Dimitrova et al., 2014; Groff et al., 2016; Korkmaz et al., 2016; Tesfaye et al.).
As an important addition to previous literature, which showed that the conserved region in exon 1 is
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sufficient to drive the expression of an exogenous reporter construct, we demonstrated that this region is
necessary for cis-regulation at the endogenous LincRNA-p21 locus (Groff et al., 2016). However, our
conclusions also diverge from those of previous genetic studies on a key point. Notably, we observed a
dual requirement for both the conserved region and the transcriptional process. This stands in contrast to
the findings of one study, which reported that LincRNA-p21 operates primarily as a DNA element whose
transcription is dispensable for its function (Groff et al., 2016). It is thus important to note that, while we
used multiple loss-of-function strategies that minimally disrupted the LincRNA-p21 sequence, Groff et al.
replaced the entire locus with a lacZ reporter (Groff et al., 2016; Sauvageau et al., 2013). Their data,
which show a reduction in p21 levels across multiple different tissue types, including tissues in which
mature LincRNA-p21 is absent, are therefore also consistent with a model in which transcription through
sequence elements in exon 1—but not the mature transcript—contributes to cis-regulation. Our results
also stand in contrast to work that used ASOs to identify a role for either the full-length transcriptional
process or mature RNA. The same ASOs mediated a significant reduction in p21 levels in mutant MEFs,
which overwhelmingly lack LincRNA-p21 RNA, perhaps implicating nonspecific effects.
As part of this work, we sought to develop complementary genetic strategies to disrupt biogenesis
of the endogenous LincRNA-p21 RNA. Self-cleaving ribozymes represent an emerging strategy for
interrogating cis-acting lncRNA function (Camblong et al., 2009; Tuck et al., 2018; Wery et al., 2018b).
Although tools such as the Hammerhead and Hepatitis Delta ribozymes have been extensively used to
study RNA processing in the context of short transgenic constructs (Bird et al., 2005; Eckner et al., 1991;
West et al., 2004), the effects of co-transcriptional ribozyme cleavage on endogenous lncRNA
transcription remain largely uncharacterized, making it difficult to evaluate the conclusions of existing
work. In this study, we used TT-qPCR to reveal that Twister mediates the co-transcriptional knockdown
of the nascent LincRNA-p21 RNA. This was surprising in light of reports that co-transcriptional ribozyme
cleavage does not destabilize transcription (Fong et al., 2009; West et al., 2004) and that downstream
ribozyme cleavage products are poor substrates for XRN2-mediated transcriptional termination
(Doamekpor et al., 2020; Jinek et al., 2011; Roth et al., 2014). Our data highlight the need to investigate
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the effects of these promising genetic tools on the transcriptional and epigenetic landscape of endogenous
lncRNAs and develop robust “design rules” for their implementation.
Ultimately, our work helps to illuminate the biological significance of the relationship between
LincRNA-p21 and p21. LncRNAs have been proposed to specify cell fate by “fine tuning” the expression
of key protein-coding genes (Cabili et al., 2011; Gil and Ulitsky, 2020; Guttman et al., 2009). In keeping
with this paradigm, an elegant study recently showed that early p21 expression dynamics specify cell fate
in response to genotoxic stress (Hsu et al., 2019). Given that LincRNA-p21 is detectably induced as early
as one hour after p53 stabilization in human colon cancer cells (Allen et al., 2014), this lncRNA may
represent a mechanism for modulating p21 levels during the initial p53 transcriptional response. This
would explain our intriguing observation that deletion of the conserved sequence element and dRNAmediated transcriptional inhibition decreased p21 expression in primary MEFs cultured in the absence of
doxorubicin treatment. Since ambient oxygen levels have been shown to induce oxidative stress
(Jagannathan et al., 2016), which in turn can activate the p53 pathway (Kastenhuber and Lowe, 2017), we
propose that LincRNA-p21 may help activate p21 levels past a critical threshold in response to low levels
of p53 signaling (Dimitrova et al., 2014).
In summary, our data demonstrate that full-length lncRNA transcription, processing, and
accumulation are dispensable for cis-regulation at the LincRNA-p21 locus. By systematically dissecting
the overlapping layers of LincRNA-p21 biogenesis, we reveal a dual requirement for transcriptional
initiation and sequence elements embedded in exon 1. Our results showcase the power of complementary
genetic and molecular tools to illuminate new facets of cis-regulation and, in doing so, enhance our
understanding of the noncoding transcription that pervades our genome.
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Chapter V: Summary and perspectives
The regulatory significance of pervasive transcription
Our work adds to the growing body of evidence that the noncoding transcriptome is often a
functional driver—and not a byproduct—of diverse regulatory programs. Unexpectedly, we found that the
process of active transcription through exon 1 of LincRNA-p21 is necessary to reinforce p21 expression.
By contrast, full-length transcription, splicing, and RNA accumulation are dispensable. Moreover, we
demonstrated that a conserved region, which itself enhances LincRNA-p21 transcription, also contributes
to cis-regulation. Notably, this region harbors predicted binding sites for a number of transcription
factors, including CEBPα/β, EGR4, and Sp1. In support of the functional relevance of these predicted
sites, both empirical and computational data indicate that the corresponding transcription factors bind
homologous sequences within the human locus. Interestingly, Sp1 has previously been shown to interact
with p53 (Koutsodontis et al., 2001), raising the possibility that transcription factors bound within the
Δ127 region might cooperate with DNA-bound p53 in order to activate LincRNA-p21 and p21 expression.
Nonetheless, it remains unclear how the transcriptional process and conserved region might cooperate to
enact their cis-regulatory function. Here, we envision several mechanistic possibilities with distinct
consequences for our understanding of cis-regulation at this locus and throughout the genome.

Model 1: transcription per se
As a first possibility, the act transcription per se might be sufficient to drive p21 expression.
Under this model, the p53RE and adjacent conserved region would function as an enhancer-like element
for LincRNA-p21 but not p21. The LincRNA-p21 transcriptional process would act, in turn, to reinforce
p21 levels. Since the identity of the transcribed sequence is irrelevant in this scenario, CRISPRa in ΔRE
or Δ127 cells would likely upregulate p21 expression, demonstrating that the transcriptional process is
sufficient for cis-regulation in the absence of regulatory DNA elements.
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This mechanistic paradigm has been described for other lncRNAs, including both Blustr and
Maenli (Allou et al., 2021; Engreitz et al., 2016). Transcription is essential to the cis-regulatory activity of
both loci, as evidenced by the functional consequences of premature transcriptional termination.
However, the underling sequences appear to be largely dispensable, since intron and exon deletions do
not dysregulate neighboring genes. Blustr and Maenli thus serve as an example for how local transcription
can enact cis-regulation in a sequence-independent manner.

Model 2: enhancer licensing through transcription
As a second model, LincRNA-p21 transcription may license the conserved region to act as a distal
p21 enhancer. Under this paradigm, the conserved region would serve as a cis-regulatory DNA element
for both LincRNA-p21 and p21. The transcriptional process would thus confer an additional layer of
regulatory specificity by modulating the local epigenetic state in order to promote transcription factor
binding.
LincRNA-p21 transcription could promote transcription factor binding through one of several
mechanisms. Firstly, it could mediate nucleosome repositioning or disassembly, leading to the formation
of a nucleosome-free region around the LincRNA-p21 promoter. Indeed, lncRNA transcription has been
shown to reduce the local nucleosome density at transcription factor binding sites, permitting binding by
cognate transcription factors (Hirota et al., 2008; Senmatsu et al., 2019). Although this phenomenon has
largely been documented in yeast, a few studies suggest that transcription may also contributes to the
formation of nucleosome-free regions at mammalian promoters (Scruggs et al., 2015; Seila et al., 2009).
Since many transcription factors are unable to bind within regions of high nucleosome occupancy (Zhu et
al., 2018), active transcription could thus expose previously-occluded binding sites within the conserved
region.
As an alternative, transcription could create a more permissive epigenetic environment around the
LincRNA-p21 promoter. This, in turn, could promote transcription factor binding within the region.
LncRNA transcription has previously been shown to modulate the local epigenetic state. For example,
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Upperhand transcription establishes and maintains high levels of H3K27ac across its associated superenhancer (Anderson et al., 2016), although it remains unclear whether H3K27ac levels have functional
consequences for enhancer activity (Zhang et al., 2020). Interestingly, regions of stable H3K4
methylation, which are associated with transcriptionally active promoters, have been shown to be more
accessible to transcription factors (Huang et al., 2019). Taken together, these findings demonstrate the
viability of a model in which transcription creates a more permissive epigenetic environment for
transcription factor binding at the LincRNA-p21 locus.

Model 3: functional sequence elements in the nascent RNA
If correct, the preceding models would point to the conclusion that the LincRNA-p21 transcript is
dispensable for cis-regulation and instead identify a sequence-independent role for transcription. By
contrast, a third model, in which the 5’ end of the nascent RNA molecule acts as a recruitment platform
for activating protein factors, implicates LincRNA-p21 sequence and structure as a key mediator of cisregulation. LincRNA-p21 has previously been shown to bind hnRNP-K via a structurally-conserved ~200
nucleotide sequence at its 5’ end (Huarte et al., 2010). Intriguingly, the conserved region described in our
work harbors a predicted binding site for hnRNP-K, suggesting that it could serve as a binding platform
for this and other proteins. This mode of action has been documented for other lncRNAs, including
Khps1, which recruits p300/CBP to its locus (Postepska-Igielska et al., 2015). As discussed previously
(see Chapter I), the Khps1 RNA interacts with the DNA duplex to form a triple helix, demonstrating the
requirement for a tether to retain the Khps1/p300/CBP complex on the chromatin (Postepska-Igielska et
al., 2015). Under our final model of LincRNA-p21 function, the nascent 5’ end would remain tethered to
the chromatin by elongating Pol II. Active transcription through exon 1 would thus maintain a pool of 5’
ends capable of recruiting protein factors to the lncRNA promoter.
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The majority of LincRNA-p21 transcription is nonfunctional
One important outcome of our work is the observation that the vast majority of LincRNA-p21
transcription is nonfunctional. Although the LincRNA-p21 locus spans over 20 kilobases, only
transcription through exon 1 contributes to cis-regulation. Our results therefore suggest that a single
transcriptional initiation event may mediate both functional and nonfunctional transcription. In particular,
if transcription through a regulatory element such as the conserved region within exon 1 contributes to
cis-regulation, then downstream transcription and RNA processing may be dispensable so long as their
absence does not impair the kinetics of upstream processes. Notably, this has been shown to hold true for
other cis-acting lncRNAs, including 118 kilobase lncRNA Airn. Although transcription through the ~30
kilobase region overlapping the Igf2r locus is required for gene silencing, premature transcriptional
termination outside of this window has no functional consequences (Latos et al., 2012). Thus, the
majority of the Airn transcriptional unit is nonfunctional, since it does not contribute to Igf2r imprinting.
Similarly, full-length transcription of Blustr has been shown to be inessential for Sfmbt2 expression.
Although Sfmbt2 levels exhibit some dependence on the length of the Blustr transcriptional unit,
transcription through the final ~ten kilobases of this 26 kilobase locus does not appear to contribute to its
cis-regulatory function (Engreitz et al., 2016). Our work thus adds to the mounting body of evidence that
many functionally transcribed lncRNAs do not act through full-length transcription.
One question that arises from our work is why lncRNAs such as LincRNA-p21, Airn, and Blustr
have such large genomic footprints if their full-length transcription is dispensable for cis-regulation. The
answer to this question may be rooted in the evolutionary dynamics of eukaryotic genomes. In humans,
and likely in other mammals, the majority of the genome evolves nearly neutrally, meaning that it is not
subject to strong selective pressure. This weak selective regime may permit the emergence of cryptic
TSSs that give rise to nonfunctional “junk” transcripts (Palazzo and Koonin, 2020). Importantly,
transcription and RNA degradation impose a negligible energetic burden on eukaryotic cells (Lynch and
Marinov, 2015), suggesting that the majority of “junk" lncRNAs are unlikely to incur a significant fitness
cost. Over time, neutral mutations may allow nonfunctional lncRNA loci to explore the sequence space
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and acquire novel functions within pre-existing cellular pathways (Palazzo and Koonin, 2020). This
functionality may not require the lncRNA transcript or even full-length transcription; in the absence of
selective pressure against unnecessarily long transcriptional units, and without neutral evolution that
results in a shortened transcriptional unit, the transcript will likely retain its initial length. Under this
paradigm, the transcription of a multi-kilobase, multi-exonic locus may thus reflect the evolutionary
process that generated a functional transcriptional event from an ancestral “junk” transcript.
Our finding that transcription through the majority of the LincRNA-p21 locus is inessential has
broad implications for our ability to successfully identify other functionally transcribed lncRNAs. In
particular, our findings show that parallel genetic and molecular approaches may be required to establish
lncRNA functionality. Although both the PAS and Twister abrogated LincRNA-p21 expression in primary
MEFs, neither mediated a reduction in p21 levels. In other experimental contexts, this might have been
interpreted as evidence that the transcriptional process does not contribute to cis-regulation, supporting a
model in which the conserved region acts as an enhancer-like DNA element. However, transcriptional
roadblock experiments indicated that transcription through exon 1, which Twister (and likely the PAS)
permits, harbors cis-regulatory activity. Our results demonstrate the need for caution when interpreting
negative results from lncRNA knockdown experiments and underscore the importance of careful tool
design and placement.

The importance of an expanded toolkit for studying noncoding RNA function
Cis-acting lncRNAs have a unique capacity to enact gene regulation through multiple features of
their locus, transcription, and RNA. This mechanistic diversity poses considerable challenges for
identifying the functional unit of cis-regulation at uncharacterized lncRNA loci. In particular, the lncRNA
field requires tools that can deconvolve the closely-interlinked effects of transcription, co-transcriptional
processes such as splicing, and the mature RNA transcript. As Orgel’s rule famously states, “evolution is
cleverer than you are.” In keeping with this, the kaleidoscopic repertoire of naturally-occurring genetic
elements provides ample inspiration for new tools. Many of these elements have the potential to act in cis
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to specifically regulate the processing, stability, and even sequence of host RNAs. This makes them
attractive candidates for development into a new generation of tools.
The current tools for modulating transcription (discussed in Chapter I) are both limited and
limiting. When implemented successfully, PAS sequences entirely abolish transcription from a locus.
While this approach is invaluable for establishing a requirement for lncRNA transcription, it is less useful
for addressing how transcription mediates gene regulation. In order to examine the temporal relationship
between lncRNA transcription and changes in the local chromatin environment, studies have often turned
to molecular approaches such as the reversible transcriptional inhibitor DRB (5,6-dichloro-1-beta-Dribofuranosylbenzimidazole). This permits the investigation of the effects of abolishing and restoring
transcription at a locus of interest. This approach has the potential to reveal intriguing correlations
between molecular events at two loci. However, because it disrupts global Pol II transcription, it cannot
specifically test the effects a lncRNA on the local epigenetic state. Novel genetic tools may help
circumvent the caveats of current approaches.
RNA-based transcriptional attenuation is one solution for specifically and reversibly inhibiting
lncRNA transcription. This approach is predicated on the ability of structured RNA sequences to
constitutively attenuate the transcription of host genes. Short RNA sequences, termed small transcriptionactivating RNAs (STARs), may bind to a complementary sequence within the attenuator, disrupting its
structure and permitting transcription through the locus (Chappell et al., 2015). Although this approach
was pioneered in bacterial cells, several lines of evidence hint at its applicability as a tool for studying
eukaryotic gene regulation. In particular, early work on the SV40 virus revealed the presence of two
hairpin elements that competently block transcriptional elongation, demonstrating the ability of structured
RNA elements to block Pol II transcription in mammalian cells (Resnekov et al., 1989). Subsequent work
showed that short DNA sequences—conceptually akin to STARS—could release this transcriptional
block (Kessler and Aloni, 1989). Taken together, these studies provide preliminary support for the
viability of a specific and reversible RNA-based transcriptional attenuator.
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Other genetic elements present attractive opportunities for modulating lncRNA processing,
particularly splicing. Riboswitches can reversibly inhibit splicing by sequestering the 5’ splice site, 3’
splice site, or branch point. As a proof of principle, insertion of the theophylline riboswitch into either the
branch point or 3’ splice site of a reporter gene has been shown to suppress splicing in the presence of
theophylline (Kim et al., 2005, 2008). It is important to note that such an approach may not prevent
splicing entirely and may instead induce exon skipping (Vogel et al., 2018). However, this may prove
useful for testing the functionality of the skipped sequence.
An additional suite of tools may alter RNA stability either co- or post-transcriptionally. Here,
self-cleaving ribozymes again demonstrate their versatility, this time as tools for mediating contextspecific transcript cleavage. As a first example, small molecule-inducible self-cleaving ribozymes may be
used to regulate RNA stability. In this approach, aptamers grafted to ribozymes permit cleavage in the
absence of a small molecule such as theophylline or xanthine (Xiang et al., 2019). Following ligand
binding, however, the aptamer inhibits the ribozyme’s self-cleaving ability. This, in turn, permits the
accumulation of the host transcript. Such an approach may prove particularly useful for elucidating the
role of lncRNAs in the initiation and long-term maintenance of subcellular structures such as
paraspeckles. Split ribozymes may also enact context-specific transcript cleavage. For example, a selfcleaving ribozyme spanning an intron may self-cleave following a splicing event that removes the
intervening intron. Such an approach would facilitate spliceform-specific transcript degradation and could
serve as a viable approach for specifically destabilizing processed transcripts. As an alternative to selfcleaving ribozymes, UTRs may be used to destabilize transcripts. For example, the c-fos 3’ UTR has
previously been used to destabilize the Kcnq1ot1 RNA (Pandey et al., 2008), demonstrating its
fundamental feasibility as an approach for regulating lncRNA functionality.
While the genetic elements discussed above provide several different strategies for destabilizing
host transcripts, other elements may enhance RNA stability. For example, elements for nuclear expression
(ENEs) protect host transcripts from degradation by 3’-5’ exonucleases by sequestering the poly(A) tail
(Conrad et al., 2006). This increased stability may result in functional lncRNA upregulation. As an
94

important note, this approach is specific to RNAs with poly(A) tails. Since many cis-acting lncRNAs
remain tethered to the chromatin by Pol II (Werner and Ruthenburg, 2015), its applicability may be
limited. Lariat-capping ribozymes are another attractive option for both cleaving and selectively
stabilizing host transcripts. The Didymium lariat-capping ribozyme self-cleaves to yield a downstream
fragment featuring a 2’,5’-phosphodiester bond between the first and third nucleotides (Krogh et al.,
2017). In yeast, this ribozyme efficiently cleaves host transcripts and stabilizes the downstream RNA
product, suggesting that it may present a new strategy for specifically interrogating RNA sequence
requirements while minimally disrupting the DNA sequence. RNA-based genetic tools therefore provide
many exciting avenues for modulating lncRNA expression in vitro and in vivo.
Even as the lncRNA field develops promising new approaches, it must remain committed to
understanding the mechanisms and caveats of existing tools. Our work reveals two surprising findings
that, taken together, demonstrate the need to rigorously evaluate current molecular and genetic
approaches. Firstly, we observed that ASOs targeting the LincRNA-p21 transcript attenuated p21
transcription in LincRNA-p21PAS/PAS and LincRNA-p21TWI/TWI MEFs despite the overwhelming absence of
spliced RNA in both cell lines. Since Twister cleavage permits a small degree of transcription into exon 2,
it is possible that ASO-mediated degradation of the remaining transcript further suppresses transcription
from the promoter, thus preventing LincRNA-p21 from enacting cis-regulation. However, it is unclear
whether this explanation could also apply to LincRNA-p21PAS/PAS MEFs. Given that transcription may
continue for more than ten kilobases after a PAS (Core et al., 2008), it is formally possible that the
remaining transcription, which ASO-I and ASO-E2 deplete, is sufficient to reinforce p21 expression.
However, our results may also indicate nonspecific or off-target effects of ASOs, demonstrating the need
to better understand this technology.
As a second outcome, we found that Twister mediates a ~60 decrease in nascent RNA expression
at the LincRNA-p21 TSS (see Chapter IV). This observation is puzzling in light of reports that ribozyme
cleavage likely does not incur transcriptional knockdown by XRN2, the primary effector of cotranscriptional termination (West et al., 2004). Since self-cleaving ribozymes have garnered increasing
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interest as tools for elucidating previously-unappreciated aspects of lncRNA biology, (Camblong et al.,
2009; Tuck and Bühler, 2021; Tuck et al., 2018; Wery et al., 2018b), it is imperative to understand their
effects on the transcription and metabolism of host RNAs.
There are several key possibilities, each with disparate implications for this tool family. Firstly,
although exoribonucleases such as XRN2 exhibit a strong preference for 5’-monophorylated substrates
(Doamekpor et al., 2020; Jinek et al., 2011; Mathy et al., 2007; Pellegrini et al., 2008), it is possible that
XRN2 eventually, if inefficiently, metabolizes substrates with 5’-hydroxyl groups, generating a 5’phosphorylated intermediate that is subsequently amenable to rapid degradation.
As a second possibility, other enzymes may modify the 5’ ends of downstream cleavage products
to promote their reentry into the XRN2 degradation pathway. In yeast, for example, RNA 5’-kinases have
been proposed to promote the degradation of 5’-hydroxylated RNAs by the XRN2 homolog XRN1
(Braglia et al., 2010; Peach et al., 2015). Provocatively, many yeast 5’-hydroxylated RNA termini arise
from genomic regions with the consensus sequence 5’-CAUU|A-3’, a perfect match for the Twister
cleavage site (Peach et al., 2015). Since mammalian cells harbor many RNA 5’-kinases (Shuman and
Hurwitz, 1979; Weitzer and Martinez, 2007), 5’ end phosphorylation may represent a general mechanism
for permitting the reentry of non-phosphorylated substrates into the major 5’ end surveillance pathway.
Alternatively, distributive exonucleases such as decapping and exoribonuclease (DXO) family proteins
may hydrolyze the 5’-terminal nucleotide, generating a 5’-phosphorylated product that is subsequently
degraded by XRN2 (Doamekpor et al., 2020). Similarly, endonuclease cleavage within the host transcript
may generate additional RNA fragments with 3’-hydroxyls and 5’-monophosphate groups; these may
serve as substrates for the nuclear exosome and XRN2, respectively.
As a final possibility, another nuclear 5’-3’ exoribonuclease may degrade downstream cleavage
products. Interestingly, the yeast exonuclease Rrp17, which acts processively to trim the 5’-hydroxylated
ends of pre-rRNAs, has a mammalian homolog (Nol12) that likely also mediates 5’-3’ RNA degradation
(Oeffinger et al., 2009; Sloan et al., 2013). This suggests that non-XRN2 exonucleases could potentially
recognize and degrade the LincRNA-p21 transcript following Twister cleavage.
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The mechanism of Twister-mediated RNA degradation has considerable implications for our
understanding of the “design rules” governing the placement of Twister and similar self-cleaving
ribozymes within host transcripts. If, as discussed above, XRN2 inefficiently metabolizes the first
nucleotide of substrates with 5’-hydroxyl groups, or if other enzymes modify the 5’ end of the cleavage
product such that it becomes a suitable substrate for XRN2, then this initial event may serve as the ratelimiting step for RNA degradation. Since kinetic competition between XRN2 and Pol II defines the
region of transcriptional termination (Fong et al., 2015), then the extent of transcription will depend in
part on the distance traversed by Pol II during the rate limiting step. Alternatively, if other 5’-3’
exonucleases progressively degrade cleaved transcripts, then their kinetics will determine how ribozyme
cleavage affects transcription. A thorough understanding of how Twister and other self-cleaving
ribozymes effect targeted transcript degradation may therefore prove critical for selecting optimal
ribozyme insertion sites and evaluating experimental results.
Although cis-regulatory lncRNAs pose many unique challenges, the lncRNA field appears wellprepared to surmount them. The steady development and implementation of novel tools, including selfcleaving ribozymes such as Twister, has given rise to an expansive array of approaches for addressing
increasingly mechanistic questions about lncRNA functionality. Continuing innovation, including the
adoption of new tools such as those described above, will further expand the suite of techniques available
for experimental application. We predict that this innovation, coupled with rigorous efforts to understand
the molecular effects of existing tools, will enable the lncRNA field to further mature.

Final remarks
Mammalian genomes harbor numerous transcribed regulatory loci that play an increasingly
recognized role as mediators of local gene expression. However, the molecular mechanisms through
which these loci enact cis-regulation have remained largely unclear. Using a comprehensive genetic and
molecular approach, we showed that active transcription through exon 1 of LincRNA-p21 is sufficient to
97

drive expression of the nearby p21 gene. Two major lessons arise from our work. Firstly, we echo the
observation that cis-regulatory lncRNA loci can harbor multiple functional elements. In light of this,
experimental efforts to dissect a lncRNA’s mechanism of action must make use of multiple
complementary approaches. Secondly, our work adds to the growing body of literature recognizing
transcription or the nascent RNA as an important mechanism of cis-activation (Allou et al., 2021;
Anderson et al., 2016; Canzio et al., 2019; Engreitz et al., 2016; Isoda et al., 2017). Like LincRNA-p21,
many functionally transcribed lncRNAs have large genomic footprints; for many of these lncRNAs,
transcription through this vast genomic distance is central to their cis-regulatory activity (Allou et al.,
2021; Anderson et al., 2016; Engreitz et al., 2014; Isoda et al., 2017). By contrast, our data demonstrate
that full-length LincRNA-p21 transcription is dispensable, pointing to a regulatory role for TSS-proximal
transcription at this locus. In narrowing down the functional element of cis-regulation at the LincRNA-p21
locus, we expand the range of mechanistic possibilities for functional cis-regulatory loci and demonstrate
the genomic significance of pervasive noncoding transcription.

98

Chapter VI: Materials and methods
Animal handling and genotyping
LincRNA-p21 knockdown mice were generated using CRISPR/Cas9-mediated engineering in
C57BL/6J mice at the Jackson Laboratory for Genomic Medicine. Briefly, blastocysts were
electroporated with Cas9, a guide RNA targeting LincRNA-p21 and one of the two HDR templates
described in Supplementary Table 1. Mice carrying each allele of interest were identified by PCR-based
genotyping using primers described in Supplementary Table 1 followed by Sanger sequencing and were
subsequently back-crossed once with wildtype C57BL/6J mice. For whole-tissue RNA expression
analysis, 2-5 month-old female mice were used. All studies and procedures were conducted with the
approval of the Yale University Institutional Animal Care and Use Committee.

Cell lines and treatments
Primary MEFs were isolated from E13.5 embryos resulting from timed heterozygote matings.
MEFs were genotyped using PCR primers described in Supplementary Table 1. All experiments were
performed between passages 2 and 10. p53-restorable (p53LSL/LSL; Rosa26-CreERT2) MEFs and
puromycin-resistant lung adenocarcinoma cells from K-rasLA2-G12D/+; p53LSL/LSL; Rosa26-CreERT2 mice
have previously been described (Feldser et al., 2010; Olivero et al., 2020; Ventura et al., 2007).
Primary MEFs were maintained in DMEM (Gibco) supplemented with 15% fetal bovine serum (FBS), 50
U mL-1 penicillin-streptomycin, 2 mM L-glutamine, 0.1 mM non-essential amino acids, and 0.055 mM βmercaptoethanol, while p53-restorable MEFs and lung adenocarcinoma cells were maintained in DMEM
supplemented with 10% FBS, 50 U mL-1 penicillin-streptomycin, 2 mM L-glutamine, and 0.1 mM nonessential amino acids. All cells were maintained at 37°C in a humidified incubator with 5% CO2.
In order to induce DNA damage, all cells were treated with 0.5 µM doxorubicin (Sigma-Aldrich)
or 25 µM etoposide (Sigma-Aldrich). To delete the loxP-STOP-loxP cassette preventing p53 expression
in p53-restorable MEFs and lung adenocarcinoma cells, cells were treated with 0.5 µM 499

hydroxytamoxifen (Cayman Chemical Company) for 24 hours prior to treatment with doxorubicin.
Tetracycline-dependent gene expression (pHAGE-TRE-dCas9-KRAB; Addgene #50917) was induced by
treating cells with 2.0 µg mL-1 for the time specified in the figure legend.

Constructs
The viral constructs, gRNAs/dRNAs, and shRNA sequences used in this work can be found in
Supplementary Tables 1 and 2.

P53RE mutagenesis and dRNA-mediated transcriptional inhibition
CRISPR/Cas9-mediated mutagenesis and transcriptional inhibition were accomplished using
guide sequences targeting the LincRNA-p21 locus. Guides were cloned downstream of the hU6 promoter
of a lentiviral construct that also expresses spCas9 and a puromycin resistance gene (Brd001) or GFP
selection marker (Brd004). Both lentiviral vectors were gifts from the Broad Institute (MIT).

CRISPRi
To perform CRISPRi, p53-restorable MEFs were serially infected with constructs expressing
dCas9-KRAB and gRNAs targeting the LincRNA-p21 TSS. Cells were first infected with the lentiviral
construct pHAGE-TRE-dCas9-KRAB (Addgene #50917), a doxycycline-inducible expression system
harboring dCas9 from S. pyogenes fused to the KRAB repressor. Successfully infected cells, which
exhibit neomycin resistance, were subsequently infected with a lentiviral vector expressing gRNAs under
the control of the hU6 promoter and harboring a zeocin selection marker (Addgene #61427).

CRISPRa
CRISPRa was accomplished by cloning 14-15 nucleotide “dead” guides downstream of the hU6
promoter of a lentiviral vector co-expressing HSF-p64-MS2 binding protein and a hygromycin resistance
gene (generated by E. Martínez-Terroba)(Olivero et al., 2020). The chimeric gRNA backbone includes
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MS2 stem-loops that facilitate interactions between the guide and the HSF-p64-MS2 binding protein
module. This system was introduced into stably-infected p53-restorable ΔRE-spCas9-GFP or ConspCas9-GFP cells.

Sh-CEBPB
To knock down CEBPB expression, primary MEFs were stably infected with TRC2-pLKO
lentiviral constructs co-expressing sh-CEBPB and a puromycin resistance gene (TRCN0000231407 and
TRCN0000231411; MilliporeSigma).

Viral transduction and infection
To generate lentivirus, HEK293 cells were co-transfected with pCMV-Δ8.2 (Addgene #8455) and
pCMV-VSV-G (Addgene #8454), and the specified lentiviral construct. Viral media was harvested at 48,
72, and 96 hours post-transfection, supplemented with 4 µg mL-1 polybrene, and applied directly to cells.
For retroviral production, Phoenix cells were transfected with retroviral constructs. Retroviral media was
harvested at four consecutive 12-hour intervals, supplemented with 4 µg mL-1 polybrene, and used
directly to infect cells. Following infection, cells were selected with puromycin (2 µg mL-1 for MEFs and
5 µg mL-1 for lung adenocarcinoma cells), neomycin (1 mg mL-1), zeocin (500 µg mL-1), or hygromycin
(400 µg mL-1). Cells stably expressing a GFP marker were selected using a FACS Aria III sorter with
FACS DIVA software (BD Biosciences).

Antisense oligonucleotide (ASO) knockdown
ASO treatment was performed as previously described (Dimitrova et al., 2014), using the 5-10-5
MOE “gapmer” oligonucleotides (Ionis Pharmaceuticals) listed in Supplementary Table 1. Briefly, 2x106
primary MEFs were nucleofected twice using the Amaxa Mouse/Rat Hepatocyte Nucleofector Kit
(Lonza) and Nucleofector 2b Device (Lonza) with a total of 1 µM of targeting or control nontargeting
ASO at 48 hour intervals. Samples were harvested 48 hours after the final nucleofection.
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RNA isolation and RT-qPCR
Total RNA was isolated following the protocol for TRIzol (Thermo Fisher Scientific) or the
RNeasy Mini Kit with or without DNAse I digestion (Qiagen). 0.5-1.0 µg RNA was reverse-transcribed
using the High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems). For qPCR, SYBR Green
mastermix was used in conjunction with the primers listed in Supplementary Table 1. Expression was
calculated relative to GAPDH and normalized to the corresponding control sample.

Transient transcriptome (TT)-qPCR
Primary MEFs cultured in the absence or presence of doxorubicin were treated with 1 mM 4thiouridine (Alfa Aesar) and cultured for 5 minutes in the dark. Samples were placed on ice, rinsed with
PBS, scrape-harvested in PBS, suspended in TRIzol, and frozen at -80°C. Total RNA was isolated using
chloroform extraction and isopropanol precipitation and treated with TURBO DNase to deplete genomic
DNA. Purified RNA was then extracted using phenol-chloroform-isoamyl alcohol followed by ethanol
precipitation. 50 μg of total RNA was biotinylated using MTSEA biotin-XX (Biotium) and enriched
using streptavidin as previously described (Duffy et al., 2015). The resulting nascent RNA was reversetranscribed using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific) and analyzed via
RT-qPCR using iTaq Universal SYBR Green Supermix (Bio-Rad) in conjunction with the primers listed
in Supplementary Table 1. Expression was calculated relative to GAPDH and normalized to the
corresponding control sample.

Protein isolation and immunoblotting
Whole-cell protein samples were prepared by resuspending cell pellets in 2X Laemmli buffer
(100mM Tris-HCl pH 6.8, 200mM DTT, 3% SDS, 20% glycerol) at a concentration of 104 cells/µL. All
samples were boiled at 95°C for 7 minutes and passed through an insulin syringe. Protein samples from
105 cells were separated by electrophoresis on a 10% or 12% SDS-polyacrylamide gel and transferred to a
102

0.2 µm nitrocellulose membrane. Immunoblotting was performed using the following antibodies: p21
(clone F-5, sc-6246, Santa Cruz Biotechnology; 1:250), p53 (clone CM5, NCL-L-p53-CM5p, Leica;
1:1000), and loading control HSP90 (clone C45G5, #4877S, Cell Signaling Technology; 1:1000) or βactin. Goat α-mouse (1706516, Bio-Rad; 1:50000) and donkey α-rabbit (711-035-152, Jackson
ImmunoResearch; 1:50000) secondary antibodies were used in conjunction with Amersham ECL Prime
Western Blotting Detection Reagent (GE Healthcare) to visualize protein bands. Densitometry analysis
was performed by normalizing background-adjusted band intensities to the loading control using Fiji
(ImageJ).

Genomic DNA isolation for genotyping and Sanger sequencing
Cells were lysed in genomic DNA lysis buffer (100 mM Tris HCl pH 8.0, 50 mM EDTA pH 8.0,
0.2% SDS, 200 mM NaCl) supplemented with 1 mg mL-1 proteinase K at 55°C. Genomic DNA was
extracted by isopropanol precipitation and resuspended in Tris-EDTA buffer (10 mM Tris-HCl, pH 8.0; 1
mM EDTA pH 8.0). PCR genotyping was performed using the primers described in Supplementary Table
1. To assess p53RE mutagenesis, a region containing the p53RE was PCR-amplified from genomic DNA
isolated from a heterogenous cell population, cloned into the pCR-Blunt II-TOPO vector (450245,
Invitrogen), and analyzed via Sanger sequencing.

Single-molecule RNA (smRNA) FISH
SmRNA-FISH was performed as previously described (Dimitrova et al., 2014). Briefly, primary
MEFs were seeded on coverslips and cultured for 24 hours in the presence or absence of etoposide before
being fixed in 4% methanol-free formaldehyde in DEPC-treated water for 10 minutes at room
temperature. After being washed twice in PBS, cells were dehydrated overnight in 70% ethanol at 4°C
and stored for up to a week. Dehydrated coverslips were transferred to a hybridization chamber and
equilibrated in Wash Buffer A for 5 minutes (LGC, Biosearch Technologies). Samples were incubated
overnight at 30°C in hybridization buffer containing a 1:50 dilution of Stellaris probes conjugated to
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Quasar 570 or Quasar 670 dye (Supplementary Table 1). The following day, samples were washed twice
with Wash Buffer A for 30 minutes at 30°C, washed once with Wash Buffer B for 5 minutes at room
temperature, and mounted in VECTASHIELD Antifade Mounting Medium with DAPI (Vector
Laboratories). Samples were imaged using the Axio Imager 2 microscope system (Zeiss) with a PlanApo
63x 1.4 oil DIC objective lens (Zeiss).

Chromosome conformation capture (3C)
3C was performed as previously described (Hagège et al., 2007; Naumova et al., 2012), with
some modifications. Briefly, 5-10x106 cells were harvested by trypsinization, rinsed once in 1X PBS, and
resuspended in 10 mL 1% formaldehyde in PBS. Samples were rotated end-over-end for 10 minutes at
room temperature and quenched with 570 µL ice cold 2.5 M glycine. Samples were incubated for five
minutes at room temperature and placed on ice for 15 minutes, with periodic inversion. Samples were
spun down at 225g for 8 minutes at 4°C and washed once in 10 mL ice cold 1X PBS. Samples were flash
frozen in a bath of dry ice and ethanol and stored for up to six months at -80°C.
For cell lysis, frozen samples were thawed on ice and resuspended in 5 mL ice cold lysis buffer
(20 mM Tris HCl pH 8.0, 85 mM KCl, 0.5% NP-40, and 1X complete protease inhibitor tablet [Roche])
for two hours, with periodic inversion. Samples were spun down at 400g for 5 minutes at 4°C and
resuspended in 0.5 mL 1.2X NEB Buffer 3.1 with 0.3% SDS. Next, samples were rotated end-over-end
for 1 hour at 37°C, quenched with 2% Triton X-100, and again rotated end-over-end for 1 hour at 37°C.
For chromatin digestion, samples were treated with 400 U BglII (NEB) and rotated end-over-end
overnight at 37°C.
To inactivate the restriction enzyme, the SDS concentration was brought up to 1.6% and samples
were shaken at 900 RPM for 25 minutes at 65°C. Next, samples were diluted by adding 6.125 mL 1.15X
ligation buffer (10X ligation buffer: 600 mM Tris HCl pH 7.5, 50 mM DTT, 50 mM MgCl2, 10 mM
ATP) and Triton X-100 to a final concentration of 1%. After incubating for 1 hour at 37°C with gentle
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shaking, 100 U of T4 DNA ligase (NEB) was added to each sample. All samples were incubated for 4
hours at 16°C followed by 30 minutes at room temperature.
To reverse the crosslinking, samples were treated with 300 µg Proteinase K and incubated
overnight at 65°C with end-over-end rotation. The next morning, samples were treated with 300 µg
RNAse A (Qiagen) and incubated for 45 minutes at 37°C. DNA was isolated using phenol-chloroform
followed by ethanol precipitation. Purified DNA was resuspended in 150 µL 10 mM Tris pH 7.5. RTqPCR was used to determine the concentration of each 3C library relative to a standard curve obtained by
running serial dilutions of a control template. Libraries were diluted to a final concentration of 50 ng µL-1.
Relative interaction frequencies were measured by performing TaqMan qPCR on 50 ng 3C library using
unidirectional primers in tandem with an anchor primer and fluorescent TaqMan probe targeting the
LincRNA-p21 promoter (Supplementary Table 1). Interactions were normalized to a control region in the
LincRNA-p21 locus.
To determine the digestion efficiency, chromatin samples from before and after BglII digestion
were diluted in 500 µL Proteinase K buffer (5 mM EDTA, pH 8.0; 10 mM Tris-HCl, pH 8.0; 0.5% SDS)
and de-crosslinked for 30 minutes at 65°C in the presence of 20 µg Proteinase K. Samples were treated
with 1 µg RNAse A and incubated for 2 hours at 37 °C. Finally, DNA was isolated using phenolchloroform followed by ethanol precipitation. Purified DNA was resuspended in 60-120 µL ultrapure
water, and digestion efficiency was measured by performing qPCR with primer sets spanning BglII sites.

Statistical analysis
Statistical tests and sample sizes are included in each figure legend. All tests were performed in GraphPad
Prism 7.0. The threshold for statistical significance was p<0.05, with *p<0.05, **p<0.01, ***p<0.001 and
****p<0.0001.

105

Supplementary Tables
Supplementary Table 1. Primers and oligos
RT-qPCR primers
Target
Gapdh
Spliced LincRNA-p21
LincRNA-p21 E1_1
LincRNA-p21 E1_2
LIncRNA-p21 I1
LincRNA-p21 E2_1
LincRNA-p21 E2_2
p21
p53

Forward
AGCTTGTCATCAACGGGAAG
CCTGTCCCACTCGCTTTC
GAGCCCCATAGCCACAACTC
CCTGTCCCACTCGCTTTC
ACGCAGGCGTGGTTGTTCATGCTG
GGAGTCTCATGCTCAGAGAAG
CCAACAGTTAAGCCACACAAAGGA
TCCACAGCGATATCCAGACA
ACGCTTCTCCGAAGACTGG

Reverse
TTTGATGTTAGTGGGGTCTCG
GGAACTGGAGACGGAATGTC
AGTGGGTGGTTCACTTCTGC
CCCCAGTGCTAGCTGTCATTG
ACGTCTTCCTACACGGAGCAACTG
CCCTGACAGACAAGTACCCTCT
CTTCATGGAAGGCAAGCAAACG
GGACATCACCAGGATTGGAC
AGGGAGCTCGAGGCTGATA

TT-qPCR primers
Target
GAPDH
LincRNA-p21 E1_1
LincRNA-p21 E1_I
LincRNA-p21 E2_1
LincRNA-p21 E2_2

Forward
GTGGAAGGGCTCATGGTATGTAGG
GAGCCCCATAGCCACAACTC
CCTGTCCCACTCGCTTTC
GGAGTCTCATGCTCAGAGAAG
CCAACAGTTAAGCCACACAAAGGA

Reverse
GGACACCTACAAAGAAGGGTCC
AGTGGGTGGTTCACTTCTGC
CCCCAGTGCTAGCTGTCATTG
CCCTGACAACAAGTACCCTCT
CTTCATGGAAGGCAAGCAAACG

Genotyping PCR primers
Target
TWI, PAS alleles
Δ127 allele
Δ151 allele
p53RE

Forward
GAAGTGAACCACCCACTCAGC
TGGCAGTCTGACCCACAC
GAGCCCCATAGCCACAACTC
TGGCAGTCTGACCCACAC

Reverse
CCCCAGTGCTAGCTGTCATTG
CCCCAGTGCTAGCTGTCATTG
CTCCCTGTGCGGAGTGTG
TCGAGGACACTCACGGAAAG

Primers for TaqMan RT-qPCR (3C)
TaqMan probe:
5'-FAM-CCATCTCTCCAGCCCTCAAGAAGAGAT-BHQR-3'
Target
Sequence
Anchor (LincRNA-p21
CACACATGCAAACACTCATTAA
promoter)
Fragment 1
AAGAAGACTTCTGTAGGCTAGTC
Fragment 2
GTTTGCCAGTATGGGTTTCC
Fragment 3
CTTCAGTTCTGGCACTCAG
Fragment 4
AAGGTTATCTTTTGGTACATAGTGAG
Fragment 5
GTCTGGGTGGAGGAAACTC
Fragment 6
TCTCGCTCTCCATCTATGTC
Fragment 7
GCCCCTGGCATTTCTTAC
Fragment 8
ATATCTTCTGTCTTCAGACACTCC
Fragment 9
GTAAGTACACTGTAGCTGTCTTC
Fragment 10
CTCTTTCACACACACACAGAG
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Fragment 11

CTTTAATCCCAGCACTTGGAG

ASOs
Target
Control (non-targeting)
LincRNA-p21 intron
(ASO-I)

Sequence
CCTTCCCTGAAGGTTCCTCC
GCCATCCTCGGTACTGAGGT

LincRNA-p21 exon 2
(ASO-E2)

TCAGTTGACCCGGGCAAGGT

RNA FISH probes
LincRNA-p21 exonic probes (conjugated to Quasar670)
Name
Sequence
lincRNA-p21_1
aggttgtccacaagttcttg
lincRNA-p21_2
tccaagtgttcactacactg
lincRNA-p21_3
gaatgtctcattccaccatc
lincRNA-p21_4
ctgatgttaggaactggaga
lincRNA-p21_5
tatgttgctggtgacacaca
lincRNA-p21_6
tttctgattggtgtaggcag
lincRNA-p21_7
actgaaaaggcctatctcac
lincRNA-p21_8
cgacagtaatgtccatgatg
lincRNA-p21_9
tgtcttcataacacaggagc
lincRNA-p21_10
atttgagattggtctgggct
lincRNA-p21_11
tgaagaggagtcacaggatt
lincRNA-p21_12
ataagtgtcaatgctctcgc
lincRNA-p21_13
gcaaggttctagtaggaagt
lincRNA-p21_14
acacacacacttcagttgac
lincRNA-p21_15
ttaagcaaacctgcagactg
lincRNA-p21_16
gcaagacctggtctctaaaa
lincRNA-p21_17
tcaagttggcttaggcaaca
lincRNA-p21_18
aaagatggagcaggagaact
lincRNA-p21_19
aagcttcagtcagctgtagt
lincRNA-p21_20
cctcagaggtagtaactcat
lincRNA-p21_21
tacagagttgagaaggccat
lincRNA-p21_22
gagacacctctaagcaacta
lincRNA-p21_23
ttacagatggggaaactgag
lincRNA-p21_24
ttgttcttgctccaagcaca
lincRNA-p21_25
tagagagtataggccaggat
lincRNA-p21_26
agtctgatagccaaagggat
lincRNA-p21_27
attcctgggggaacctttat
lincRNA-p21_28
tcttctctgagcatgagact
lincRNA-p21_29
tttccctgacagacaagtac
lincRNA-p21_30
aggtttgagagagatgcaca
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lincRNA-p21_31
atccatcttcagactgaggt
lincRNA-p21_32
tgacaagtaatgaggtccag
lincRNA-p21_33
agatgtattcgcttcgctgt
lincRNA-p21_34
agctacgtagtgaaaagcag
lincRNA-p21_35
ttcttcttatcagaggcagg
lincRNA-p21_36
ctcggttcctggaaatcata
lincRNA-p21_37
ttattgaacacccttgacgg
lincRNA-p21_38
tgttggctcaatcgatacgt
lincRNA-p21_39
tgtccattttctcctctgca
lincRNA-p21_40
agattgttggctccagttct
lincRNA-p21_41
ttgaaacccagaggtgaact
lincRNA-p21_42
aaagaaggaaaggggaaagg
lincRNA-p21_43
agctttcagggattcctaag
lincRNA-p21_44
agaagtcacagaagccacaa
lincRNA-p21_45
tgtgtgtgcacaagagatgt
lincRNA-p21_46
atgaactgcttagacacagg
lincRNA-p21_47
ggtgacagaaatggaatcag
lincRNA-p21_48
tcagctttaagaggtctgag
LincRNA-p21 intronic probes (conjugated to Quasar570)
Name
Sequence
Intron lincRNA-p21_1
tggctgaggtttcctaaaac
Intron lincRNA-p21_2
tcctgggaatgtattacgga
Intron lincRNA-p21_3
gttatgtgtgccgctactac
Intron lincRNA-p21_4
ggtcaactgtttcaaccaga
Intron lincRNA-p21_5
cactctctcctggaataggt
Intron lincRNA-p21_6
agtagccaaagtgaaccttg
Intron lincRNA-p21_7
cttcgcccagtctcttaaag
Intron lincRNA-p21_8
attgtcaggatgaccaacac
Intron lincRNA-p21_9
gttttttgcagccattgaca
Intron lincRNA-p21_10
atttaggcaggcaattgaca
Intron lincRNA-p21_11
agcggcataaaattgtctga
Intron lincRNA-p21_12
gcctttcacgacctaaagtt
Intron lincRNA-p21_13
cactcgcagtaaacacaagt
Intron lincRNA-p21_14
tcctttcggagttaaagctg
Intron lincRNA-p21_15
tcgccatgtttagatggttc
Intron lincRNA-p21_16
taaagctcacctgagctact
Intron lincRNA-p21_17
tcaaattcataagccacggt
Intron lincRNA-p21_18
gctcactggctattaagtcc
Intron lincRNA-p21_19
cacagagccagggataaaac
Intron lincRNA-p21_20
acaacgaacttggaacatga
Intron lincRNA-p21_21
cagggttacttgcctttctt
Intron lincRNA-p21_22
tagaggctactgttgtcctc
Intron lincRNA-p21_23
gacagtttgtaacactggct
Intron lincRNA-p21_24
tctggaaactcagtgtttgc
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Intron lincRNA-p21_25
Intron lincRNA-p21_26
Intron lincRNA-p21_27
Intron lincRNA-p21_28
Intron lincRNA-p21_29
Intron lincRNA-p21_30
Intron lincRNA-p21_31
Intron lincRNA-p21_32
Intron lincRNA-p21_33
Intron lincRNA-p21_34
Intron lincRNA-p21_35
Intron lincRNA-p21_36
Intron lincRNA-p21_37
Intron lincRNA-p21_38
Intron lincRNA-p21_39
Intron lincRNA-p21_40
Intron lincRNA-p21_41
Intron lincRNA-p21_42
Intron lincRNA-p21_43
Intron lincRNA-p21_44
Intron lincRNA-p21_45
Intron lincRNA-p21_46
Intron lincRNA-p21_47
Intron lincRNA-p21_48

ttatagggtcactctagggc
gttggcttcctgtggaaata
ctcattgtatcgcggtcatc
ctaaatgcacctgtgtcctt
gcctgaaattataccagggg
ctaaaatagctctctggggc
agctgtttaaggcacatcaa
tttcattccgtcctaatggg
tcagatctgggagaagtctc
cctttgacccctttgactag
agctcctaaactccagaaga
ctgtgcacaaagacatctga
cagacagacaaacgtaccag
attacgtcttcctacacgga
taacagcattactcgtgcag
catggttcactgaacaccat
ctcaggtttttgccagagaa
cacagccagtaacagcttta
cacttctttctgcactaggg
cagtcacctgtgccaaatat
gtggacgtttgagagtcttc
atttcctaaaacgtgcctgt
aagcctacactttggacatg
gaaaggaaaggcctcttagg

sgRNAs and dRNAs
Experiment

Guide name

Sequence

In vivo targeting for
TWI/PAS insertion
LincRNA-p21 p53RE
mutagenesis
LincRNA-p21 p53RE
mutagenesis
LincRNA-p21
transcriptional inhibition
LincRNA-p21
transcriptional inhibition
LincRNA-p21
transcriptional inhibition
LincRNA-p21 CRISPRa

N/A

GGGACAGGCCAGGCCAGCTG

sgCon

GGCCACGAGTTCGAGATCGA

sgRE

GATGCAACCGAAGGCAAGCC

dCon

gCGAGTTCGAGATCGA

d1

gCTGCCGGCCTTGCCC

d2

GGGCGTGGGGAGTGT

A1

GGGGGCGCTCTGTTC

LincRNA-p21 CRISPRa

A2

GGGCTTTTAATCAAC

LincRNA-p21 CRISPRa

A3

GCCATCCGTGGCAAC

LincRNA-p21 CRISPRa

A4

GGTGGAAGAGTCCG

LincRNA-p21 CRISPRa

A5

AGTTGTTACTGTGC

LincRNA-p21 CRISPRi

I-6

CGGAGACTTGGGCAGCCGGC

LincRNA-p21 CRISPRi

I-7

gAGTTGTTACTGTGCAGGGAT

109

LincRNA-p21 CRISPRi

I-8

gTCCCAGAACAGAGCGCCCCC

LincRNA-p21 CRISPRi

I-9

gCTGTTCTGGGAGATTAAATC

LincRNA-p21 CRISPRi

I-10

GCTGCAGGTGGAAGAGTCCG

LincRNA-p21 CRISPRi

I-11

GTGAACCACCCACTCAGCGC

LincRNA-p21 CRISPRi

I-12

GCTATGGGGCTCAGGCGACT

LincRNA-p21 CRISPRi

I-13

gCTGGGAGATGATGCAACCGA

LincRNA-p21 CRISPRi

I-14

gACCGAAGGCAAGCCCGGGCA

HDR templates
Name
PAS_HDR_template

TWI_HDR_template

Sequence
ggtgcagaagtgaaccacccactcagcgctggaaaaaccagctaattatatctccaaagacccagggcaagaacttgtggaca
acctcagAATAAAAGATCTTTATTTTCATTAGATCTGTGTGTTGGTTTTTTGTGTG
ctggcctggcctgtcccactcgctttccgtgagtgtcctc
tgcagaagtgaaccacccactcagcgctggaaaaaccagctaattatatctccaaagacccagggcaagaacttgtggacaac
ctcagCAATAAAGCGGTTACAAGCCCGCAAAAATAGCAGAGTAATGTCGCGAT
AGCGCGGCATTAATGCAGCTTTATTGctggcctggcctgtcccactcgctttccgtgagtgtcc

Supplementary Table 2. Key plasmids used in this work
Name

Details

Source

pCMV-dR8.2

Lentiviral packaging vector

Addgene #8455

pCMV-VSV-G

Lentiviral packaging vector

Addgene #8454

Brd001

Lentiviral; spCas9; hU6-gRNA; Puro

Broad Institute

Brd004

Lentiviral; spCas9; hU6-gRNA; GFP

Broad Institute

Lenti SAM Hygro

Lentiviral; p65-HSF1-MBP; hU6-gRNA-MS2;
Generated by E. Martínez-Terroba
Hygro

MSCV puro

Retroviral; puro

pHAGE-TRE-dCas9-KRAB

Lentiviral; doxy-inducible dCas9-KRAB; Neo

Addgene #50917

Lenti sgRNA(MS2)_zeo backbone Lentiviral; hU6-gRNA; Hygro

Addgene #61427

pCR-Blunt II-TOPO vector

Invitrogen (K280002)

Blunt DNA cloning vector
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